<html lang="en" data-cache-buster="?version=1661179095599" data-stencil-build="ag9yx82h" class="theme--page hydrated" data-react-helmet="lang,class"><head><meta charset="utf-8"><style data-styles="">roche-on-click-notice,roche-list-search,roche-registration,roche-search,roche-login,roche-story-teaser,roche-event-teaser,roche-pipeline-diagnostics,roche-back-to-branch,roche-footer,roche-header,roche-hero-teaser,roche-pipeline-table,roche-responsive-table,roche-add-to-calendar,roche-contact-person,roche-pipeline-changes-table,roche-dropdown,roche-language-switch,roche-navigation-mobile,roche-single-sign-in,roche-story-staging-hero,roche-subline,roche-table,roche-teaser-wall,roche-emergency-banner,roche-modal,roche-slider,roche-social-media,roche-stage-home,roche-stock-price,roche-animated-words,roche-animation-manager,roche-breadcrumbs,roche-filters,roche-fouc-preventer,roche-highlight-box,roche-horizontal-center,roche-lead-text,roche-link-list,roche-list,roche-list-text-item,roche-magnet,roche-navigation,roche-offcanvas-panel,roche-popular-search,roche-published-date,roche-quote,roche-side-by-side,roche-stage-home-teaser,roche-staging-hero,roche-text-image,roche-avatar,roche-pipeline-changes-row,roche-pipeline-table-row,roche-overline,roche-pipeline-diagnostics-row,roche-tag,roche-teaser,roche-empty-state,roche-select,roche-date,roche-table-sort-header,roche-jumpmark,roche-offcanvas-trigger,roche-pipeline-caption,roche-scale-on-scroll,roche-icon,roche-accordion-tabs-item,roche-accordion-tabs,roche-richtext,roche-text-link,roche-loading-spinner,roche-pagination,roche-generic-link,roche-tooltip,roche-button,roche-form,roche-input,roche-message,roche-headline,roche-grid,roche-column,roche-columns,roche-container,roche-image,roche-video-player{visibility:hidden}.hydrated{visibility:inherit}</style><meta name="viewport" content="width=device-width,initial-scale=1"><meta name="theme-color" content="#fff"><meta name="theme-color" content="#663399"><meta data-react-helmet="true" name="title" content="Product Development Portfolio"><meta data-react-helmet="true" name="image" content="https://a.storyblok.com/f/126832/432x432/1226146644/pipeline-teaser.jpg"><meta data-react-helmet="true" name="published-date" content="2021-10-20T12:48:56.000Z"><meta data-react-helmet="true" name="story-type" content="none"><meta data-react-helmet="true" name="content-type" content="pages"><meta data-react-helmet="true" name="private" content="no"><meta data-react-helmet="true" name="twitter:description" content=""><meta data-react-helmet="true" name="twitter:title" content=""><meta data-react-helmet="true" name="twitter:creator" content="@roche"><meta data-react-helmet="true" name="twitter:card" content="summary"><meta data-react-helmet="true" name="twitter:image" content=""><meta data-react-helmet="true" property="og:url" content="https://www.roche.com/solutions/pipeline/"><meta data-react-helmet="true" property="og:type" content="website"><meta data-react-helmet="true" property="og:description" content="We are turning today’s understanding of disease biology, diagnosis, detection and treatment into tomorrow's solutions. Discover our promising pipeline.
"><meta data-react-helmet="true" property="og:title" content="Roche | Product Development Portfolio"><meta data-react-helmet="true" property="og:image" content="https://a.storyblok.com/f/126832/432x432/1226146644/pipeline-teaser.jpg"><meta data-react-helmet="true" name="description" content="We are turning today’s understanding of disease biology, diagnosis, detection and treatment into tomorrow's solutions. Discover our promising pipeline.
"><meta name="generator" content="Gatsby 4.15.1"><title>Roche | Pipeline</title><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}roche-navigation-mobile{margin-top:0;display:block;box-sizing:border-box;max-width:100%}@media (min-width: 64rem){roche-navigation-mobile{margin-top:0}}roche-navigation-mobile ul,roche-navigation-mobile li{margin:0;padding:0;list-style:none}roche-navigation-mobile a,roche-navigation-mobile span{text-decoration:none;color:#544f4f;fill:#544f4f}roche-navigation-mobile span{pointer-events:none;display:flex;justify-content:space-between;align-items:center}roche-navigation-mobile span roche-icon{transition:transform 150ms ease-in;transform:rotate3d(0, 0, 1, 0deg)}roche-navigation-mobile .open span roche-icon{transform:rotate3d(0, 0, 1, 180deg)}roche-navigation-mobile .header{display:flex;flex-direction:row-reverse;justify-content:space-between;align-items:center;padding:1rem 1.25rem;border-bottom:1px solid #dbd6d1}roche-navigation-mobile .header__close{color:#544f4f;fill:#544f4f}roche-navigation-mobile .header__link{font-family:"roche-sans";font-style:normal;font-weight:200;font-size:1rem;line-height:1.625rem;display:flex;justify-content:flex-start;align-items:center}@media (min-width: 48rem){roche-navigation-mobile .header__link{font-size:1.125rem;line-height:1.8125rem}}roche-navigation-mobile .header__link-icon{padding:0 0.875rem 0 0}roche-navigation-mobile nav{padding:0 1.25rem 3rem}roche-navigation-mobile nav>ul{padding:0;color:var(--color-text--primary);font-family:"roche-sans";font-style:normal;font-weight:400;font-size:1.5rem;line-height:1.9375rem;padding:0 0 1rem;margin:2rem 0 0;border-bottom:1px solid #dbd6d1}roche-navigation-mobile nav>ul strong{font-weight:600}@media (min-width: 48rem){roche-navigation-mobile nav>ul{font-size:1.5rem;line-height:2.125rem}}@media (min-width: 90rem){roche-navigation-mobile nav>ul{font-size:1.875rem;line-height:2.5625rem}}roche-navigation-mobile nav>ul+ul{margin:1.5rem 0 0}roche-navigation-mobile nav>ul>li{transform:translate3d(0, 0, 0);transition:height 150ms ease-in 150ms}roche-navigation-mobile nav>ul>li ul{transition:opacity 150ms ease-in 0ms;opacity:0;pointer-events:none}roche-navigation-mobile nav>ul>li.open{transition:height 150ms ease-in}roche-navigation-mobile nav>ul>li.open ul{transition:opacity 150ms ease-in 150ms;opacity:1;pointer-events:inherit}roche-navigation-mobile nav>ul>li:not(:first-child){margin:1.5rem 0 0}roche-navigation-mobile ul ul{font-family:"roche-sans";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:1.125rem;line-height:1.8125rem;opacity:0}@media (min-width: 64rem){roche-navigation-mobile ul ul{font-size:1.25rem;line-height:2rem}}roche-navigation-mobile ul>li>ul>li{margin:0;padding:0.625rem 0 0.625rem 2rem;border-left:1px solid #dbd6d1}roche-navigation-mobile ul>li>ul>li>a{font-family:"roche-sans";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:1.125rem;line-height:1.8125rem;font-weight:400;color:#544f4f}@media (min-width: 64rem){roche-navigation-mobile ul>li>ul>li>a{font-size:1.25rem;line-height:2rem}}roche-navigation-mobile ul>li>ul>li:first-child{padding:1.5rem 0 0.625rem;border-left:none}roche-navigation-mobile ul>li>ul>li:first-child>a{display:flex;align-items:center;color:#000}roche-navigation-mobile ul>li>ul>li:first-child>a roche-icon{margin:0 0 0 0.5rem}roche-navigation-mobile ul>li>ul>li:last-child{padding:0.625rem 0 0 2rem}roche-navigation-mobile .current-page{border-color:var(--color-interactive--primary-idle)}roche-navigation-mobile .current-page a{color:var(--color-interactive--primary-idle)}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}roche-richtext{display:block;margin-top:3rem;font-family:"roche-sans";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:1.125rem;line-height:1.8125rem;white-space:normal;}@media (min-width: 90rem){roche-richtext{margin-top:4.5rem}}roche-richtext,roche-richtext *{box-sizing:border-box}@media (min-width: 64rem){roche-richtext{font-size:1.25rem;line-height:2rem}}roche-richtext *{margin:0;padding:0;box-sizing:border-box}roche-richtext>*{margin:1.625rem 0 0;padding:0}@media (min-width: 48rem){roche-richtext>*{margin:1.75rem 0 0}}roche-richtext>*:first-child{margin:0}roche-richtext ul>li,roche-richtext ol>li{display:block;margin:0.5rem 0 0;padding:0 0 0 1.25rem;position:relative}roche-richtext ol{counter-reset:item;padding:0 0 0 1.25rem}roche-richtext ol li{counter-increment:item;padding:0 0 0 0.625rem}roche-richtext ol li::before{content:counter(item) ".";position:absolute;left:-1.25rem}roche-richtext ul{list-style:none}@media print{roche-richtext ul{list-style:disc !important;}roche-richtext ul li::before{content:"";display:list-item !important;top:0 !important;margin-left:1.25rem;background-color:rgba(0, 0, 0, 0.2)}}roche-richtext ul li::before{content:"";display:block;position:absolute;left:0;top:0.625rem;width:0.4375rem;height:0.4375rem;background-color:rgba(0, 0, 0, 0.2);border-radius:50%}roche-richtext ul li ul li::before{width:0.3125rem;height:0.3125rem;background-color:transparent;border:1.5px solid rgba(0, 0, 0, 0.2)}roche-richtext[footnote]{font-family:"roche-sans";font-style:normal;font-weight:200;font-size:0.875rem;font-weight:400;line-height:1.1875rem;color:var(--color-text--secondary);color:#544f4f}@media (min-width: 48rem){roche-richtext[footnote]{font-size:1rem;line-height:1.3125rem}}roche-richtext[footnote] ul li::before{top:0.375rem}roche-richtext[footnote] ol li{padding:0 0 0 0.3125rem}roche-richtext roche-icon{display:inline-block}roche-richtext .superscript{vertical-align:super;font-size:80%}roche-richtext .subscript{vertical-align:sub;font-size:80%}roche-richtext roche-headline{margin-top:3rem}@media (min-width: 90rem){roche-richtext roche-headline{margin-top:4.5rem}}roche-richtext table{margin-top:0.6875rem;margin-bottom:1.25rem;padding-left:0.125rem}@media (min-width: 20rem){roche-richtext table{display:block;max-width:100vw;overflow-y:scroll}}@media (min-width: 48rem){roche-richtext table{display:inline;width:100%;overflow-y:none}}roche-richtext table .gnw_border_top_solid{border-top:0.0625rem solid rgba(0, 0, 0, 0.2)}roche-richtext table .gnw_border_right_solid{border-right:0.0625rem solid rgba(0, 0, 0, 0.2)}roche-richtext table .gnw_border_bottom_solid{border-bottom:0.0625rem solid rgba(0, 0, 0, 0.2)}roche-richtext table .gnw_border_left_solid{border-left:0.0625rem solid rgba(0, 0, 0, 0.2)}roche-richtext table .gnw_vertical_align_top{vertical-align:top}roche-richtext table tbody,roche-richtext table td{padding:0.625rem 1.25rem 0.625rem 0}roche-richtext figure,roche-richtext img{max-width:100%;height:auto}roche-richtext sup.hugin{vertical-align:middle !important}roche-richtext[type=footer]{font-family:"roche-sans";font-style:normal;font-weight:200;font-weight:400;font-size:0.875rem;line-height:1.1875rem;margin-top:0;color:var(--color-text--primary)}roche-richtext[type=on-click-notice]{margin-top:1rem}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}roche-navigation{margin-top:0;display:block;box-sizing:border-box;max-width:100%}@media (min-width: 64rem){roche-navigation{margin-top:0}}roche-navigation *{box-sizing:border-box;color:#544f4f}roche-navigation ul,roche-navigation li{margin:0;padding:0;list-style:none}roche-navigation a{text-decoration:none;color:#544f4f;fill:#544f4f}roche-navigation .current-page>a,roche-navigation .current-page>span{color:var(--color-interactive--primary-idle);border-bottom-color:var(--color-interactive--primary-idle) !important}roche-navigation .current-page>a>roche-icon{fill:var(--color-interactive--primary-idle);border-bottom-color:var(--color-interactive--primary-idle) !important}roche-navigation nav>ul{padding:0;color:var(--color-text--primary);font-family:"roche-sans";font-style:normal;font-weight:400;font-size:1.125rem;line-height:1.6875rem;display:flex;user-select:none}roche-navigation nav>ul strong{font-weight:600}@media (min-width: 48rem){roche-navigation nav>ul{font-size:1.125rem;line-height:1.8125rem}}@media (min-width: 90rem){roche-navigation nav>ul{font-size:1.25rem;line-height:1.875rem}}roche-navigation nav>ul>li{position:relative;display:flex;flex-direction:column;justify-content:center;padding:0;margin:0 2rem 0 0}roche-navigation nav>ul>li:first-child{margin-left:-4px}roche-navigation nav>ul>li:empty::before{content:"";height:1.125rem;width:1px;transform:translateY(-0.25rem);background-color:#9d948e}roche-navigation nav>ul>li>span,roche-navigation nav>ul>li>a{transition:border-color 100ms ease-in;border:4px solid transparent;padding:0 0 0.5rem}roche-navigation nav>ul>li:hover>span,roche-navigation nav>ul>li:hover>a,roche-navigation nav>ul>li:focus-within>span,roche-navigation nav>ul>li:focus-within>a{border-bottom-color:var(--color-interactive--primary-idle)}roche-navigation nav>ul>li:hover>ul,roche-navigation nav>ul>li:focus-within>ul{pointer-events:initial;opacity:1;transform:translateY(1rem)}roche-navigation nav>ul>li>ul{transition:opacity 150ms ease-in, transform 150ms ease-in;position:absolute;left:-2rem;top:2.5rem;min-width:25rem;transform:translateY(4rem);padding:1.5rem 1rem;white-space:nowrap;background-color:#fff;box-shadow:0 0.25rem 0.75rem rgba(0, 0, 0, 0.1);opacity:0;pointer-events:none}roche-navigation nav>ul>li>ul::before{content:"";display:block;position:absolute;left:0;top:-1rem;width:50%;height:1rem;background-color:transparent}roche-navigation nav>ul>li>ul>li{margin:0.5rem 0 0}roche-navigation nav>ul>li>ul>li:first-child{padding:0;color:var(--color-text--primary);font-family:"roche-sans";font-style:normal;font-weight:400;font-size:1.25rem;line-height:1.625rem;margin:0}roche-navigation nav>ul>li>ul>li:first-child strong{font-weight:600}@media (min-width: 48rem){roche-navigation nav>ul>li>ul>li:first-child{font-size:1.25rem;line-height:1.875rem}}@media (min-width: 90rem){roche-navigation nav>ul>li>ul>li:first-child{font-size:1.5rem;line-height:2.125rem}}roche-navigation nav>ul>li>ul>li:first-child a,roche-navigation nav>ul>li>ul>li:first-child roche-icon{color:#000}roche-navigation nav>ul>li>ul a{transition:background-color 100ms ease-in;display:flex;justify-content:flex-start;align-items:center;padding:0.5rem 1rem;border-radius:6px}roche-navigation nav>ul>li>ul a:hover{background-color:#f5f5f2}roche-navigation nav>ul>li>ul roche-icon{margin:0 0 0 0.5rem}roche-navigation[slot=secondary] nav>ul>li{margin:0 1.75rem 0 0}roche-navigation[slot=secondary] nav>ul>li.reduced-margin{margin:0 1.25rem 0 0}roche-navigation[slot=secondary] nav>ul>li a{transition:border-color 100ms ease-in;padding:0 0 0.125rem;border:2px solid transparent}roche-navigation[slot=secondary] nav>ul>li a:hover{border-bottom-color:var(--color-interactive--primary-idle)}roche-navigation[slot=secondary] nav>ul>li roche-icon{padding:0 0 0.25rem}roche-navigation[slot=secondary] nav>ul>li:empty::before{transform:translateY(-0.125rem)}roche-navigation[slot=secondary] nav>ul>li:last-child{margin:0}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}roche-offcanvas-trigger{display:inline}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}roche-accordion-tabs{display:block;margin-top:3rem}@media (min-width: 90rem){roche-accordion-tabs{margin-top:4.5rem}}roche-accordion-tabs,roche-accordion-tabs *{box-sizing:border-box}roche-accordion-tabs[no-margin]{margin-top:0}@media (min-width: 64rem){roche-accordion-tabs[no-margin]{margin-top:0}}roche-accordion-tabs .tabs{display:flex;overflow-x:auto;padding:0;margin:0;border-bottom:1px solid #c2bab5;opacity:0;pointer-events:none;scrollbar-width:none;position:relative;z-index:50}roche-accordion-tabs .tabs::-webkit-scrollbar{display:none}roche-accordion-tabs .tabs li{display:inline-block;list-style:none}roche-accordion-tabs .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs .tabs li+li{margin-left:2rem}}roche-accordion-tabs .tabs--visible{height:auto;opacity:1;pointer-events:all}roche-accordion-tabs .tabs__item{all:unset;padding:0;color:var(--color-text--primary);font-family:"roche-sans";font-style:normal;font-weight:400;font-size:1.125rem;line-height:1.6875rem;position:relative;color:#544f4f;cursor:pointer;white-space:nowrap;padding-bottom:0.5rem;border-bottom:0.1875rem solid transparent;transition:border-color 100ms ease-in, color 100ms ease-in}roche-accordion-tabs .tabs__item strong{font-weight:600}@media (min-width: 48rem){roche-accordion-tabs .tabs__item{font-size:1.125rem;line-height:1.8125rem}}@media (min-width: 90rem){roche-accordion-tabs .tabs__item{font-size:1.25rem;line-height:1.875rem}}@media (min-width: 48rem){roche-accordion-tabs .tabs__item{padding-bottom:1rem}}roche-accordion-tabs .tabs__item:focus,roche-accordion-tabs .tabs__item:focus-visible{outline-width:2px;outline-style:dashed;outline-color:var(--color-interactive--focus);outline-offset:-2px}roche-accordion-tabs .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs .tabs__item:hover{border-bottom-color:var(--color-interactive--primary-hover)}roche-accordion-tabs .tabs__item.active{border-bottom-color:var(--color-interactive--primary-hover);color:var(--color-interactive--primary-hover)}roche-accordion-tabs .tabs--centered.tabs--visible{display:table;margin-left:auto;margin-right:auto}roche-accordion-tabs .tabs--centered .tabs__item{padding-left:1rem;padding-right:1rem;text-align:center}roche-accordion-tabs[blur-ends=both] .tabs{mask-image:linear-gradient(to right, transparent 0%, black 4rem), linear-gradient(to left, transparent 0%, black 4rem);mask-composite:intersect;-webkit-mask-image:linear-gradient(to right, transparent 0%, black 4rem), linear-gradient(to left, transparent 0%, black 4rem);-webkit-mask-composite:source-in}roche-accordion-tabs[blur-ends=left] .tabs{mask-image:linear-gradient(to right, transparent 0%, black 4rem);-webkit-mask-image:linear-gradient(to right, transparent 0%, black 4rem)}roche-accordion-tabs[blur-ends=right] .tabs{mask-image:linear-gradient(to left, transparent 0%, black 4rem);-webkit-mask-image:linear-gradient(to left, transparent 0%, black 4rem)}roche-accordion-tabs[appearance=filter] .tabs{border-bottom:none}roche-accordion-tabs[appearance=filter] .tabs__item{font-family:"roche-sans";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:1.125rem;line-height:1.8125rem;font-weight:400;display:inline;position:relative;border:1px solid #dbd6d1;padding:0.34375rem 1rem;color:#544f4f;white-space:nowrap}@media (min-width: 64rem){roche-accordion-tabs[appearance=filter] .tabs__item{font-size:1.25rem;line-height:2rem}}@media (min-width: 90rem){roche-accordion-tabs[appearance=filter] .tabs__item{font-size:1.125rem;line-height:1.8125rem}}roche-accordion-tabs[appearance=filter] .tabs__item:focus,roche-accordion-tabs[appearance=filter] .tabs__item:focus-visible{outline-width:2px;outline-style:dashed;outline-color:var(--color-interactive--focus);outline-offset:unset}roche-accordion-tabs[appearance=filter] .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs[appearance=filter] .tabs__item:hover,roche-accordion-tabs[appearance=filter] .tabs__item.active{background-color:var(--color-interactive--primary-hover);border-color:var(--color-interactive--primary-hover);color:#fff;transition:background-color 200ms ease, border-color 200ms ease, color 200ms ease;text-decoration:none}roche-accordion-tabs[appearance=filter] .tabs__item:hover:not(.tabs__item.active){background-color:#eae8e5;border-color:#706b69;color:#544f4f;cursor:pointer}roche-accordion-tabs[appearance=filter] .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs[appearance=filter] .tabs li+li{margin-left:1rem}}roche-accordion-tabs[appearance=pipeline] .tabs{border-bottom:none}roche-accordion-tabs[appearance=pipeline] .tabs__item{font-family:"roche-sans";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:1.125rem;line-height:1.8125rem;font-weight:400;display:inline;position:relative;border:1px solid #9d948e;padding:0.34375rem 1rem;color:#9d948e;white-space:nowrap}@media (min-width: 64rem){roche-accordion-tabs[appearance=pipeline] .tabs__item{font-size:1.25rem;line-height:2rem}}@media (min-width: 90rem){roche-accordion-tabs[appearance=pipeline] .tabs__item{font-size:1.125rem;line-height:1.8125rem}}roche-accordion-tabs[appearance=pipeline] .tabs__item:focus,roche-accordion-tabs[appearance=pipeline] .tabs__item:focus-visible{outline-width:2px;outline-style:dashed;outline-color:var(--color-interactive--focus);outline-offset:unset}roche-accordion-tabs[appearance=pipeline] .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs[appearance=pipeline] .tabs__item:hover,roche-accordion-tabs[appearance=pipeline] .tabs__item.active{background-color:#9d948e;border-color:#9d948e;color:#fff;transition:background-color 200ms ease, border-color 200ms ease, color 200ms ease;text-decoration:none}roche-accordion-tabs[appearance=pipeline] .tabs__item:hover:not(.tabs__item.active){background-color:#eae8e5;border-color:#706b69;color:#544f4f;cursor:pointer}roche-accordion-tabs[appearance=pipeline] .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs[appearance=pipeline] .tabs li+li{margin-left:1rem}}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}:host{display:block;margin-top:3rem;display:block}@media (min-width: 90rem){:host{margin-top:4.5rem}}:host,:host *{box-sizing:border-box}:host [data-aos^=fade][data-aos^=fade]{opacity:0;transition-property:opacity, transform}:host [data-aos^=fade][data-aos^=fade].aos-animate{opacity:1;transform:none}:host [data-aos=fade-up]{transform:translate3d(0, 100px, 0)}:host [data-aos=fade-down]{transform:translate3d(0, -100px, 0)}:host [data-aos=fade-right]{transform:translate3d(-100px, 0, 0)}:host [data-aos=fade-left]{transform:translate3d(100px, 0, 0)}:host [data-aos]{pointer-events:none}:host [data-aos].aos-animate{pointer-events:auto}body[data-aos-easing=linear] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=linear]{transition-timing-function:cubic-bezier(0.25, 0.25, 0.75, 0.75)}body[data-aos-easing=ease] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease]{transition-timing-function:cubic-bezier(0.25, 0.1, 0.25, 1)}body[data-aos-easing=ease-in] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in]{transition-timing-function:cubic-bezier(0.42, 0, 1, 1)}body[data-aos-easing=ease-out] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out]{transition-timing-function:cubic-bezier(0, 0, 0.58, 1)}body[data-aos-easing=ease-in-out] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out]{transition-timing-function:cubic-bezier(0.42, 0, 0.58, 1)}body[data-aos-easing=ease-in-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-back]{transition-timing-function:cubic-bezier(0.6, -0.28, 0.735, 0.045)}body[data-aos-easing=ease-out-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-back]{transition-timing-function:cubic-bezier(0.175, 0.885, 0.32, 1.275)}body[data-aos-easing=ease-in-out-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-back]{transition-timing-function:cubic-bezier(0.68, -0.55, 0.265, 1.55)}body[data-aos-easing=ease-in-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-sine]{transition-timing-function:cubic-bezier(0.47, 0, 0.745, 0.715)}body[data-aos-easing=ease-out-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-sine]{transition-timing-function:cubic-bezier(0.39, 0.575, 0.565, 1)}body[data-aos-easing=ease-in-out-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-sine]{transition-timing-function:cubic-bezier(0.445, 0.05, 0.55, 0.95)}body[data-aos-easing=ease-in-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-quad]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-quad]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-quad]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-cubic]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-cubic]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-cubic]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-quart]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-quart]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-quart]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-duration="50"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="50"]{transition-duration:50ms}body[data-aos-delay="50"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="50"]{transition-delay:0s}body[data-aos-delay="50"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="50"].aos-animate{transition-delay:50ms}body[data-aos-duration="100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="100"]{transition-duration:100ms}body[data-aos-delay="100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="100"]{transition-delay:0s}body[data-aos-delay="100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="100"].aos-animate{transition-delay:100ms}body[data-aos-duration="150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="150"]{transition-duration:150ms}body[data-aos-delay="150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="150"]{transition-delay:0s}body[data-aos-delay="150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="150"].aos-animate{transition-delay:150ms}body[data-aos-duration="200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="200"]{transition-duration:200ms}body[data-aos-delay="200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="200"]{transition-delay:0s}body[data-aos-delay="200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="200"].aos-animate{transition-delay:200ms}body[data-aos-duration="250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="250"]{transition-duration:250ms}body[data-aos-delay="250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="250"]{transition-delay:0s}body[data-aos-delay="250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="250"].aos-animate{transition-delay:250ms}body[data-aos-duration="300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="300"]{transition-duration:300ms}body[data-aos-delay="300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="300"]{transition-delay:0s}body[data-aos-delay="300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="300"].aos-animate{transition-delay:300ms}body[data-aos-duration="350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="350"]{transition-duration:350ms}body[data-aos-delay="350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="350"]{transition-delay:0s}body[data-aos-delay="350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="350"].aos-animate{transition-delay:350ms}body[data-aos-duration="400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="400"]{transition-duration:400ms}body[data-aos-delay="400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="400"]{transition-delay:0s}body[data-aos-delay="400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="400"].aos-animate{transition-delay:400ms}body[data-aos-duration="450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="450"]{transition-duration:450ms}body[data-aos-delay="450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="450"]{transition-delay:0s}body[data-aos-delay="450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="450"].aos-animate{transition-delay:450ms}body[data-aos-duration="500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="500"]{transition-duration:500ms}body[data-aos-delay="500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="500"]{transition-delay:0s}body[data-aos-delay="500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="500"].aos-animate{transition-delay:500ms}body[data-aos-duration="550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="550"]{transition-duration:550ms}body[data-aos-delay="550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="550"]{transition-delay:0s}body[data-aos-delay="550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="550"].aos-animate{transition-delay:550ms}body[data-aos-duration="600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="600"]{transition-duration:600ms}body[data-aos-delay="600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="600"]{transition-delay:0s}body[data-aos-delay="600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="600"].aos-animate{transition-delay:600ms}body[data-aos-duration="650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="650"]{transition-duration:650ms}body[data-aos-delay="650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="650"]{transition-delay:0s}body[data-aos-delay="650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="650"].aos-animate{transition-delay:650ms}body[data-aos-duration="700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="700"]{transition-duration:700ms}body[data-aos-delay="700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="700"]{transition-delay:0s}body[data-aos-delay="700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="700"].aos-animate{transition-delay:700ms}body[data-aos-duration="750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="750"]{transition-duration:750ms}body[data-aos-delay="750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="750"]{transition-delay:0s}body[data-aos-delay="750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="750"].aos-animate{transition-delay:750ms}body[data-aos-duration="800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="800"]{transition-duration:800ms}body[data-aos-delay="800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="800"]{transition-delay:0s}body[data-aos-delay="800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="800"].aos-animate{transition-delay:800ms}body[data-aos-duration="850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="850"]{transition-duration:850ms}body[data-aos-delay="850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="850"]{transition-delay:0s}body[data-aos-delay="850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="850"].aos-animate{transition-delay:850ms}body[data-aos-duration="900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="900"]{transition-duration:900ms}body[data-aos-delay="900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="900"]{transition-delay:0s}body[data-aos-delay="900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="900"].aos-animate{transition-delay:900ms}body[data-aos-duration="950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="950"]{transition-duration:950ms}body[data-aos-delay="950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="950"]{transition-delay:0s}body[data-aos-delay="950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="950"].aos-animate{transition-delay:950ms}body[data-aos-duration="1000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1000"]{transition-duration:1000ms}body[data-aos-delay="1000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1000"]{transition-delay:0s}body[data-aos-delay="1000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1000"].aos-animate{transition-delay:1000ms}body[data-aos-duration="1050"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1050"]{transition-duration:1050ms}body[data-aos-delay="1050"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1050"]{transition-delay:0s}body[data-aos-delay="1050"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1050"].aos-animate{transition-delay:1050ms}body[data-aos-duration="1100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1100"]{transition-duration:1100ms}body[data-aos-delay="1100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1100"]{transition-delay:0s}body[data-aos-delay="1100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1100"].aos-animate{transition-delay:1100ms}body[data-aos-duration="1150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1150"]{transition-duration:1150ms}body[data-aos-delay="1150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1150"]{transition-delay:0s}body[data-aos-delay="1150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1150"].aos-animate{transition-delay:1150ms}body[data-aos-duration="1200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1200"]{transition-duration:1200ms}body[data-aos-delay="1200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1200"]{transition-delay:0s}body[data-aos-delay="1200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1200"].aos-animate{transition-delay:1200ms}body[data-aos-duration="1250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1250"]{transition-duration:1250ms}body[data-aos-delay="1250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1250"]{transition-delay:0s}body[data-aos-delay="1250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1250"].aos-animate{transition-delay:1250ms}body[data-aos-duration="1300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1300"]{transition-duration:1300ms}body[data-aos-delay="1300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1300"]{transition-delay:0s}body[data-aos-delay="1300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1300"].aos-animate{transition-delay:1300ms}body[data-aos-duration="1350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1350"]{transition-duration:1350ms}body[data-aos-delay="1350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1350"]{transition-delay:0s}body[data-aos-delay="1350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1350"].aos-animate{transition-delay:1350ms}body[data-aos-duration="1400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1400"]{transition-duration:1400ms}body[data-aos-delay="1400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1400"]{transition-delay:0s}body[data-aos-delay="1400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1400"].aos-animate{transition-delay:1400ms}body[data-aos-duration="1450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1450"]{transition-duration:1450ms}body[data-aos-delay="1450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1450"]{transition-delay:0s}body[data-aos-delay="1450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1450"].aos-animate{transition-delay:1450ms}body[data-aos-duration="1500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1500"]{transition-duration:1500ms}body[data-aos-delay="1500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1500"]{transition-delay:0s}body[data-aos-delay="1500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1500"].aos-animate{transition-delay:1500ms}body[data-aos-duration="1550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1550"]{transition-duration:1550ms}body[data-aos-delay="1550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1550"]{transition-delay:0s}body[data-aos-delay="1550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1550"].aos-animate{transition-delay:1550ms}body[data-aos-duration="1600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1600"]{transition-duration:1600ms}body[data-aos-delay="1600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1600"]{transition-delay:0s}body[data-aos-delay="1600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1600"].aos-animate{transition-delay:1600ms}body[data-aos-duration="1650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1650"]{transition-duration:1650ms}body[data-aos-delay="1650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1650"]{transition-delay:0s}body[data-aos-delay="1650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1650"].aos-animate{transition-delay:1650ms}body[data-aos-duration="1700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1700"]{transition-duration:1700ms}body[data-aos-delay="1700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1700"]{transition-delay:0s}body[data-aos-delay="1700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1700"].aos-animate{transition-delay:1700ms}body[data-aos-duration="1750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1750"]{transition-duration:1750ms}body[data-aos-delay="1750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1750"]{transition-delay:0s}body[data-aos-delay="1750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1750"].aos-animate{transition-delay:1750ms}body[data-aos-duration="1800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1800"]{transition-duration:1800ms}body[data-aos-delay="1800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1800"]{transition-delay:0s}body[data-aos-delay="1800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1800"].aos-animate{transition-delay:1800ms}body[data-aos-duration="1850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1850"]{transition-duration:1850ms}body[data-aos-delay="1850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1850"]{transition-delay:0s}body[data-aos-delay="1850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1850"].aos-animate{transition-delay:1850ms}body[data-aos-duration="1900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1900"]{transition-duration:1900ms}body[data-aos-delay="1900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1900"]{transition-delay:0s}body[data-aos-delay="1900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1900"].aos-animate{transition-delay:1900ms}body[data-aos-duration="1950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1950"]{transition-duration:1950ms}body[data-aos-delay="1950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1950"]{transition-delay:0s}body[data-aos-delay="1950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1950"].aos-animate{transition-delay:1950ms}body[data-aos-duration="2000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2000"]{transition-duration:2000ms}body[data-aos-delay="2000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2000"]{transition-delay:0s}body[data-aos-delay="2000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2000"].aos-animate{transition-delay:2000ms}body[data-aos-duration="2050"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2050"]{transition-duration:2050ms}body[data-aos-delay="2050"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2050"]{transition-delay:0s}body[data-aos-delay="2050"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2050"].aos-animate{transition-delay:2050ms}body[data-aos-duration="2100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2100"]{transition-duration:2100ms}body[data-aos-delay="2100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2100"]{transition-delay:0s}body[data-aos-delay="2100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2100"].aos-animate{transition-delay:2100ms}body[data-aos-duration="2150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2150"]{transition-duration:2150ms}body[data-aos-delay="2150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2150"]{transition-delay:0s}body[data-aos-delay="2150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2150"].aos-animate{transition-delay:2150ms}body[data-aos-duration="2200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2200"]{transition-duration:2200ms}body[data-aos-delay="2200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2200"]{transition-delay:0s}body[data-aos-delay="2200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2200"].aos-animate{transition-delay:2200ms}body[data-aos-duration="2250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2250"]{transition-duration:2250ms}body[data-aos-delay="2250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2250"]{transition-delay:0s}body[data-aos-delay="2250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2250"].aos-animate{transition-delay:2250ms}body[data-aos-duration="2300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2300"]{transition-duration:2300ms}body[data-aos-delay="2300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2300"]{transition-delay:0s}body[data-aos-delay="2300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2300"].aos-animate{transition-delay:2300ms}body[data-aos-duration="2350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2350"]{transition-duration:2350ms}body[data-aos-delay="2350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2350"]{transition-delay:0s}body[data-aos-delay="2350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2350"].aos-animate{transition-delay:2350ms}body[data-aos-duration="2400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2400"]{transition-duration:2400ms}body[data-aos-delay="2400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2400"]{transition-delay:0s}body[data-aos-delay="2400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2400"].aos-animate{transition-delay:2400ms}body[data-aos-duration="2450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2450"]{transition-duration:2450ms}body[data-aos-delay="2450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2450"]{transition-delay:0s}body[data-aos-delay="2450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2450"].aos-animate{transition-delay:2450ms}body[data-aos-duration="2500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2500"]{transition-duration:2500ms}body[data-aos-delay="2500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2500"]{transition-delay:0s}body[data-aos-delay="2500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2500"].aos-animate{transition-delay:2500ms}body[data-aos-duration="2550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2550"]{transition-duration:2550ms}body[data-aos-delay="2550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2550"]{transition-delay:0s}body[data-aos-delay="2550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2550"].aos-animate{transition-delay:2550ms}body[data-aos-duration="2600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2600"]{transition-duration:2600ms}body[data-aos-delay="2600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2600"]{transition-delay:0s}body[data-aos-delay="2600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2600"].aos-animate{transition-delay:2600ms}body[data-aos-duration="2650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2650"]{transition-duration:2650ms}body[data-aos-delay="2650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2650"]{transition-delay:0s}body[data-aos-delay="2650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2650"].aos-animate{transition-delay:2650ms}body[data-aos-duration="2700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2700"]{transition-duration:2700ms}body[data-aos-delay="2700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2700"]{transition-delay:0s}body[data-aos-delay="2700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2700"].aos-animate{transition-delay:2700ms}body[data-aos-duration="2750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2750"]{transition-duration:2750ms}body[data-aos-delay="2750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2750"]{transition-delay:0s}body[data-aos-delay="2750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2750"].aos-animate{transition-delay:2750ms}body[data-aos-duration="2800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2800"]{transition-duration:2800ms}body[data-aos-delay="2800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2800"]{transition-delay:0s}body[data-aos-delay="2800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2800"].aos-animate{transition-delay:2800ms}body[data-aos-duration="2850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2850"]{transition-duration:2850ms}body[data-aos-delay="2850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2850"]{transition-delay:0s}body[data-aos-delay="2850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2850"].aos-animate{transition-delay:2850ms}body[data-aos-duration="2900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2900"]{transition-duration:2900ms}body[data-aos-delay="2900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2900"]{transition-delay:0s}body[data-aos-delay="2900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2900"].aos-animate{transition-delay:2900ms}body[data-aos-duration="2950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2950"]{transition-duration:2950ms}body[data-aos-delay="2950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2950"]{transition-delay:0s}body[data-aos-delay="2950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2950"].aos-animate{transition-delay:2950ms}body[data-aos-duration="3000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="3000"]{transition-duration:3000ms}body[data-aos-delay="3000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="3000"]{transition-delay:0s}body[data-aos-delay="3000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="3000"].aos-animate{transition-delay:3000ms}.diagnostics-caption{max-width:18.75rem;margin-top:3rem}@media (min-width: 20rem){.diagnostics-caption{margin-top:2rem}}@media (min-width: 48rem){.diagnostics-caption{margin-top:3rem}}.diagnostics-caption__item .abbreviation{font-family:"roche-sans";font-style:normal;font-weight:200;font-size:0.875rem;line-height:1.1875rem;font-weight:400}@media (min-width: 48rem){.diagnostics-caption__item .abbreviation{font-size:1rem;line-height:1.375rem}}.diagnostics-caption__item .description{font-family:"roche-sans";font-style:normal;font-weight:200;font-size:0.875rem;line-height:1.1875rem}@media (min-width: 48rem){.diagnostics-caption__item .description{font-size:1rem;line-height:1.375rem}}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}:host{display:block;margin-top:3rem;margin-top:0}@media (min-width: 90rem){:host{margin-top:4.5rem}}:host,:host *{box-sizing:border-box}:host [data-aos^=fade][data-aos^=fade]{opacity:0;transition-property:opacity, transform}:host [data-aos^=fade][data-aos^=fade].aos-animate{opacity:1;transform:none}:host [data-aos=fade-up]{transform:translate3d(0, 100px, 0)}:host [data-aos=fade-down]{transform:translate3d(0, -100px, 0)}:host [data-aos=fade-right]{transform:translate3d(-100px, 0, 0)}:host [data-aos=fade-left]{transform:translate3d(100px, 0, 0)}:host [data-aos]{pointer-events:none}:host [data-aos].aos-animate{pointer-events:auto}body[data-aos-easing=linear] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=linear]{transition-timing-function:cubic-bezier(0.25, 0.25, 0.75, 0.75)}body[data-aos-easing=ease] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease]{transition-timing-function:cubic-bezier(0.25, 0.1, 0.25, 1)}body[data-aos-easing=ease-in] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in]{transition-timing-function:cubic-bezier(0.42, 0, 1, 1)}body[data-aos-easing=ease-out] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out]{transition-timing-function:cubic-bezier(0, 0, 0.58, 1)}body[data-aos-easing=ease-in-out] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out]{transition-timing-function:cubic-bezier(0.42, 0, 0.58, 1)}body[data-aos-easing=ease-in-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-back]{transition-timing-function:cubic-bezier(0.6, -0.28, 0.735, 0.045)}body[data-aos-easing=ease-out-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-back]{transition-timing-function:cubic-bezier(0.175, 0.885, 0.32, 1.275)}body[data-aos-easing=ease-in-out-back] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-back]{transition-timing-function:cubic-bezier(0.68, -0.55, 0.265, 1.55)}body[data-aos-easing=ease-in-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-sine]{transition-timing-function:cubic-bezier(0.47, 0, 0.745, 0.715)}body[data-aos-easing=ease-out-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-sine]{transition-timing-function:cubic-bezier(0.39, 0.575, 0.565, 1)}body[data-aos-easing=ease-in-out-sine] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-sine]{transition-timing-function:cubic-bezier(0.445, 0.05, 0.55, 0.95)}body[data-aos-easing=ease-in-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-quad]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-quad]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quad] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-quad]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-cubic]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-cubic]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-cubic] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-cubic]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-quart]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-out-quart]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quart] :host [data-aos],:host [data-aos][data-aos][data-aos-easing=ease-in-out-quart]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-duration="50"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="50"]{transition-duration:50ms}body[data-aos-delay="50"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="50"]{transition-delay:0s}body[data-aos-delay="50"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="50"].aos-animate{transition-delay:50ms}body[data-aos-duration="100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="100"]{transition-duration:100ms}body[data-aos-delay="100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="100"]{transition-delay:0s}body[data-aos-delay="100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="100"].aos-animate{transition-delay:100ms}body[data-aos-duration="150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="150"]{transition-duration:150ms}body[data-aos-delay="150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="150"]{transition-delay:0s}body[data-aos-delay="150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="150"].aos-animate{transition-delay:150ms}body[data-aos-duration="200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="200"]{transition-duration:200ms}body[data-aos-delay="200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="200"]{transition-delay:0s}body[data-aos-delay="200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="200"].aos-animate{transition-delay:200ms}body[data-aos-duration="250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="250"]{transition-duration:250ms}body[data-aos-delay="250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="250"]{transition-delay:0s}body[data-aos-delay="250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="250"].aos-animate{transition-delay:250ms}body[data-aos-duration="300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="300"]{transition-duration:300ms}body[data-aos-delay="300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="300"]{transition-delay:0s}body[data-aos-delay="300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="300"].aos-animate{transition-delay:300ms}body[data-aos-duration="350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="350"]{transition-duration:350ms}body[data-aos-delay="350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="350"]{transition-delay:0s}body[data-aos-delay="350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="350"].aos-animate{transition-delay:350ms}body[data-aos-duration="400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="400"]{transition-duration:400ms}body[data-aos-delay="400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="400"]{transition-delay:0s}body[data-aos-delay="400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="400"].aos-animate{transition-delay:400ms}body[data-aos-duration="450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="450"]{transition-duration:450ms}body[data-aos-delay="450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="450"]{transition-delay:0s}body[data-aos-delay="450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="450"].aos-animate{transition-delay:450ms}body[data-aos-duration="500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="500"]{transition-duration:500ms}body[data-aos-delay="500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="500"]{transition-delay:0s}body[data-aos-delay="500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="500"].aos-animate{transition-delay:500ms}body[data-aos-duration="550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="550"]{transition-duration:550ms}body[data-aos-delay="550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="550"]{transition-delay:0s}body[data-aos-delay="550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="550"].aos-animate{transition-delay:550ms}body[data-aos-duration="600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="600"]{transition-duration:600ms}body[data-aos-delay="600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="600"]{transition-delay:0s}body[data-aos-delay="600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="600"].aos-animate{transition-delay:600ms}body[data-aos-duration="650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="650"]{transition-duration:650ms}body[data-aos-delay="650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="650"]{transition-delay:0s}body[data-aos-delay="650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="650"].aos-animate{transition-delay:650ms}body[data-aos-duration="700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="700"]{transition-duration:700ms}body[data-aos-delay="700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="700"]{transition-delay:0s}body[data-aos-delay="700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="700"].aos-animate{transition-delay:700ms}body[data-aos-duration="750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="750"]{transition-duration:750ms}body[data-aos-delay="750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="750"]{transition-delay:0s}body[data-aos-delay="750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="750"].aos-animate{transition-delay:750ms}body[data-aos-duration="800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="800"]{transition-duration:800ms}body[data-aos-delay="800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="800"]{transition-delay:0s}body[data-aos-delay="800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="800"].aos-animate{transition-delay:800ms}body[data-aos-duration="850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="850"]{transition-duration:850ms}body[data-aos-delay="850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="850"]{transition-delay:0s}body[data-aos-delay="850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="850"].aos-animate{transition-delay:850ms}body[data-aos-duration="900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="900"]{transition-duration:900ms}body[data-aos-delay="900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="900"]{transition-delay:0s}body[data-aos-delay="900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="900"].aos-animate{transition-delay:900ms}body[data-aos-duration="950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="950"]{transition-duration:950ms}body[data-aos-delay="950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="950"]{transition-delay:0s}body[data-aos-delay="950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="950"].aos-animate{transition-delay:950ms}body[data-aos-duration="1000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1000"]{transition-duration:1000ms}body[data-aos-delay="1000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1000"]{transition-delay:0s}body[data-aos-delay="1000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1000"].aos-animate{transition-delay:1000ms}body[data-aos-duration="1050"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1050"]{transition-duration:1050ms}body[data-aos-delay="1050"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1050"]{transition-delay:0s}body[data-aos-delay="1050"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1050"].aos-animate{transition-delay:1050ms}body[data-aos-duration="1100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1100"]{transition-duration:1100ms}body[data-aos-delay="1100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1100"]{transition-delay:0s}body[data-aos-delay="1100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1100"].aos-animate{transition-delay:1100ms}body[data-aos-duration="1150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1150"]{transition-duration:1150ms}body[data-aos-delay="1150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1150"]{transition-delay:0s}body[data-aos-delay="1150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1150"].aos-animate{transition-delay:1150ms}body[data-aos-duration="1200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1200"]{transition-duration:1200ms}body[data-aos-delay="1200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1200"]{transition-delay:0s}body[data-aos-delay="1200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1200"].aos-animate{transition-delay:1200ms}body[data-aos-duration="1250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1250"]{transition-duration:1250ms}body[data-aos-delay="1250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1250"]{transition-delay:0s}body[data-aos-delay="1250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1250"].aos-animate{transition-delay:1250ms}body[data-aos-duration="1300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1300"]{transition-duration:1300ms}body[data-aos-delay="1300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1300"]{transition-delay:0s}body[data-aos-delay="1300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1300"].aos-animate{transition-delay:1300ms}body[data-aos-duration="1350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1350"]{transition-duration:1350ms}body[data-aos-delay="1350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1350"]{transition-delay:0s}body[data-aos-delay="1350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1350"].aos-animate{transition-delay:1350ms}body[data-aos-duration="1400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1400"]{transition-duration:1400ms}body[data-aos-delay="1400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1400"]{transition-delay:0s}body[data-aos-delay="1400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1400"].aos-animate{transition-delay:1400ms}body[data-aos-duration="1450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1450"]{transition-duration:1450ms}body[data-aos-delay="1450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1450"]{transition-delay:0s}body[data-aos-delay="1450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1450"].aos-animate{transition-delay:1450ms}body[data-aos-duration="1500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1500"]{transition-duration:1500ms}body[data-aos-delay="1500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1500"]{transition-delay:0s}body[data-aos-delay="1500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1500"].aos-animate{transition-delay:1500ms}body[data-aos-duration="1550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1550"]{transition-duration:1550ms}body[data-aos-delay="1550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1550"]{transition-delay:0s}body[data-aos-delay="1550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1550"].aos-animate{transition-delay:1550ms}body[data-aos-duration="1600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1600"]{transition-duration:1600ms}body[data-aos-delay="1600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1600"]{transition-delay:0s}body[data-aos-delay="1600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1600"].aos-animate{transition-delay:1600ms}body[data-aos-duration="1650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1650"]{transition-duration:1650ms}body[data-aos-delay="1650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1650"]{transition-delay:0s}body[data-aos-delay="1650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1650"].aos-animate{transition-delay:1650ms}body[data-aos-duration="1700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1700"]{transition-duration:1700ms}body[data-aos-delay="1700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1700"]{transition-delay:0s}body[data-aos-delay="1700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1700"].aos-animate{transition-delay:1700ms}body[data-aos-duration="1750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1750"]{transition-duration:1750ms}body[data-aos-delay="1750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1750"]{transition-delay:0s}body[data-aos-delay="1750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1750"].aos-animate{transition-delay:1750ms}body[data-aos-duration="1800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1800"]{transition-duration:1800ms}body[data-aos-delay="1800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1800"]{transition-delay:0s}body[data-aos-delay="1800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1800"].aos-animate{transition-delay:1800ms}body[data-aos-duration="1850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1850"]{transition-duration:1850ms}body[data-aos-delay="1850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1850"]{transition-delay:0s}body[data-aos-delay="1850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1850"].aos-animate{transition-delay:1850ms}body[data-aos-duration="1900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1900"]{transition-duration:1900ms}body[data-aos-delay="1900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1900"]{transition-delay:0s}body[data-aos-delay="1900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1900"].aos-animate{transition-delay:1900ms}body[data-aos-duration="1950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="1950"]{transition-duration:1950ms}body[data-aos-delay="1950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="1950"]{transition-delay:0s}body[data-aos-delay="1950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="1950"].aos-animate{transition-delay:1950ms}body[data-aos-duration="2000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2000"]{transition-duration:2000ms}body[data-aos-delay="2000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2000"]{transition-delay:0s}body[data-aos-delay="2000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2000"].aos-animate{transition-delay:2000ms}body[data-aos-duration="2050"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2050"]{transition-duration:2050ms}body[data-aos-delay="2050"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2050"]{transition-delay:0s}body[data-aos-delay="2050"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2050"].aos-animate{transition-delay:2050ms}body[data-aos-duration="2100"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2100"]{transition-duration:2100ms}body[data-aos-delay="2100"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2100"]{transition-delay:0s}body[data-aos-delay="2100"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2100"].aos-animate{transition-delay:2100ms}body[data-aos-duration="2150"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2150"]{transition-duration:2150ms}body[data-aos-delay="2150"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2150"]{transition-delay:0s}body[data-aos-delay="2150"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2150"].aos-animate{transition-delay:2150ms}body[data-aos-duration="2200"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2200"]{transition-duration:2200ms}body[data-aos-delay="2200"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2200"]{transition-delay:0s}body[data-aos-delay="2200"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2200"].aos-animate{transition-delay:2200ms}body[data-aos-duration="2250"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2250"]{transition-duration:2250ms}body[data-aos-delay="2250"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2250"]{transition-delay:0s}body[data-aos-delay="2250"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2250"].aos-animate{transition-delay:2250ms}body[data-aos-duration="2300"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2300"]{transition-duration:2300ms}body[data-aos-delay="2300"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2300"]{transition-delay:0s}body[data-aos-delay="2300"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2300"].aos-animate{transition-delay:2300ms}body[data-aos-duration="2350"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2350"]{transition-duration:2350ms}body[data-aos-delay="2350"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2350"]{transition-delay:0s}body[data-aos-delay="2350"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2350"].aos-animate{transition-delay:2350ms}body[data-aos-duration="2400"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2400"]{transition-duration:2400ms}body[data-aos-delay="2400"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2400"]{transition-delay:0s}body[data-aos-delay="2400"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2400"].aos-animate{transition-delay:2400ms}body[data-aos-duration="2450"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2450"]{transition-duration:2450ms}body[data-aos-delay="2450"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2450"]{transition-delay:0s}body[data-aos-delay="2450"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2450"].aos-animate{transition-delay:2450ms}body[data-aos-duration="2500"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2500"]{transition-duration:2500ms}body[data-aos-delay="2500"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2500"]{transition-delay:0s}body[data-aos-delay="2500"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2500"].aos-animate{transition-delay:2500ms}body[data-aos-duration="2550"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2550"]{transition-duration:2550ms}body[data-aos-delay="2550"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2550"]{transition-delay:0s}body[data-aos-delay="2550"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2550"].aos-animate{transition-delay:2550ms}body[data-aos-duration="2600"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2600"]{transition-duration:2600ms}body[data-aos-delay="2600"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2600"]{transition-delay:0s}body[data-aos-delay="2600"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2600"].aos-animate{transition-delay:2600ms}body[data-aos-duration="2650"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2650"]{transition-duration:2650ms}body[data-aos-delay="2650"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2650"]{transition-delay:0s}body[data-aos-delay="2650"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2650"].aos-animate{transition-delay:2650ms}body[data-aos-duration="2700"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2700"]{transition-duration:2700ms}body[data-aos-delay="2700"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2700"]{transition-delay:0s}body[data-aos-delay="2700"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2700"].aos-animate{transition-delay:2700ms}body[data-aos-duration="2750"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2750"]{transition-duration:2750ms}body[data-aos-delay="2750"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2750"]{transition-delay:0s}body[data-aos-delay="2750"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2750"].aos-animate{transition-delay:2750ms}body[data-aos-duration="2800"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2800"]{transition-duration:2800ms}body[data-aos-delay="2800"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2800"]{transition-delay:0s}body[data-aos-delay="2800"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2800"].aos-animate{transition-delay:2800ms}body[data-aos-duration="2850"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2850"]{transition-duration:2850ms}body[data-aos-delay="2850"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2850"]{transition-delay:0s}body[data-aos-delay="2850"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2850"].aos-animate{transition-delay:2850ms}body[data-aos-duration="2900"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2900"]{transition-duration:2900ms}body[data-aos-delay="2900"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2900"]{transition-delay:0s}body[data-aos-delay="2900"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2900"].aos-animate{transition-delay:2900ms}body[data-aos-duration="2950"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="2950"]{transition-duration:2950ms}body[data-aos-delay="2950"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="2950"]{transition-delay:0s}body[data-aos-delay="2950"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="2950"].aos-animate{transition-delay:2950ms}body[data-aos-duration="3000"] :host [data-aos],:host [data-aos][data-aos][data-aos-duration="3000"]{transition-duration:3000ms}body[data-aos-delay="3000"] :host [data-aos],:host [data-aos][data-aos][data-aos-delay="3000"]{transition-delay:0s}body[data-aos-delay="3000"] :host [data-aos].aos-animate,:host [data-aos][data-aos][data-aos-delay="3000"].aos-animate{transition-delay:3000ms}@media (min-width: 64rem){:host{margin-top:0}}.pipeline-table{display:block;width:100%}</style><style>html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@font-face{font-family:RocheIconFont;src:url(assets/fonts/RocheIconFont.woff) format("woff"), url(assets/fonts/RocheIconFont.ttf) format("truetype"), url(assets/fonts/RocheIconFont.svg#RocheIconFont) format("svg");font-weight:400;font-style:normal}.icon-bullet::before{content:"\e03d"}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}100%{background-color:#0b41cd}}html{--background-aware-gradient-bottom-right:linear-gradient(136.47deg, #fff 35.41%, #fff7f5 58%, #bde3ff 128.14%);--background-aware-gradient-top-left:linear-gradient(121.21deg, #bde3ff -17.31%, #fff7f5 46.37%, #fff 65.87%)}.theme--story{--background-aware-gradient-bottom-right:linear-gradient(319deg, #fac9b5 -68%, #fff 52%);--background-aware-gradient-top-left:linear-gradient(140.87deg, #fac9b5 -68.64%, #fff 52.89%)}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}html{--color-interactive--primary-idle:#0b41cd;--color-interactive--secondary-idle:#f5f5f2;--color-interactive--primary-hover:#052066;--color-interactive--secondary-hover:#d7e0f7;--color-interactive--active:#5c80de;--color-interactive--focus:#0b41cd;--color-interactive--disabled:#eae8e5;--color-text--primary:#000;--color-text--secondary:#c2bab5;--color-background--default:#f5f5f2;--color-background--soft:#fff7f5;--color-background--gradient-effect:#bde3ff;--color-border--default:#aec0ee;--color-status--success:#00b458;--color-status--warning:#ffd60c;--color-status--error:#ff1f26;--color-background--footer:#fff;--color-divider--footer:#052066}.theme--story{--color-background--gradient-effect:#fac9b5;--color-divider--footer:#b22b0d}:host{width:100%}.table>div{font-family:"roche-sans";width:100%;margin-top:1.5rem;overflow-x:auto;display:block}.table__header{background:transparent;position:relative;display:grid}@media (min-width: 20rem){.table__header{grid-template-columns:1fr 1fr}}@media (min-width: 48rem){.table__header{grid-template-columns:24% 21% 30% 15% 10%}}.table__headline{font-family:"roche-sans";font-style:normal;font-weight:200;font-weight:400;font-size:1rem;line-height:1.3125rem;vertical-align:bottom;text-transform:capitalize}@media (min-width: 48rem){.table__headline{font-size:1.125rem;line-height:1.4375rem}}.table__headline--sortable{position:relative;}.table__headline--sortable:hover roche-icon{fill:var(--color-interactive--primary-hover)}.table__headline--sortable__item{cursor:pointer}.table__headline--sortable roche-icon{position:absolute;right:0.625rem;bottom:1.4375rem;fill:var(--color-interactive--primary-idle)}.table__headline--sortable roche-icon:hover{fill:var(--color-interactive--primary-hover)}roche-table-sort-header[appearance=pipeline] .table__headline{font-family:"roche-sans";font-style:normal;font-weight:200;font-weight:400;font-size:0.875rem;line-height:1.1875rem;vertical-align:top;padding:1rem calc(1rem / 2);color:#544f4f;border-bottom:1px solid #eae8e5;}roche-table-sort-header[appearance=pipeline] .table__headline--sortable span{display:flex}roche-table-sort-header[appearance=pipeline] .table__headline--sortable__item{float:left;clear:left;white-space:pre}roche-table-sort-header[appearance=pipeline] .table__headline--sortable roche-icon{bottom:2.875rem;padding:4px 0 0 4px;position:unset}@media (min-width: 20rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:last-of-type{display:flex;align-items:center;justify-content:flex-end;padding-right:1rem}}@media (min-width: 48rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:last-of-type{display:block}}roche-table-sort-header[appearance=pipeline] .table__headline--sortable:first-of-type{padding:1rem 0 1rem 0}roche-table-sort-header[appearance=pipeline] .table__headline--sortable:first-of-type .table__headline--sortable__item:last-child roche-icon{bottom:1.4375rem}@media (min-width: 48rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:nth-child(2){padding-left:1rem}}roche-table-sort-header[appearance=diagnostics] .table__header{background:transparent;position:relative;display:grid}@media (min-width: 20rem){roche-table-sort-header[appearance=diagnostics] .table__header{grid-template-columns:1fr 1fr}}@media (min-width: 64rem){roche-table-sort-header[appearance=diagnostics] .table__header{grid-template-columns:15% 15% 60% 10%}}roche-table-sort-header[appearance=diagnostics] .table__headline{font-family:"roche-sans";font-style:normal;font-weight:200;font-weight:400;font-size:0.875rem;line-height:1.1875rem;vertical-align:top;padding:1rem calc(1rem / 2) 1rem calc(1rem * 2);color:#544f4f;border-bottom:1px solid #eae8e5;}roche-table-sort-header[appearance=diagnostics] .table__headline--sortable__item{cursor:default}@media (min-width: 20rem){roche-table-sort-header[appearance=diagnostics] .table__headline:last-of-type{display:flex;align-items:center;justify-content:flex-end}}@media (min-width: 1024px){roche-table-sort-header[appearance=diagnostics] .table__headline:last-of-type{display:block}}roche-table-sort-header[appearance=diagnostics] .table__headline:first-of-type{padding:1rem 0 1rem 0}</style><link rel="icon" href="/favicon-32x32.png?v=27644c9d4a401143e26484f023b100bf" type="image/png"><link rel="manifest" href="/manifest.webmanifest" crossorigin="anonymous"><link rel="apple-touch-icon" sizes="48x48" href="/icons/icon-48x48.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="72x72" href="/icons/icon-72x72.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="96x96" href="/icons/icon-96x96.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="144x144" href="/icons/icon-144x144.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="192x192" href="/icons/icon-192x192.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="256x256" href="/icons/icon-256x256.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="384x384" href="/icons/icon-384x384.png?v=27644c9d4a401143e26484f023b100bf"><link rel="apple-touch-icon" sizes="512x512" href="/icons/icon-512x512.png?v=27644c9d4a401143e26484f023b100bf"><link rel="sitemap" type="application/xml" href="/sitemap/sitemap-index.xml"><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script src="https://connect.facebook.net/signals/config/151550135513853?v=2.9.77&amp;r=stable" async=""></script><script src="https://connect.facebook.net/signals/config/723337645254359?v=2.9.77&amp;r=stable" async=""></script><script src="https://connect.facebook.net/signals/config/864118870904956?v=2.9.77&amp;r=stable" async=""></script><script async="" src="https://connect.facebook.net/en_US/fbevents.js"></script><script type="text/javascript" async="" src="https://www.googleadservices.com/pagead/conversion_async.js"></script><script type="text/javascript" async="" src="https://static.hotjar.com/c/hotjar-1221911.js?sv=7"></script><script type="text/javascript" async="" src="https://static.ads-twitter.com/uwt.js"></script><script gtm="GTM-MS8297" type="text/javascript" async="" src="https://www.google-analytics.com/gtm/optimize.js?id=OPT-5VPXP6J"></script><script type="text/javascript" async="" src="https://snap.licdn.com/li.lms-analytics/insight.min.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MS8297"></script><script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" async="true" defer="true" data-domain-script="8831b9b2-1d9d-4efb-8a91-ddd8af0c32f4" data-document-language="true"></script><script defer="">function OptanonWrapper(){window.dispatchEvent(new CustomEvent("onetrustInitialized"))}</script><link rel="stylesheet" href="https://components-library-dot-com.cwp.roche.com/releases/latest/build/roche-component-library.css?version=1661179095599" as="style" onload="this.onload=null;this.rel=&quot;stylesheet&quot;"><script async="" defer="">document.querySelectorAll('link[href="https://components-library-dot-com.cwp.roche.com/releases/latest/build/roche-component-library.css?version=1661179095599"]').forEach((e=>e.setAttribute("onload",'this.onload=null;this.rel="stylesheet"')))</script><noscript><link rel="stylesheet" href="https://components-library-dot-com.cwp.roche.com/releases/latest/build/roche-component-library.css?version=1661179095599"></noscript><script type="module" src="https://components-library-dot-com.cwp.roche.com/releases/latest/build/roche-component-library.esm.js?version=1661179095599" async="" defer=""></script><script nomodule="" src="https://components-library-dot-com.cwp.roche.com/releases/latest/build/roche-component-library.js?version=1661179095599" async="" defer=""></script><link rel="canonical" key="https://www.roche.com/solutions/pipeline/" href="https://www.roche.com/solutions/pipeline/" data-react-helmet="true"><meta name="release-type" content="" data-react-helmet="true"><meta name="release-date" content="" data-react-helmet="true"><script src="https://cdn.cookielaw.org/scripttemplates/6.38.0/otBannerSdk.js" async="" type="text/javascript"></script><style id="onetrust-style">#onetrust-banner-sdk{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}#onetrust-banner-sdk .onetrust-vendors-list-handler{cursor:pointer;color:#1f96db;font-size:inherit;font-weight:bold;text-decoration:none;margin-left:5px}#onetrust-banner-sdk .onetrust-vendors-list-handler:hover{color:#1f96db}#onetrust-banner-sdk:focus{outline:2px solid #000;outline-offset:-2px}#onetrust-banner-sdk a:focus{outline:2px solid #000}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{outline-offset:1px}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{height:64px;width:64px}#onetrust-banner-sdk .ot-close-icon,#onetrust-pc-sdk .ot-close-icon,#ot-sync-ntfy .ot-close-icon{background-image:url("data:image/svg+xml;base64,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");background-size:contain;background-repeat:no-repeat;background-position:center;height:12px;width:12px}#onetrust-banner-sdk .powered-by-logo,#onetrust-banner-sdk .ot-pc-footer-logo a,#onetrust-pc-sdk .powered-by-logo,#onetrust-pc-sdk .ot-pc-footer-logo a,#ot-sync-ntfy .powered-by-logo,#ot-sync-ntfy .ot-pc-footer-logo a{background-size:contain;background-repeat:no-repeat;background-position:center;height:25px;width:152px;display:block;text-decoration:none;font-size:0.75em}#onetrust-banner-sdk .powered-by-logo:hover,#onetrust-banner-sdk .ot-pc-footer-logo a:hover,#onetrust-pc-sdk .powered-by-logo:hover,#onetrust-pc-sdk .ot-pc-footer-logo a:hover,#ot-sync-ntfy .powered-by-logo:hover,#ot-sync-ntfy .ot-pc-footer-logo a:hover{color:#565656}#onetrust-banner-sdk h3 *,#onetrust-banner-sdk h4 *,#onetrust-banner-sdk h6 *,#onetrust-banner-sdk button *,#onetrust-banner-sdk a[data-parent-id] *,#onetrust-pc-sdk h3 *,#onetrust-pc-sdk h4 *,#onetrust-pc-sdk h6 *,#onetrust-pc-sdk button *,#onetrust-pc-sdk a[data-parent-id] *,#ot-sync-ntfy h3 *,#ot-sync-ntfy h4 *,#ot-sync-ntfy h6 *,#ot-sync-ntfy button *,#ot-sync-ntfy a[data-parent-id] *{font-size:inherit;font-weight:inherit;color:inherit}#onetrust-banner-sdk .ot-hide,#onetrust-pc-sdk .ot-hide,#ot-sync-ntfy .ot-hide{display:none !important}#onetrust-banner-sdk button.ot-link-btn:hover,#onetrust-pc-sdk button.ot-link-btn:hover,#ot-sync-ntfy button.ot-link-btn:hover{text-decoration:underline;opacity:1}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-column{padding:0}#onetrust-pc-sdk .ot-sdk-container{padding-right:0}#onetrust-pc-sdk .ot-sdk-row{flex-direction:initial;width:100%}#onetrust-pc-sdk [type="checkbox"]:checked,#onetrust-pc-sdk [type="checkbox"]:not(:checked){pointer-events:initial}#onetrust-pc-sdk [type="checkbox"]:disabled+label::before,#onetrust-pc-sdk [type="checkbox"]:disabled+label:after,#onetrust-pc-sdk [type="checkbox"]:disabled+label{pointer-events:none;opacity:0.7}#onetrust-pc-sdk #vendor-list-content{transform:translate3d(0, 0, 0)}#onetrust-pc-sdk li input[type="checkbox"]{z-index:1}#onetrust-pc-sdk li .ot-checkbox label{z-index:2}#onetrust-pc-sdk li .ot-checkbox input[type="checkbox"]{height:auto;width:auto}#onetrust-pc-sdk li .host-title a,#onetrust-pc-sdk li .ot-host-name a,#onetrust-pc-sdk li .accordion-text,#onetrust-pc-sdk li .ot-acc-txt{z-index:2;position:relative}#onetrust-pc-sdk input{margin:3px 0.1ex}#onetrust-pc-sdk .pc-logo,#onetrust-pc-sdk .ot-pc-logo{height:60px;width:180px;background-position:center;background-size:contain;background-repeat:no-repeat}#onetrust-pc-sdk .screen-reader-only,#onetrust-pc-sdk .ot-scrn-rdr,.ot-sdk-cookie-policy .screen-reader-only,.ot-sdk-cookie-policy .ot-scrn-rdr{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}#onetrust-pc-sdk.ot-fade-in,.onetrust-pc-dark-filter.ot-fade-in,#onetrust-banner-sdk.ot-fade-in{animation-name:onetrust-fade-in;animation-duration:400ms;animation-timing-function:ease-in-out}#onetrust-pc-sdk.ot-hide{display:none !important}.onetrust-pc-dark-filter.ot-hide{display:none !important}#ot-sdk-btn.ot-sdk-show-settings,#ot-sdk-btn.optanon-show-settings{color:#68b631;border:1px solid #68b631;height:auto;white-space:normal;word-wrap:break-word;padding:0.8em 2em;font-size:0.8em;line-height:1.2;cursor:pointer;-moz-transition:0.1s ease;-o-transition:0.1s ease;-webkit-transition:1s ease;transition:0.1s ease}#ot-sdk-btn.ot-sdk-show-settings:hover,#ot-sdk-btn.optanon-show-settings:hover{color:#fff;background-color:#68b631}.onetrust-pc-dark-filter{background:rgba(0,0,0,0.5);z-index:2147483646;width:100%;height:100%;overflow:hidden;position:fixed;top:0;bottom:0;left:0}@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}.ot-cookie-label{text-decoration:underline}@media only screen and (min-width: 426px) and (max-width: 896px) and (orientation: landscape){#onetrust-pc-sdk p{font-size:0.75em}}#onetrust-banner-sdk .banner-option-input:focus+label{outline:1px solid #000;outline-style:auto}.category-vendors-list-handler+a:focus,.category-vendors-list-handler+a:focus-visible{outline:2px solid #000}#onetrust-pc-sdk .ot-userid-title{margin-top:10px}#onetrust-pc-sdk .ot-userid-title>span,#onetrust-pc-sdk .ot-userid-timestamp>span{font-weight:700}#onetrust-pc-sdk .ot-userid-desc{font-style:italic}#onetrust-pc-sdk .ot-host-desc a{pointer-events:initial}#onetrust-pc-sdk .ot-ven-hdr>p a{position:relative;z-index:2;pointer-events:initial}#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info a{margin-right:auto}
#onetrust-banner-sdk,#onetrust-pc-sdk,#ot-sdk-cookie-policy,#ot-sync-ntfy{font-size:16px}#onetrust-banner-sdk *,#onetrust-banner-sdk ::after,#onetrust-banner-sdk ::before,#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before,#ot-sdk-cookie-policy *,#ot-sdk-cookie-policy ::after,#ot-sdk-cookie-policy ::before,#ot-sync-ntfy *,#ot-sync-ntfy ::after,#ot-sync-ntfy ::before{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}#onetrust-banner-sdk div,#onetrust-banner-sdk span,#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-banner-sdk p,#onetrust-banner-sdk img,#onetrust-banner-sdk svg,#onetrust-banner-sdk button,#onetrust-banner-sdk section,#onetrust-banner-sdk a,#onetrust-banner-sdk label,#onetrust-banner-sdk input,#onetrust-banner-sdk ul,#onetrust-banner-sdk li,#onetrust-banner-sdk nav,#onetrust-banner-sdk table,#onetrust-banner-sdk thead,#onetrust-banner-sdk tr,#onetrust-banner-sdk td,#onetrust-banner-sdk tbody,#onetrust-banner-sdk .ot-main-content,#onetrust-banner-sdk .ot-toggle,#onetrust-banner-sdk #ot-content,#onetrust-banner-sdk #ot-pc-content,#onetrust-banner-sdk .checkbox,#onetrust-pc-sdk div,#onetrust-pc-sdk span,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#onetrust-pc-sdk p,#onetrust-pc-sdk img,#onetrust-pc-sdk svg,#onetrust-pc-sdk button,#onetrust-pc-sdk section,#onetrust-pc-sdk a,#onetrust-pc-sdk label,#onetrust-pc-sdk input,#onetrust-pc-sdk ul,#onetrust-pc-sdk li,#onetrust-pc-sdk nav,#onetrust-pc-sdk table,#onetrust-pc-sdk thead,#onetrust-pc-sdk tr,#onetrust-pc-sdk td,#onetrust-pc-sdk tbody,#onetrust-pc-sdk .ot-main-content,#onetrust-pc-sdk .ot-toggle,#onetrust-pc-sdk #ot-content,#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk .checkbox,#ot-sdk-cookie-policy div,#ot-sdk-cookie-policy span,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy p,#ot-sdk-cookie-policy img,#ot-sdk-cookie-policy svg,#ot-sdk-cookie-policy button,#ot-sdk-cookie-policy section,#ot-sdk-cookie-policy a,#ot-sdk-cookie-policy label,#ot-sdk-cookie-policy input,#ot-sdk-cookie-policy ul,#ot-sdk-cookie-policy li,#ot-sdk-cookie-policy nav,#ot-sdk-cookie-policy table,#ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy tr,#ot-sdk-cookie-policy td,#ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy .ot-main-content,#ot-sdk-cookie-policy .ot-toggle,#ot-sdk-cookie-policy #ot-content,#ot-sdk-cookie-policy #ot-pc-content,#ot-sdk-cookie-policy .checkbox,#ot-sync-ntfy div,#ot-sync-ntfy span,#ot-sync-ntfy h1,#ot-sync-ntfy h2,#ot-sync-ntfy h3,#ot-sync-ntfy h4,#ot-sync-ntfy h5,#ot-sync-ntfy h6,#ot-sync-ntfy p,#ot-sync-ntfy img,#ot-sync-ntfy svg,#ot-sync-ntfy button,#ot-sync-ntfy section,#ot-sync-ntfy a,#ot-sync-ntfy label,#ot-sync-ntfy input,#ot-sync-ntfy ul,#ot-sync-ntfy li,#ot-sync-ntfy nav,#ot-sync-ntfy table,#ot-sync-ntfy thead,#ot-sync-ntfy tr,#ot-sync-ntfy td,#ot-sync-ntfy tbody,#ot-sync-ntfy .ot-main-content,#ot-sync-ntfy .ot-toggle,#ot-sync-ntfy #ot-content,#ot-sync-ntfy #ot-pc-content,#ot-sync-ntfy .checkbox{font-family:inherit;font-weight:normal;-webkit-font-smoothing:auto;letter-spacing:normal;line-height:normal;padding:0;margin:0;height:auto;min-height:0;max-height:none;width:auto;min-width:0;max-width:none;border-radius:0;border:none;clear:none;float:none;position:static;bottom:auto;left:auto;right:auto;top:auto;text-align:left;text-decoration:none;text-indent:0;text-shadow:none;text-transform:none;white-space:normal;background:none;overflow:visible;vertical-align:baseline;visibility:visible;z-index:auto;box-shadow:none}#onetrust-banner-sdk label:before,#onetrust-banner-sdk label:after,#onetrust-banner-sdk .checkbox:after,#onetrust-banner-sdk .checkbox:before,#onetrust-pc-sdk label:before,#onetrust-pc-sdk label:after,#onetrust-pc-sdk .checkbox:after,#onetrust-pc-sdk .checkbox:before,#ot-sdk-cookie-policy label:before,#ot-sdk-cookie-policy label:after,#ot-sdk-cookie-policy .checkbox:after,#ot-sdk-cookie-policy .checkbox:before,#ot-sync-ntfy label:before,#ot-sync-ntfy label:after,#ot-sync-ntfy .checkbox:after,#ot-sync-ntfy .checkbox:before{content:"";content:none}
#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{position:relative;width:100%;max-width:100%;margin:0 auto;padding:0 20px;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{width:100%;float:left;box-sizing:border-box;padding:0;display:initial}@media (min-width: 400px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:90%;padding:0}}@media (min-width: 550px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:100%}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{margin-left:4%}#onetrust-banner-sdk .ot-sdk-column:first-child,#onetrust-banner-sdk .ot-sdk-columns:first-child,#onetrust-pc-sdk .ot-sdk-column:first-child,#onetrust-pc-sdk .ot-sdk-columns:first-child,#ot-sdk-cookie-policy .ot-sdk-column:first-child,#ot-sdk-cookie-policy .ot-sdk-columns:first-child{margin-left:0}#onetrust-banner-sdk .ot-sdk-two.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-two.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-two.ot-sdk-columns{width:13.3333333333%}#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-three.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-three.ot-sdk-columns{width:22%}#onetrust-banner-sdk .ot-sdk-four.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-four.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-four.ot-sdk-columns{width:30.6666666667%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eight.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eight.ot-sdk-columns{width:65.3333333333%}#onetrust-banner-sdk .ot-sdk-nine.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-nine.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-nine.ot-sdk-columns{width:74%}#onetrust-banner-sdk .ot-sdk-ten.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-ten.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-ten.ot-sdk-columns{width:82.6666666667%}#onetrust-banner-sdk .ot-sdk-eleven.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eleven.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eleven.ot-sdk-columns{width:91.3333333333%}#onetrust-banner-sdk .ot-sdk-twelve.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-twelve.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-twelve.ot-sdk-columns{width:100%;margin-left:0}}#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6{margin-top:0;font-weight:600;font-family:inherit}#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem;line-height:1.2}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem;line-height:1.25}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem;line-height:1.3}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem;line-height:1.35}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem;line-height:1.5}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem;line-height:1.6}@media (min-width: 550px){#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem}}#onetrust-banner-sdk p,#onetrust-pc-sdk p,#ot-sdk-cookie-policy p{margin:0 0 1em 0;font-family:inherit;line-height:normal}#onetrust-banner-sdk a,#onetrust-pc-sdk a,#ot-sdk-cookie-policy a{color:#565656;text-decoration:underline}#onetrust-banner-sdk a:hover,#onetrust-pc-sdk a:hover,#ot-sdk-cookie-policy a:hover{color:#565656;text-decoration:none}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{display:inline-block;height:38px;padding:0 30px;color:#555;text-align:center;font-size:0.9em;font-weight:400;line-height:38px;letter-spacing:0.01em;text-decoration:none;white-space:nowrap;background-color:transparent;border-radius:2px;border:1px solid #bbb;cursor:pointer;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-button:hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#onetrust-pc-sdk .ot-sdk-button:hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#ot-sdk-cookie-policy .ot-sdk-button:hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus{color:#333;border-color:#888;opacity:0.7}#onetrust-banner-sdk .ot-sdk-button:focus,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:focus,#onetrust-pc-sdk .ot-sdk-button:focus,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:focus,#ot-sdk-cookie-policy .ot-sdk-button:focus,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:focus{outline:2px solid #000}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-banner-sdk button.ot-sdk-button-primary,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-pc-sdk button.ot-sdk-button-primary,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary,#ot-sdk-cookie-policy button.ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary{color:#fff;background-color:#33c3f0;border-color:#33c3f0}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-banner-sdk button.ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary:hover,#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-banner-sdk button.ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="submit"].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="reset"].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type="button"].ot-sdk-button-primary:focus,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-pc-sdk button.ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary:hover,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-pc-sdk button.ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="submit"].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="reset"].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type="button"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="submit"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="reset"].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type="button"].ot-sdk-button-primary:focus{color:#fff;background-color:#1eaedb;border-color:#1eaedb}#onetrust-banner-sdk input[type="text"],#onetrust-pc-sdk input[type="text"],#ot-sdk-cookie-policy input[type="text"]{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-banner-sdk input[type="text"],#onetrust-pc-sdk input[type="text"],#ot-sdk-cookie-policy input[type="text"]{-webkit-appearance:none;-moz-appearance:none;appearance:none}#onetrust-banner-sdk input[type="text"]:focus,#onetrust-pc-sdk input[type="text"]:focus,#ot-sdk-cookie-policy input[type="text"]:focus{border:1px solid #000;outline:0}#onetrust-banner-sdk label,#onetrust-pc-sdk label,#ot-sdk-cookie-policy label{display:block;margin-bottom:0.5rem;font-weight:600}#onetrust-banner-sdk input[type="checkbox"],#onetrust-pc-sdk input[type="checkbox"],#ot-sdk-cookie-policy input[type="checkbox"]{display:inline}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{list-style:circle inside}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{padding-left:0;margin-top:0}#onetrust-banner-sdk ul ul,#onetrust-pc-sdk ul ul,#ot-sdk-cookie-policy ul ul{margin:1.5rem 0 1.5rem 3rem;font-size:90%}#onetrust-banner-sdk li,#onetrust-pc-sdk li,#ot-sdk-cookie-policy li{margin-bottom:1rem}#onetrust-banner-sdk th,#onetrust-banner-sdk td,#onetrust-pc-sdk th,#onetrust-pc-sdk td,#ot-sdk-cookie-policy th,#ot-sdk-cookie-policy td{padding:12px 15px;text-align:left;border-bottom:1px solid #e1e1e1}#onetrust-banner-sdk button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-container:after,#onetrust-banner-sdk .ot-sdk-row:after,#onetrust-pc-sdk .ot-sdk-container:after,#onetrust-pc-sdk .ot-sdk-row:after,#ot-sdk-cookie-policy .ot-sdk-container:after,#ot-sdk-cookie-policy .ot-sdk-row:after{content:"";display:table;clear:both}#onetrust-banner-sdk .ot-sdk-row,#onetrust-pc-sdk .ot-sdk-row,#ot-sdk-cookie-policy .ot-sdk-row{margin:0;max-width:none;display:block}
#onetrust-banner-sdk{box-shadow:0 0 18px rgba(0,0,0,.2)}#onetrust-banner-sdk.otFlat{position:fixed;z-index:2147483645;bottom:0;right:0;left:0;background-color:#fff;max-height:90%;overflow-x:hidden;overflow-y:auto}#onetrust-banner-sdk.otFlat.top{top:0px;bottom:auto}#onetrust-banner-sdk.otRelFont{font-size:1rem}#onetrust-banner-sdk>.ot-sdk-container{overflow:hidden}#onetrust-banner-sdk::-webkit-scrollbar{width:11px}#onetrust-banner-sdk::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-banner-sdk{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-banner-sdk #onetrust-policy{margin:1.25em 0 .625em 2em;overflow:hidden}#onetrust-banner-sdk #onetrust-policy .ot-gv-list-handler{float:left;font-size:.82em;padding:0;margin-bottom:0;border:0;line-height:normal;height:auto;width:auto}#onetrust-banner-sdk #onetrust-policy-title{font-size:1.2em;line-height:1.3;margin-bottom:10px}#onetrust-banner-sdk #onetrust-policy-text{clear:both;text-align:left;font-size:.88em;line-height:1.4}#onetrust-banner-sdk #onetrust-policy-text *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk #onetrust-policy-text a{font-weight:bold;margin-left:5px}#onetrust-banner-sdk #onetrust-policy-title,#onetrust-banner-sdk #onetrust-policy-text{color:dimgray;float:left}#onetrust-banner-sdk #onetrust-button-group-parent{min-height:1px;text-align:center}#onetrust-banner-sdk #onetrust-button-group{display:inline-block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{background-color:#68b631;color:#fff;border-color:#68b631;margin-right:1em;min-width:125px;height:auto;white-space:normal;word-break:break-word;word-wrap:break-word;padding:12px 10px;line-height:1.2;font-size:.813em;font-weight:600}#onetrust-banner-sdk #onetrust-pc-btn-handler.cookie-setting-link{background-color:#fff;border:none;color:#68b631;text-decoration:underline;padding-left:0;padding-right:0}#onetrust-banner-sdk .onetrust-close-btn-ui{width:44px;height:44px;background-size:12px;border:none;position:relative;margin:auto;padding:0}#onetrust-banner-sdk .banner_logo{display:none}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{position:absolute;top:50%;transform:translateY(-50%);left:0px}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-policy{margin-left:65px}#onetrust-banner-sdk .ot-b-addl-desc{clear:both;float:left;display:block}#onetrust-banner-sdk #banner-options{float:left;display:table;margin-right:0;margin-left:1em;width:calc(100% - 1em)}#onetrust-banner-sdk .banner-option-input{cursor:pointer;width:auto;height:auto;border:none;padding:0;padding-right:3px;margin:0 0 10px;font-size:.82em;line-height:1.4}#onetrust-banner-sdk .banner-option-input *{pointer-events:none;font-size:inherit;line-height:inherit}#onetrust-banner-sdk .banner-option-input[aria-expanded=true]~.banner-option-details{display:block;height:auto}#onetrust-banner-sdk .banner-option-input[aria-expanded=true] .ot-arrow-container{transform:rotate(90deg)}#onetrust-banner-sdk .banner-option{margin-bottom:12px;margin-left:0;border:none;float:left;padding:0}#onetrust-banner-sdk .banner-option:first-child{padding-left:2px}#onetrust-banner-sdk .banner-option:not(:first-child){padding:0;border:none}#onetrust-banner-sdk .banner-option-header{cursor:pointer;display:inline-block}#onetrust-banner-sdk .banner-option-header :first-child{color:dimgray;font-weight:bold;float:left}#onetrust-banner-sdk .banner-option-header .ot-arrow-container{display:inline-block;border-top:6px solid transparent;border-bottom:6px solid transparent;border-left:6px solid dimgray;margin-left:10px;vertical-align:middle}#onetrust-banner-sdk .banner-option-details{display:none;font-size:.83em;line-height:1.5;padding:10px 0px 5px 10px;margin-right:10px;height:0px}#onetrust-banner-sdk .banner-option-details *{font-size:inherit;line-height:inherit;color:dimgray}#onetrust-banner-sdk .ot-arrow-container,#onetrust-banner-sdk .banner-option-details{transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .ot-dpd-container{float:left}#onetrust-banner-sdk .ot-dpd-title{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-title,#onetrust-banner-sdk .ot-dpd-desc{font-size:.88em;line-height:1.4;color:dimgray}#onetrust-banner-sdk .ot-dpd-title *,#onetrust-banner-sdk .ot-dpd-desc *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text *{margin-bottom:0}#onetrust-banner-sdk.ot-iab-2 .onetrust-vendors-list-handler{display:block;margin-left:0;margin-top:5px;clear:both;margin-bottom:0;padding:0;border:0;height:auto;width:auto}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk.ot-close-btn-link{padding-top:25px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container{top:15px;transform:none;right:15px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container button{padding:0;white-space:pre-wrap;border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-dpd-desc,#onetrust-banner-sdk .ot-b-addl-desc{font-size:.813em;line-height:1.5}#onetrust-banner-sdk .ot-dpd-desc{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-desc>.ot-b-addl-desc{margin-top:10px;margin-bottom:10px;font-size:1em}@media only screen and (max-width: 425px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:6px;right:2px}#onetrust-banner-sdk #onetrust-policy{margin-left:0;margin-top:3em}#onetrust-banner-sdk #onetrust-button-group{display:block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk .onetrust-close-btn-ui{top:auto;transform:none}#onetrust-banner-sdk #onetrust-policy-title{display:inline;float:none}#onetrust-banner-sdk #banner-options{margin:0;padding:0;width:100%}}@media only screen and (min-width: 426px)and (max-width: 896px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:0;right:0}#onetrust-banner-sdk #onetrust-policy{margin-left:1em;margin-right:1em}#onetrust-banner-sdk .onetrust-close-btn-ui{top:10px;right:10px}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:95%}#onetrust-banner-sdk.ot-iab-2 #onetrust-group-container{width:100%}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-button-group-parent{padding-left:50px}#onetrust-banner-sdk #onetrust-button-group-parent{width:100%;position:relative;margin-left:0}#onetrust-banner-sdk #onetrust-button-group button{display:inline-block}#onetrust-banner-sdk #onetrust-button-group{margin-right:0;text-align:center}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler{float:left}#onetrust-banner-sdk .has-reject-all-button #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-accept-btn-handler{float:right}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group{width:calc(100% - 2em);margin-right:0}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler.cookie-setting-link{padding-left:0px;text-align:left}#onetrust-banner-sdk.ot-buttons-fw .ot-sdk-three button{width:100%;text-align:center}#onetrust-banner-sdk.ot-buttons-fw #onetrust-button-group-parent button{float:none}#onetrust-banner-sdk.ot-buttons-fw #onetrust-pc-btn-handler.cookie-setting-link{text-align:center}}@media only screen and (min-width: 550px){#onetrust-banner-sdk .banner-option:not(:first-child){border-left:1px solid #d8d8d8;padding-left:25px}}@media only screen and (min-width: 425px)and (max-width: 550px){#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group,#onetrust-banner-sdk.ot-iab-2 #onetrust-policy,#onetrust-banner-sdk.ot-iab-2 .banner-option{width:100%}}@media only screen and (min-width: 769px){#onetrust-banner-sdk #onetrust-button-group{margin-right:30%}#onetrust-banner-sdk #banner-options{margin-left:2em;margin-right:5em;margin-bottom:1.25em;width:calc(100% - 7em)}}@media only screen and (min-width: 897px)and (max-width: 1023px){#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:75%;transform:translateY(-50%)}#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;padding:0;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{position:relative;margin:0;right:-22px;top:2px}}@media only screen and (min-width: 1024px){#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{right:-12px}#onetrust-banner-sdk #onetrust-policy{margin-left:2em}#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:60%;transform:translateY(-50%)}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-title{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text,#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:1em;width:50%;border-right:1px solid #d8d8d8;padding-right:1rem}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-container{width:45%;padding-left:1rem;display:inline-block;float:none}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-title{line-height:1.7}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group-parent{left:auto;right:4%;margin-left:0}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:auto;width:30%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:60%}#onetrust-banner-sdk #onetrust-button-group{margin-right:auto}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{margin-top:1em}}@media only screen and (min-width: 890px){#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group-parent{padding-left:3%;padding-right:4%;margin-left:0}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{margin-right:0;margin-top:1.25em;width:100%}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button{width:100%;margin-bottom:5px;margin-top:5px}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type{margin-bottom:20px}}@media only screen and (min-width: 1280px){#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:55%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{width:44%;padding-left:2%;padding-right:2%}#onetrust-banner-sdk:not(.ot-iab-2).vertical-align-content #onetrust-button-group-parent{position:absolute;left:55%}}
        #onetrust-consent-sdk #onetrust-banner-sdk {background-color: #FFFFFF;}
            #onetrust-consent-sdk #onetrust-policy-title,
                    #onetrust-consent-sdk #onetrust-policy-text,
                    #onetrust-consent-sdk .ot-b-addl-desc,
                    #onetrust-consent-sdk .ot-dpd-desc,
                    #onetrust-consent-sdk .ot-dpd-title,
                    #onetrust-consent-sdk #onetrust-policy-text *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk .ot-dpd-desc *:not(.onetrust-vendors-list-handler),
                    #onetrust-consent-sdk #onetrust-banner-sdk #banner-options *,
                    #onetrust-banner-sdk .ot-cat-header {
                        color: #696969;
                    }
            #onetrust-consent-sdk #onetrust-banner-sdk .banner-option-details {
                    background-color: #E9E9E9;}
             #onetrust-consent-sdk #onetrust-banner-sdk a[href],
                    #onetrust-consent-sdk #onetrust-banner-sdk a[href] font,
                    #onetrust-consent-sdk #onetrust-banner-sdk .ot-link-btn
                        {
                            color: #3860BE;
                        }#onetrust-consent-sdk #onetrust-accept-btn-handler,
                         #onetrust-banner-sdk #onetrust-reject-all-handler {
                            background-color: #3168b6;border-color: #3168b6;
                color: #FFFFFF;
            }
            #onetrust-consent-sdk #onetrust-banner-sdk *:focus,
            #onetrust-consent-sdk #onetrust-banner-sdk:focus {
               outline-color: #000000;
               outline-width: 1px;
            }
            #onetrust-consent-sdk #onetrust-pc-btn-handler,
            #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link {
                color: #FFFFFF; border-color: #FFFFFF;
                background-color:
                #3168b6;
            }#onetrust-pc-sdk.otPcCenter{overflow:hidden;position:fixed;margin:0 auto;top:5%;right:0;left:0;width:40%;max-width:575px;min-width:575px;border-radius:2.5px;z-index:2147483647;background-color:#fff;-webkit-box-shadow:0px 2px 10px -3px #999;-moz-box-shadow:0px 2px 10px -3px #999;box-shadow:0px 2px 10px -3px #999}#onetrust-pc-sdk.otPcCenter[dir=rtl]{right:0;left:0}#onetrust-pc-sdk.otRelFont{font-size:1rem}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus,#onetrust-pc-sdk .ot-hide-tgl{visibility:hidden}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr *,#onetrust-pc-sdk #ot-addtl-venlst .ot-plus-minus *,#onetrust-pc-sdk .ot-hide-tgl *{visibility:hidden}#onetrust-pc-sdk #ot-gn-venlst .ot-ven-item .ot-acc-hdr{min-height:40px}#onetrust-pc-sdk .ot-pc-header{height:39px;padding:10px 0 10px 30px;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk #ot-pc-title,#onetrust-pc-sdk #ot-category-title,#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk #ot-lst-title,#onetrust-pc-sdk .ot-ven-hdr .ot-ven-name,#onetrust-pc-sdk .ot-always-active{font-weight:bold;color:dimgray}#onetrust-pc-sdk .ot-always-active-group .ot-cat-header{width:55%;font-weight:700}#onetrust-pc-sdk .ot-cat-item p{clear:both;float:left;margin-top:10px;margin-bottom:5px;line-height:1.5;font-size:.812em;color:dimgray}#onetrust-pc-sdk .ot-close-icon{height:44px;width:44px;background-size:10px}#onetrust-pc-sdk #ot-pc-title{float:left;font-size:1em;line-height:1.5;margin-bottom:10px;margin-top:10px;width:100%}#onetrust-pc-sdk #accept-recommended-btn-handler{margin-right:10px;margin-bottom:25px;outline-offset:-1px}#onetrust-pc-sdk #ot-pc-desc{clear:both;width:100%;font-size:.812em;line-height:1.5;margin-bottom:25px}#onetrust-pc-sdk #ot-pc-desc a{margin-left:5px}#onetrust-pc-sdk #ot-pc-desc *{font-size:inherit;line-height:inherit}#onetrust-pc-sdk #ot-pc-desc ul li{padding:10px 0px}#onetrust-pc-sdk a{color:#656565;cursor:pointer}#onetrust-pc-sdk a:hover{color:#3860be}#onetrust-pc-sdk label{margin-bottom:0}#onetrust-pc-sdk #vdr-lst-dsc{font-size:.812em;line-height:1.5;padding:10px 15px 5px 15px}#onetrust-pc-sdk button{max-width:394px;padding:12px 30px;line-height:1;word-break:break-word;word-wrap:break-word;white-space:normal;font-weight:bold;height:auto}#onetrust-pc-sdk .ot-link-btn{padding:0;margin-bottom:0;border:0;font-weight:normal;line-height:normal;width:auto;height:auto}#onetrust-pc-sdk #ot-pc-content{position:absolute;overflow-y:scroll;padding-left:0px;padding-right:30px;top:60px;bottom:110px;margin:1px 3px 0 30px;width:calc(100% - 63px)}#onetrust-pc-sdk .ot-vs-list .ot-always-active,#onetrust-pc-sdk .ot-cat-grp .ot-always-active{float:right;clear:none;color:#3860be;margin:0;font-size:.813em;line-height:1.3}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-track{margin-right:20px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar{width:11px}#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-thumb{border-radius:10px;background:#d8d8d8}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-pc-scrollbar{scrollbar-arrow-color:#d8d8d8;scrollbar-darkshadow-color:#d8d8d8;scrollbar-face-color:#d8d8d8;scrollbar-shadow-color:#d8d8d8}#onetrust-pc-sdk .save-preference-btn-handler{margin-right:20px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-right:10px}#onetrust-pc-sdk #ot-pc-desc .privacy-notice-link{margin-left:0;margin-right:8px}#onetrust-pc-sdk #ot-pc-desc .ot-imprint-handler{margin-left:0;margin-right:8px}#onetrust-pc-sdk .ot-subgrp-cntr{display:inline-block;clear:both;width:100%;padding-top:15px}#onetrust-pc-sdk .ot-switch+.ot-subgrp-cntr{padding-top:10px}#onetrust-pc-sdk ul.ot-subgrps{margin:0;font-size:initial}#onetrust-pc-sdk ul.ot-subgrps li p,#onetrust-pc-sdk ul.ot-subgrps li h5{font-size:.813em;line-height:1.4;color:dimgray}#onetrust-pc-sdk ul.ot-subgrps .ot-switch{min-height:auto}#onetrust-pc-sdk ul.ot-subgrps .ot-switch-nob{top:0}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr{display:inline-block;width:100%}#onetrust-pc-sdk ul.ot-subgrps .ot-acc-txt{margin:0}#onetrust-pc-sdk ul.ot-subgrps li{padding:0;border:none}#onetrust-pc-sdk ul.ot-subgrps li h5{position:relative;top:5px;font-weight:bold;margin-bottom:0;float:left}#onetrust-pc-sdk li.ot-subgrp{margin-left:20px;overflow:auto}#onetrust-pc-sdk li.ot-subgrp>h5{width:calc(100% - 100px)}#onetrust-pc-sdk .ot-cat-item p>ul,#onetrust-pc-sdk li.ot-subgrp p>ul{margin:0px;list-style:disc;margin-left:15px;font-size:inherit}#onetrust-pc-sdk .ot-cat-item p>ul li,#onetrust-pc-sdk li.ot-subgrp p>ul li{font-size:inherit;padding-top:10px;padding-left:0px;padding-right:0px;border:none}#onetrust-pc-sdk .ot-cat-item p>ul li:last-child,#onetrust-pc-sdk li.ot-subgrp p>ul li:last-child{padding-bottom:10px}#onetrust-pc-sdk .ot-pc-logo{height:40px;width:120px;display:inline-block}#onetrust-pc-sdk .ot-pc-footer{position:absolute;bottom:0px;width:100%;max-height:160px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-refuse-all-handler{margin-bottom:0px}#onetrust-pc-sdk.ot-ftr-stacked #ot-pc-content{bottom:160px}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-footer button{width:100%;max-width:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:0 30px;width:calc(100% - 60px);padding-right:0}#onetrust-pc-sdk .ot-pc-footer-logo{height:30px;width:100%;text-align:right;background:#f4f4f4}#onetrust-pc-sdk .ot-pc-footer-logo a{display:inline-block;margin-top:5px;margin-right:10px}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo{direction:rtl}#onetrust-pc-sdk[dir=rtl] .ot-pc-footer-logo a{margin-right:25px}#onetrust-pc-sdk .ot-tgl{float:right;position:relative;z-index:1}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background-color:#cddcf2;border:1px solid #3860be}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{-webkit-transform:translateX(20px);-ms-transform:translateX(20px);transform:translateX(20px);background-color:#3860be;border-color:#3860be}#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch{outline:#000 solid 1px}#onetrust-pc-sdk .ot-switch{position:relative;display:inline-block;width:45px;height:25px}#onetrust-pc-sdk .ot-switch-nob{position:absolute;cursor:pointer;top:0;left:0;right:0;bottom:0;background-color:#f2f1f1;border:1px solid #ddd;transition:all .2s ease-in 0s;-moz-transition:all .2s ease-in 0s;-o-transition:all .2s ease-in 0s;-webkit-transition:all .2s ease-in 0s;border-radius:20px}#onetrust-pc-sdk .ot-switch-nob:before{position:absolute;content:"";height:21px;width:21px;bottom:1px;background-color:#7d7d7d;-webkit-transition:.4s;transition:.4s;border-radius:20px}#onetrust-pc-sdk .ot-chkbox input:checked~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk .ot-chkbox label{position:relative;display:inline-block;padding-left:30px;cursor:pointer;font-weight:500}#onetrust-pc-sdk .ot-chkbox label::before,#onetrust-pc-sdk .ot-chkbox label::after{position:absolute;content:"";display:inline-block;border-radius:3px}#onetrust-pc-sdk .ot-chkbox label::before{height:18px;width:18px;border:1px solid #3860be;left:0px;top:auto}#onetrust-pc-sdk .ot-chkbox label::after{height:5px;width:9px;border-left:3px solid;border-bottom:3px solid;transform:rotate(-45deg);-o-transform:rotate(-45deg);-ms-transform:rotate(-45deg);-webkit-transform:rotate(-45deg);left:4px;top:5px}#onetrust-pc-sdk .ot-label-txt{display:none}#onetrust-pc-sdk .ot-chkbox input,#onetrust-pc-sdk .ot-tgl input{position:absolute;opacity:0;width:0;height:0}#onetrust-pc-sdk .ot-arw-cntr{float:right;position:relative;pointer-events:none}#onetrust-pc-sdk .ot-arw-cntr .ot-arw{width:16px;height:16px;margin-left:5px;color:dimgray;display:inline-block;vertical-align:middle;-webkit-transition:all 150ms ease-in 0s;-moz-transition:all 150ms ease-in 0s;-o-transition:all 150ms ease-in 0s;transition:all 150ms ease-in 0s}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw-cntr svg{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk input[type=checkbox]:focus+.ot-acc-hdr{outline:#000 1px solid}#onetrust-pc-sdk .ot-tgl-cntr,#onetrust-pc-sdk .ot-arw-cntr{display:inline-block}#onetrust-pc-sdk .ot-tgl-cntr{width:45px;float:right;margin-top:2px}#onetrust-pc-sdk #ot-lst-cnt .ot-tgl-cntr{margin-top:10px}#onetrust-pc-sdk .ot-always-active-subgroup{width:auto;padding-left:0px !important;top:3px;position:relative}#onetrust-pc-sdk .ot-label-status{padding-left:5px;font-size:.75em;display:none}#onetrust-pc-sdk .ot-arw-cntr{margin-top:-1px}#onetrust-pc-sdk .ot-arw-cntr svg{-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s;transition:all 300ms ease-in 0s;height:10px;width:10px}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk .ot-arw{width:10px;margin-left:15px;transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0}#onetrust-pc-sdk .ot-hlst-cntr{margin-top:5px;display:inline-block;width:100%}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{clear:both;color:#3860be;margin-left:0;font-size:.813em;text-decoration:none;float:left;overflow:hidden}#onetrust-pc-sdk .category-vendors-list-handler:hover,#onetrust-pc-sdk .category-vendors-list-handler+a:hover,#onetrust-pc-sdk .category-host-list-handler:hover{text-decoration-line:underline}#onetrust-pc-sdk .category-vendors-list-handler+a{clear:none}#onetrust-pc-sdk .category-vendors-list-handler+a::after{content:"";height:15px;width:15px;background-repeat:no-repeat;margin-left:5px;float:right;background-image:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 511.626 511.627'%3E%3Cg fill='%231276CE'%3E%3Cpath d='M392.857 292.354h-18.274c-2.669 0-4.859.855-6.563 2.573-1.718 1.708-2.573 3.897-2.573 6.563v91.361c0 12.563-4.47 23.315-13.415 32.262-8.945 8.945-19.701 13.414-32.264 13.414H82.224c-12.562 0-23.317-4.469-32.264-13.414-8.945-8.946-13.417-19.698-13.417-32.262V155.31c0-12.562 4.471-23.313 13.417-32.259 8.947-8.947 19.702-13.418 32.264-13.418h200.994c2.669 0 4.859-.859 6.57-2.57 1.711-1.713 2.566-3.9 2.566-6.567V82.221c0-2.662-.855-4.853-2.566-6.563-1.711-1.713-3.901-2.568-6.57-2.568H82.224c-22.648 0-42.016 8.042-58.102 24.125C8.042 113.297 0 132.665 0 155.313v237.542c0 22.647 8.042 42.018 24.123 58.095 16.086 16.084 35.454 24.13 58.102 24.13h237.543c22.647 0 42.017-8.046 58.101-24.13 16.085-16.077 24.127-35.447 24.127-58.095v-91.358c0-2.669-.856-4.859-2.574-6.57-1.713-1.718-3.903-2.573-6.565-2.573z'/%3E%3Cpath d='M506.199 41.971c-3.617-3.617-7.905-5.424-12.85-5.424H347.171c-4.948 0-9.233 1.807-12.847 5.424-3.617 3.615-5.428 7.898-5.428 12.847s1.811 9.233 5.428 12.85l50.247 50.248-186.147 186.151c-1.906 1.903-2.856 4.093-2.856 6.563 0 2.479.953 4.668 2.856 6.571l32.548 32.544c1.903 1.903 4.093 2.852 6.567 2.852s4.665-.948 6.567-2.852l186.148-186.148 50.251 50.248c3.614 3.617 7.898 5.426 12.847 5.426s9.233-1.809 12.851-5.426c3.617-3.616 5.424-7.898 5.424-12.847V54.818c-.001-4.952-1.814-9.232-5.428-12.847z'/%3E%3C/g%3E%3C/svg%3E")}#onetrust-pc-sdk .back-btn-handler{font-size:1em;text-decoration:none}#onetrust-pc-sdk .back-btn-handler:hover{opacity:.6}#onetrust-pc-sdk #ot-lst-title h3{display:inline-block;word-break:break-word;word-wrap:break-word;margin-bottom:0;color:#656565;font-size:1em;font-weight:bold;margin-left:15px}#onetrust-pc-sdk #ot-lst-title{margin:10px 0 10px 0px;font-size:1em;text-align:left}#onetrust-pc-sdk #ot-pc-hdr{margin:0 0 0 30px;height:auto;width:auto}#onetrust-pc-sdk #ot-pc-hdr input::placeholder{color:#d4d4d4;font-style:italic}#onetrust-pc-sdk #vendor-search-handler{height:31px;width:100%;border-radius:50px;font-size:.8em;padding-right:35px;padding-left:15px;float:left;margin-left:15px}#onetrust-pc-sdk .ot-ven-name{display:block;width:auto;padding-right:5px}#onetrust-pc-sdk #ot-lst-cnt{overflow-y:auto;margin-left:20px;margin-right:7px;width:calc(100% - 27px);max-height:calc(100% - 80px);height:100%;transform:translate3d(0, 0, 0)}#onetrust-pc-sdk #ot-pc-lst{width:100%;bottom:100px;position:absolute;top:60px}#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr .ot-arw-cntr *{visibility:hidden}#onetrust-pc-sdk #ot-pc-lst .ot-tgl-cntr{right:12px;position:absolute}#onetrust-pc-sdk #ot-pc-lst .ot-arw-cntr{float:right;position:relative}#onetrust-pc-sdk #ot-pc-lst .ot-arw{margin-left:10px}#onetrust-pc-sdk #ot-pc-lst .ot-acc-hdr{overflow:hidden;cursor:pointer}#onetrust-pc-sdk .ot-vlst-cntr{overflow:hidden}#onetrust-pc-sdk #ot-sel-blk{overflow:hidden;width:100%;position:sticky;position:-webkit-sticky;top:0;z-index:3}#onetrust-pc-sdk #ot-back-arw{height:12px;width:12px}#onetrust-pc-sdk .ot-lst-subhdr{width:100%;display:inline-block}#onetrust-pc-sdk .ot-search-cntr{float:left;width:78%;position:relative}#onetrust-pc-sdk .ot-search-cntr>svg{width:30px;height:30px;position:absolute;float:left;right:-15px}#onetrust-pc-sdk .ot-fltr-cntr{float:right;right:50px;position:relative}#onetrust-pc-sdk #filter-btn-handler{background-color:#3860be;border-radius:17px;display:inline-block;position:relative;width:32px;height:32px;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease;padding:0;margin:0}#onetrust-pc-sdk #filter-btn-handler:hover{background-color:#3860be}#onetrust-pc-sdk #filter-btn-handler svg{width:12px;height:12px;margin:3px 10px 0 10px;display:block;position:static;right:auto;top:auto}#onetrust-pc-sdk .ot-ven-link{color:#3860be;text-decoration:none;font-weight:100;display:inline-block;padding-top:10px;transform:translate(0, 1%);-o-transform:translate(0, 1%);-ms-transform:translate(0, 1%);-webkit-transform:translate(0, 1%);position:relative;z-index:2}#onetrust-pc-sdk .ot-ven-link *{font-size:inherit}#onetrust-pc-sdk .ot-ven-link:hover{text-decoration:underline}#onetrust-pc-sdk .ot-ven-hdr{width:calc(100% - 160px);height:auto;float:left;word-break:break-word;word-wrap:break-word;vertical-align:middle;padding-bottom:3px}#onetrust-pc-sdk .ot-ven-link{letter-spacing:.03em;font-size:.75em;font-weight:400}#onetrust-pc-sdk .ot-ven-dets{border-radius:2px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-ven-dets li:first-child p:first-child{border-top:none}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:not(:first-child){border-top:1px solid #e9e9e9}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(odd){width:30%}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(even){width:50%;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p,#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h4{padding-top:5px;padding-bottom:5px;display:block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h4{display:inline-block}#onetrust-pc-sdk .ot-ven-dets p,#onetrust-pc-sdk .ot-ven-dets h4,#onetrust-pc-sdk .ot-ven-dets span{font-size:.69em;text-align:left;vertical-align:middle;word-break:break-word;word-wrap:break-word;margin:0;padding-bottom:10px;padding-left:15px;color:#2e3644}#onetrust-pc-sdk .ot-ven-dets h4{padding-top:5px}#onetrust-pc-sdk .ot-ven-dets span{color:dimgray;padding:0;vertical-align:baseline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-pur h4{border-top:1px solid #e9e9e9;border-bottom:1px solid #e9e9e9;padding-bottom:5px;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk #ot-host-lst .ot-sel-all{float:right;position:relative;margin-right:42px;top:10px}#onetrust-pc-sdk #ot-host-lst .ot-sel-all input[type=checkbox]{width:auto;height:auto}#onetrust-pc-sdk #ot-host-lst .ot-sel-all label{height:20px;width:20px;padding-left:0px}#onetrust-pc-sdk #ot-host-lst .ot-acc-txt{overflow:hidden;width:95%}#onetrust-pc-sdk .ot-host-hdr{position:relative;z-index:1;pointer-events:none;width:calc(100% - 125px);float:left}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-desc{display:inline-block;width:90%}#onetrust-pc-sdk .ot-host-name{pointer-events:none}#onetrust-pc-sdk .ot-host-hdr>a{text-decoration:underline;font-size:.82em;position:relative;z-index:2;float:left;margin-bottom:5px;pointer-events:initial}#onetrust-pc-sdk .ot-host-name+a{margin-top:5px}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a,#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{color:dimgray;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-name,#onetrust-pc-sdk .ot-host-name a{font-weight:bold;font-size:.82em;line-height:1.3}#onetrust-pc-sdk .ot-host-name a{font-size:1em}#onetrust-pc-sdk .ot-host-expand{margin-top:3px;margin-bottom:3px;clear:both;display:block;color:#3860be;font-size:.72em;font-weight:normal}#onetrust-pc-sdk .ot-host-expand *{font-size:inherit}#onetrust-pc-sdk .ot-host-desc,#onetrust-pc-sdk .ot-host-info{font-size:.688em;line-height:1.4;font-weight:normal}#onetrust-pc-sdk .ot-host-desc{margin-top:10px}#onetrust-pc-sdk .ot-host-opt{margin:0;font-size:inherit;display:inline-block;width:100%}#onetrust-pc-sdk .ot-host-opt li>div div{font-size:.8em;padding:5px 0}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(1){width:30%;float:left}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(2){width:70%;float:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-host-info{border:none;display:inline-block;width:calc(100% - 10px);padding:10px;margin-bottom:10px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-host-info>div{overflow:auto}#onetrust-pc-sdk #no-results{text-align:center;margin-top:30px}#onetrust-pc-sdk #no-results p{font-size:1em;color:#2e3644;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #no-results p span{font-weight:bold}#onetrust-pc-sdk #ot-fltr-modal{width:100%;height:auto;display:none;-moz-transition:.2s ease;-o-transition:.2s ease;-webkit-transition:2s ease;transition:.2s ease;overflow:hidden;opacity:1;right:0}#onetrust-pc-sdk #ot-fltr-modal .ot-label-txt{display:inline-block;font-size:.85em;color:dimgray}#onetrust-pc-sdk #ot-fltr-cnt{z-index:2147483646;background-color:#fff;position:absolute;height:90%;max-height:300px;width:325px;left:210px;margin-top:10px;margin-bottom:20px;padding-right:10px;border-radius:3px;-webkit-box-shadow:0px 0px 12px 2px #c7c5c7;-moz-box-shadow:0px 0px 12px 2px #c7c5c7;box-shadow:0px 0px 12px 2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-scrlcnt{overflow-y:auto;overflow-x:hidden;clear:both;max-height:calc(100% - 60px)}#onetrust-pc-sdk #ot-anchor{border:12px solid transparent;display:none;position:absolute;z-index:2147483647;right:55px;top:75px;transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);-webkit-transform:rotate(45deg);background-color:#fff;-webkit-box-shadow:-3px -3px 5px -2px #c7c5c7;-moz-box-shadow:-3px -3px 5px -2px #c7c5c7;box-shadow:-3px -3px 5px -2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-btns{margin-left:15px}#onetrust-pc-sdk #filter-apply-handler{margin-right:15px}#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:25px;margin-left:15px;width:75%;position:relative}#onetrust-pc-sdk .ot-fltr-opt p{display:inline-block;margin:0;font-size:.9em;color:#2e3644}#onetrust-pc-sdk .ot-chkbox label span{font-size:.85em;color:dimgray}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:checked+label::after{content:""}#onetrust-pc-sdk .ot-chkbox input[type=checkbox]:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk #ot-selall-vencntr,#onetrust-pc-sdk #ot-selall-adtlvencntr,#onetrust-pc-sdk #ot-selall-hostcntr,#onetrust-pc-sdk #ot-selall-licntr,#onetrust-pc-sdk #ot-selall-gnvencntr{right:15px;position:relative;width:20px;height:20px;float:right}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label,#onetrust-pc-sdk #ot-selall-gnvencntr label{float:left;padding-left:0}#onetrust-pc-sdk #ot-ven-lst:first-child{border-top:1px solid #e2e2e2}#onetrust-pc-sdk ul{list-style:none;padding:0}#onetrust-pc-sdk ul li{position:relative;margin:0;padding:15px 15px 15px 10px;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk ul li h3{font-size:.75em;color:#656565;margin:0;display:inline-block;width:70%;height:auto;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk ul li p{margin:0;font-size:.7em}#onetrust-pc-sdk ul li input[type=checkbox]{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0}#onetrust-pc-sdk .ot-cat-item>button:focus,#onetrust-pc-sdk .ot-acc-cntr>button:focus,#onetrust-pc-sdk li>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-cat-item>button,#onetrust-pc-sdk .ot-acc-cntr>button,#onetrust-pc-sdk li>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-cat-item>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-grpcntr,#onetrust-pc-sdk li>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-host-item>button:focus,#onetrust-pc-sdk .ot-ven-item>button:focus{outline:0;border:2px solid #000}#onetrust-pc-sdk .ot-hide-acc>button{pointer-events:none}#onetrust-pc-sdk .ot-hide-acc .ot-plus-minus>*,#onetrust-pc-sdk .ot-hide-acc .ot-arw-cntr>*{visibility:hidden}#onetrust-pc-sdk .ot-hide-acc .ot-acc-hdr{min-height:30px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt){padding-right:10px;width:calc(100% - 37px);margin-top:10px;max-height:calc(100% - 90px)}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk{background-color:#f9f9fc;border:1px solid #e2e2e2;width:calc(100% - 2px);padding-bottom:5px;padding-top:5px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt{border:unset;background-color:unset}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all-hdr{display:none}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all{padding-right:.5rem}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk.ot-vnd-list-cnt .ot-sel-all .ot-chkbox{right:0}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all{padding-right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-chkbox{width:auto}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) ul li{border:1px solid #e2e2e2;margin-bottom:10px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-acc-cntr>.ot-acc-hdr{padding:10px 0 10px 15px}#onetrust-pc-sdk.ot-addtl-vendors .ot-sel-all-chkbox{float:right}#onetrust-pc-sdk.ot-addtl-vendors .ot-plus-minus~.ot-sel-all-chkbox{right:34px}#onetrust-pc-sdk.ot-addtl-vendors #ot-ven-lst:first-child{border-top:none}#onetrust-pc-sdk .ot-acc-cntr{position:relative;border-left:1px solid #e2e2e2;border-right:1px solid #e2e2e2;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr input{z-index:1}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr{background-color:#f9f9fc;padding:5px 0 5px 15px;width:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-plus-minus{vertical-align:middle;top:auto}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr .ot-arw-cntr{right:10px}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-hdr input{z-index:2}#onetrust-pc-sdk .ot-acc-cntr>input[type=checkbox]:checked~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk .ot-acc-cntr>.ot-acc-txt{padding-left:10px;padding-right:10px}#onetrust-pc-sdk .ot-acc-cntr button[aria-expanded=true]~.ot-acc-txt{width:auto}#onetrust-pc-sdk .ot-acc-cntr .ot-addtl-venbox{display:none}#onetrust-pc-sdk .ot-vlst-cntr{margin-bottom:0;width:100%}#onetrust-pc-sdk .ot-vensec-title{font-size:.813em;vertical-align:middle;display:inline-block}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a{margin-left:0;margin-top:10px}#onetrust-pc-sdk #ot-selall-vencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-adtlvencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-licntr.line-through label::after,#onetrust-pc-sdk #ot-selall-hostcntr.line-through label::after,#onetrust-pc-sdk #ot-selall-gnvencntr.line-through label::after{height:auto;border-left:0;transform:none;-o-transform:none;-ms-transform:none;-webkit-transform:none;left:5px;top:9px}#onetrust-pc-sdk #ot-category-title{float:left;padding-bottom:10px;font-size:1em;width:100%}#onetrust-pc-sdk .ot-cat-grp{margin-top:10px}#onetrust-pc-sdk .ot-cat-item{line-height:1.1;margin-top:10px;display:inline-block;width:100%}#onetrust-pc-sdk .ot-btn-container{text-align:right}#onetrust-pc-sdk .ot-btn-container button{display:inline-block;font-size:.75em;letter-spacing:.08em;margin-top:19px}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon{position:absolute;top:10px;right:0;z-index:1;padding:0;background-color:transparent;border:none}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon svg{display:block;height:10px;width:10px}#onetrust-pc-sdk #clear-filters-handler{margin-top:20px;margin-bottom:10px;float:right;max-width:200px;text-decoration:none;color:#3860be;font-size:.9em;font-weight:bold;background-color:transparent;border-color:transparent;padding:1px}#onetrust-pc-sdk #clear-filters-handler:hover{color:#2285f7}#onetrust-pc-sdk #clear-filters-handler:focus{outline:#000 solid 1px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl,#onetrust-pc-sdk .ot-enbl-chr h4~.ot-always-active{right:45px}#onetrust-pc-sdk .ot-enbl-chr h4~.ot-tgl+.ot-tgl{right:120px}#onetrust-pc-sdk .ot-enbl-chr .ot-pli-hdr.ot-leg-border-color span:first-child{width:90px}#onetrust-pc-sdk .ot-enbl-chr li.ot-subgrp>h5+.ot-tgl-cntr{padding-right:25px}#onetrust-pc-sdk .ot-plus-minus{width:20px;height:20px;font-size:1.5em;position:relative;display:inline-block;margin-right:5px;top:3px}#onetrust-pc-sdk .ot-plus-minus span{position:absolute;background:#27455c;border-radius:1px}#onetrust-pc-sdk .ot-plus-minus span:first-of-type{top:25%;bottom:25%;width:10%;left:45%}#onetrust-pc-sdk .ot-plus-minus span:last-of-type{left:25%;right:25%;height:10%;top:45%}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:first-of-type,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{transform:rotate(90deg)}#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-plus-minus span:last-of-type{left:50%;right:50%}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label,#onetrust-pc-sdk #ot-selall-hostcntr label,#onetrust-pc-sdk #ot-selall-licntr label{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk .ot-host-item .ot-plus-minus,#onetrust-pc-sdk .ot-ven-item .ot-plus-minus{float:left;margin-right:8px;top:10px}#onetrust-pc-sdk .ot-ven-item ul{list-style:none inside;font-size:100%;margin:0}#onetrust-pc-sdk .ot-ven-item ul li{margin:0 !important;padding:0;border:none !important}#onetrust-pc-sdk .ot-pli-hdr{color:#77808e;overflow:hidden;padding-top:7.5px;padding-bottom:7.5px;width:calc(100% - 2px);border-top-left-radius:3px;border-top-right-radius:3px}#onetrust-pc-sdk .ot-pli-hdr span:first-child{top:50%;transform:translateY(50%);max-width:90px}#onetrust-pc-sdk .ot-pli-hdr span:last-child{padding-right:10px;max-width:95px;text-align:center}#onetrust-pc-sdk .ot-li-title{float:right;font-size:.813em}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color{background-color:#f4f4f4;border:1px solid #d8d8d8}#onetrust-pc-sdk .ot-pli-hdr.ot-leg-border-color span:first-child{text-align:left;width:70px}#onetrust-pc-sdk li.ot-subgrp>h5,#onetrust-pc-sdk .ot-cat-header{width:calc(100% - 130px)}#onetrust-pc-sdk li.ot-subgrp>h5+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-acc-grpdesc{margin-bottom:5px}#onetrust-pc-sdk .ot-acc-grpcntr .ot-subgrp-cntr{border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-acc-grpcntr .ot-vlst-cntr+.ot-subgrp-cntr{border-top:none}#onetrust-pc-sdk .ot-acc-hdr .ot-arw-cntr+.ot-tgl-cntr,#onetrust-pc-sdk .ot-acc-txt h4+.ot-tgl-cntr{padding-left:13px}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-subgrp>h5,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header{width:calc(100% - 145px)}#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item h5+.ot-tgl-cntr,#onetrust-pc-sdk .ot-pli-hdr~.ot-cat-item .ot-cat-header+.ot-tgl{padding-left:28px}#onetrust-pc-sdk .ot-sel-all-hdr,#onetrust-pc-sdk .ot-sel-all-chkbox{display:inline-block;width:100%;position:relative}#onetrust-pc-sdk .ot-sel-all-chkbox{z-index:1}#onetrust-pc-sdk .ot-sel-all{margin:0;position:relative;padding-right:23px;float:right}#onetrust-pc-sdk .ot-consent-hdr,#onetrust-pc-sdk .ot-li-hdr{float:right;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-li-hdr{max-width:100px;padding-right:10px}#onetrust-pc-sdk .ot-consent-hdr{max-width:55px}#onetrust-pc-sdk #ot-selall-licntr{display:block;width:21px;height:auto;float:right;position:relative;right:80px}#onetrust-pc-sdk #ot-selall-licntr label{position:absolute}#onetrust-pc-sdk .ot-ven-ctgl{margin-left:66px}#onetrust-pc-sdk .ot-ven-litgl+.ot-arw-cntr{margin-left:81px}#onetrust-pc-sdk .ot-enbl-chr .ot-host-cnt .ot-tgl-cntr{width:auto}#onetrust-pc-sdk #ot-lst-cnt:not(.ot-host-cnt) .ot-tgl-cntr{width:auto;top:auto;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox{position:relative;display:inline-block;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-chkbox label{position:absolute;padding:0;width:20px;height:20px}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-acc-grpdesc+.ot-leg-btn-container{padding-left:20px;padding-right:20px;width:calc(100% - 40px);margin-bottom:5px}#onetrust-pc-sdk .ot-subgrp .ot-leg-btn-container{margin-bottom:5px}#onetrust-pc-sdk #ot-ven-lst .ot-leg-btn-container{margin-top:10px}#onetrust-pc-sdk .ot-leg-btn-container{display:inline-block;width:100%;margin-bottom:10px}#onetrust-pc-sdk .ot-leg-btn-container button{height:auto;padding:6.5px 8px;margin-bottom:0;letter-spacing:0;font-size:.75em;line-height:normal}#onetrust-pc-sdk .ot-leg-btn-container svg{display:none;height:14px;width:14px;padding-right:5px;vertical-align:sub}#onetrust-pc-sdk .ot-active-leg-btn{cursor:default;pointer-events:none}#onetrust-pc-sdk .ot-active-leg-btn svg{display:inline-block}#onetrust-pc-sdk .ot-remove-objection-handler{text-decoration:underline;padding:0;font-size:.75em;font-weight:600;line-height:1;padding-left:10px}#onetrust-pc-sdk .ot-obj-leg-btn-handler span{font-weight:bold;text-align:center;font-size:inherit;line-height:1.5}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;background:none;right:15px;top:15px;width:auto;font-weight:normal}#onetrust-pc-sdk .ot-cat-header{float:left;font-weight:600;font-size:.875em;line-height:1.5;max-width:90%;vertical-align:middle}#onetrust-pc-sdk .ot-vnd-item>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-vnd-item>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:2px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;width:calc(100% - 2px);float:left}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc{padding-left:20px;padding-right:20px;width:calc(100% - 40px);font-size:.812em;margin-bottom:10px;margin-top:15px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul{padding-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpdesc>ul li{padding-top:0;line-height:1.5;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout div+.ot-acc-grpdesc{margin-top:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:first-child{margin-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:last-child,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr:last-child{margin-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:20px;width:calc(100% - 40px);display:inline-block}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr{padding-left:20px;padding-right:15px;padding-bottom:0;width:calc(100% - 35px)}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp{padding-right:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%);right:20px;margin-top:-2px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr .ot-arw{width:15px;height:20px;margin-left:5px;color:dimgray}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{position:absolute;top:50%;transform:translateY(-50%);right:20px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:95px}#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler,#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler+a{margin-top:5px}#onetrust-pc-sdk #ot-lst-cnt{margin-top:1rem;max-height:calc(100% - 96px)}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list,#onetrust-pc-sdk .ot-vnd-serv{width:auto;padding:1rem 1.25rem;padding-bottom:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:600;font-size:.95em;line-height:2;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item{border:none;margin:0;padding:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button{outline:none;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button[aria-expanded=true],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button[aria-expanded=true]{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:first-child{margin-top:.25rem;border-top:unset}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child{margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child button{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 1.75rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-lbl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-cnt,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt{padding-left:40px}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-size:.8em}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-cat-header{font-size:.8em}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv{margin-bottom:1rem;padding:1rem .95rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:700;font-size:.8em;line-height:20px;margin-left:.82rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-cat-header{font-weight:700;font-size:.8em;line-height:20px}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-vnd-serv .ot-vnd-lst-cont .ot-accordion-layout .ot-acc-hdr div.ot-chkbox{margin-left:.82rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr{padding:.5rem 0;margin:0;display:flex;width:100%;align-items:center;justify-content:space-between}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:first-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:first-child{margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:last-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:last-child{margin-right:.5rem;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-always-active{position:relative;right:unset;top:unset;transform:unset}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-plus-minus,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-plus-minus{top:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-arw-cntr{float:none;top:unset;right:unset;transform:unset;margin-top:-2px;position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-cat-header{flex:1;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-tgl{position:relative;transform:none;right:0;top:0;float:none}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox{position:relative;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label{padding:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label::before{position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox input{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0;z-index:1}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h5.ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h4.ot-cat-header{margin:0}#onetrust-pc-sdk .ot-vs-config .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp h5{top:0;line-height:20px}#onetrust-pc-sdk .ot-vs-list{display:flex;flex-direction:column;padding:0;margin:.5rem 4px}#onetrust-pc-sdk .ot-vs-selc-all{display:flex;padding:0;float:unset;align-items:center;justify-content:flex-start}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf{justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:48px}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin:0;padding:0;margin-right:14px;justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-chkbox,#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-tgl{display:inline-block;right:unset;width:auto;height:auto;float:none}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:45px;height:25px}#onetrust-pc-sdk .ot-vs-selc-all .ot-sel-all-chkbox{margin-right:11px;margin-left:.75rem;display:flex;align-items:center}#onetrust-pc-sdk .ot-vs-selc-all .sel-all-hdr{margin:0 1.25rem;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-vnd-list-cnt #ot-selall-vencntr.ot-chkbox{float:unset;right:0}#onetrust-pc-sdk[dir=rtl] #ot-back-arw,#onetrust-pc-sdk[dir=rtl] input~.ot-acc-hdr .ot-arw{transform:rotate(180deg);-o-transform:rotate(180deg);-ms-transform:rotate(180deg);-webkit-transform:rotate(180deg)}#onetrust-pc-sdk[dir=rtl] input:checked~.ot-acc-hdr .ot-arw{transform:rotate(270deg);-o-transform:rotate(270deg);-ms-transform:rotate(270deg);-webkit-transform:rotate(270deg)}#onetrust-pc-sdk[dir=rtl] .ot-chkbox label::after{transform:rotate(45deg);-webkit-transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);border-left:0;border-right:3px solid}#onetrust-pc-sdk[dir=rtl] .ot-search-cntr>svg{right:0}@media only screen and (max-width: 600px){#onetrust-pc-sdk.otPcCenter{left:0;min-width:100%;height:100%;top:0;border-radius:0}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{margin:1px 3px 0 10px;padding-right:10px;width:calc(100% - 23px)}#onetrust-pc-sdk .ot-btn-container button{max-width:none;letter-spacing:.01em}#onetrust-pc-sdk #close-pc-btn-handler{top:10px;right:17px}#onetrust-pc-sdk p{font-size:.7em}#onetrust-pc-sdk #ot-pc-hdr{margin:10px 10px 0 5px;width:calc(100% - 15px)}#onetrust-pc-sdk .vendor-search-handler{font-size:1em}#onetrust-pc-sdk #ot-back-arw{margin-left:12px}#onetrust-pc-sdk #ot-lst-cnt{margin:0;padding:0 5px 0 10px;min-width:95%}#onetrust-pc-sdk .switch+p{max-width:80%}#onetrust-pc-sdk .ot-ftr-stacked button{width:100%}#onetrust-pc-sdk #ot-fltr-cnt{max-width:320px;width:90%;border-top-right-radius:0;border-bottom-right-radius:0;margin:0;margin-left:15px;left:auto;right:40px;top:85px}#onetrust-pc-sdk .ot-fltr-opt{margin-left:25px;margin-bottom:10px}#onetrust-pc-sdk .ot-pc-refuse-all-handler{margin-bottom:0}#onetrust-pc-sdk #ot-fltr-cnt{right:40px}}@media only screen and (max-width: 476px){#onetrust-pc-sdk .ot-fltr-cntr,#onetrust-pc-sdk #ot-fltr-cnt{right:10px}#onetrust-pc-sdk #ot-anchor{right:25px}#onetrust-pc-sdk button{width:100%}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-sel-all{padding-right:9px}#onetrust-pc-sdk:not(.ot-addtl-vendors) #ot-pc-lst:not(.ot-enbl-chr) .ot-tgl-cntr{right:0}}@media only screen and (max-width: 896px)and (max-height: 425px)and (orientation: landscape){#onetrust-pc-sdk.otPcCenter{left:0;top:0;min-width:100%;height:100%;border-radius:0}#onetrust-pc-sdk #ot-anchor{left:initial;right:50px}#onetrust-pc-sdk #ot-lst-title{margin-top:12px}#onetrust-pc-sdk #ot-lst-title *{font-size:inherit}#onetrust-pc-sdk #ot-pc-hdr input{margin-right:0;padding-right:45px}#onetrust-pc-sdk .switch+p{max-width:85%}#onetrust-pc-sdk #ot-sel-blk{position:static}#onetrust-pc-sdk #ot-pc-lst{overflow:auto}#onetrust-pc-sdk #ot-lst-cnt{max-height:none;overflow:initial}#onetrust-pc-sdk #ot-lst-cnt.no-results{height:auto}#onetrust-pc-sdk input{font-size:1em !important}#onetrust-pc-sdk p{font-size:.6em}#onetrust-pc-sdk #ot-fltr-modal{width:100%;top:0}#onetrust-pc-sdk ul li p,#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a,#onetrust-pc-sdk .category-host-list-handler{font-size:.6em}#onetrust-pc-sdk.ot-shw-fltr #ot-anchor{display:none !important}#onetrust-pc-sdk.ot-shw-fltr #ot-pc-lst{height:100% !important;overflow:hidden;top:0px}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-cnt{margin:0;height:100%;max-height:none;padding:10px;top:0;width:calc(100% - 20px);position:absolute;right:0;left:0;max-width:none}#onetrust-pc-sdk.ot-shw-fltr .ot-fltr-scrlcnt{max-height:calc(100% - 65px)}}
            #onetrust-consent-sdk #onetrust-pc-sdk,
                #onetrust-consent-sdk #ot-search-cntr,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch.ot-toggle,
                #onetrust-consent-sdk #onetrust-pc-sdk ot-grp-hdr1 .checkbox,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title:after
                ,#onetrust-consent-sdk #onetrust-pc-sdk #ot-sel-blk,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-cnt,
                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-anchor {
                    background-color: #FFFFFF;
                }
               
            #onetrust-consent-sdk #onetrust-pc-sdk h3,
                #onetrust-consent-sdk #onetrust-pc-sdk h4,
                #onetrust-consent-sdk #onetrust-pc-sdk h5,
                #onetrust-consent-sdk #onetrust-pc-sdk h6,
                #onetrust-consent-sdk #onetrust-pc-sdk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-ven-lst .ot-ven-opts p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-li-title,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-sel-all-hdr span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-modal #modal-header,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-checkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-sel-blk p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-lst-title h3,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .back-btn-handler p,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .ot-ven-name,
                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .consent-category,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-label-status,
                #onetrust-consent-sdk #onetrust-pc-sdk .ot-chkbox label span,
                #onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler
                {
                    color: #696969;
                }
             #onetrust-consent-sdk #onetrust-pc-sdk .privacy-notice-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler + a,
                    #onetrust-consent-sdk #onetrust-pc-sdk .category-host-list-handler,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-link,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-name a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-acc-hdr .ot-host-expand,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-content #ot-pc-desc .ot-link-btn,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,
                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info a
                    {
                        color: #3860BE;
                    }
            #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler:hover { text-decoration: underline;}
            
             #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,
                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-ven-dets
                            {
                                background-color: #F8F8F8;
                            }
        #onetrust-consent-sdk #onetrust-pc-sdk
            button:not(#clear-filters-handler):not(.ot-close-icon):not(#filter-btn-handler):not(.ot-remove-objection-handler):not(.ot-obj-leg-btn-handler):not([aria-expanded]):not(.ot-link-btn),
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-active-leg-btn {
                background-color: #3168b6;border-color: #3168b6;
                color: #FFFFFF;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {
                border-color: #3168b6;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-remove-objection-handler{
                background-color: transparent;
                border: 1px solid transparent;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn {
                background-color: #FFFFFF;
                color: #78808E; border-color: #78808E;
            }
            
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:focus + .ot-switch, .ot-switch .ot-switch-nob, .ot-switch .ot-switch-nob:before,
            #onetrust-pc-sdk .ot-checkbox input[type="checkbox"]:focus + label::before,
            #onetrust-pc-sdk .ot-chkbox input[type="checkbox"]:focus + label::before {
                outline-color: #000000;
                outline-width: 1px;
            }
            #onetrust-pc-sdk .ot-host-item > button:focus, #onetrust-pc-sdk .ot-ven-item > button:focus {
                border: 1px solid #000000;
            }
            #onetrust-consent-sdk #onetrust-pc-sdk *:focus,
            #onetrust-consent-sdk #onetrust-pc-sdk .ot-vlst-cntr > a:focus {
               outline: 1px solid #000000;
            }#onetrust-consent-sdk .powered-by-logo {
    display: none;!important;
}.ot-sdk-cookie-policy{font-family:inherit;font-size:16px}.ot-sdk-cookie-policy.otRelFont{font-size:1rem}.ot-sdk-cookie-policy h3,.ot-sdk-cookie-policy h4,.ot-sdk-cookie-policy h6,.ot-sdk-cookie-policy p,.ot-sdk-cookie-policy li,.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy th,.ot-sdk-cookie-policy #cookie-policy-description,.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}.ot-sdk-cookie-policy h4{font-size:1.2em}.ot-sdk-cookie-policy h6{font-size:1em;margin-top:2em}.ot-sdk-cookie-policy th{min-width:75px}.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy a:hover{background:#fff}.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}.ot-sdk-cookie-policy .ot-mobile-border{display:none}.ot-sdk-cookie-policy section{margin-bottom:2em}.ot-sdk-cookie-policy table{border-collapse:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy{font-family:inherit;font-size:1rem}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup{margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group-desc,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-table-header,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td{font-size:.9em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td a{font-size:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group{font-size:1em;margin-bottom:.6em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-title{margin-bottom:1.2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy>section{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th{min-width:75px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a:hover{background:#fff}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-mobile-border{display:none}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy section{margin-bottom:2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li{list-style:disc;margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li h4{display:inline-block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{border-collapse:inherit;margin:auto;border:1px solid #d7d7d7;border-radius:5px;border-spacing:initial;width:100%;overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border-bottom:1px solid #d7d7d7;border-right:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr th:last-child,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr td:last-child{border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:25%}.ot-sdk-cookie-policy[dir=rtl]{text-align:left}#ot-sdk-cookie-policy h3{font-size:1.5em}@media only screen and (max-width: 530px){.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) table,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tbody,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) th,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{display:block}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead tr{position:absolute;top:-9999px;left:-9999px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{margin:0 0 1em 0}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd),.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd) a{background:#f6f6f4}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td{border:none;border-bottom:1px solid #eee;position:relative;padding-left:50%}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{position:absolute;height:100%;left:6px;width:40%;padding-right:10px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) .ot-mobile-border{display:inline-block;background-color:#e4e4e4;position:absolute;height:100%;top:0;left:45%;width:2px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{content:attr(data-label);font-weight:bold}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border:none;border-bottom:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{display:block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:auto}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{margin:0 0 1em 0}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{height:100%;width:40%;padding-right:10px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{content:attr(data-label);font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead tr{position:absolute;top:-9999px;left:-9999px;z-index:-9999}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:1px solid #d7d7d7;border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td:last-child{border-bottom:0px}}
                
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h5,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th {
                        color: #696969;
                    }
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group {
                        color: #696969;
                    }
                    
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title {
                            color: #696969;
                        }
                    
            
                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th {
                            background-color: #F8F8F8;
                        }
                    
            .ot-floating-button__front{background-image:url('https://cdn.cookielaw.org/logos/static/ot_persistent_cookie.png')}
                      @keyframes slide-up-custom {
                          0% {
                              top: -99px !important;
                          }
                          100% {
                              top: 0px;
                          }
                      }
                      @-webkit-keyframes slide-up-custom {
                          0% {
                              top: -99px !important;
                          }
                          100% {
                              top: 0px;
                          }
                      }
                      @-moz-keyframes slide-up-custom {
                          0% {
                              top: -99px !important;
                          }
                          100% {
                              top: 0px;
                          }
                      }
                      </style><script data-react-helmet="true" type="text/javascript" class="optanon-category-C0002">(function (h, o, t, j, a, r) { h.hj = h.hj || function () { (h.hj.q = h.hj.q || []).push(arguments) }; h._hjSettings = { hjid: 1221911, hjsv: 6 }; a = o.getElementsByTagName('head')[0]; r = o.createElement('script'); r.async = 1; r.src = t + h._hjSettings.hjid + j + h._hjSettings.hjsv; a.appendChild(r); })(window, document, 'https://static.hotjar.com/c/hotjar-', '.js?sv=');</script><script async="" src="https://static.hotjar.com/c/hotjar-1221911.js?sv=6"></script><script type="text/javascript" class="optanon-category-C0002" data-react-helmet="true">
          !function() {
            var e = function(e, t, n) {
                if (n) {
                    var o = new Date;
                    o.setTime(o.getTime() + 24 * n * 60 * 60 * 1e3);
                    var a = "; expires=" + o.toGMTString()
                } else a = "";
                document.cookie = e + "=" + t + a + ";domain=.roche.com;path=/"
            };
            var t = new Image;
            t.addEventListener("error", function() {
                e("netLocation", "external")
            }), t.addEventListener("load", function() {
                e("netLocation", "internal")
            })
            t.src = "https://digitalregistry.roche.com/favicon.ico"
          }();
        </script><script type="text/javascript" class="optanon-category-C0002" data-react-helmet="true">
          (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
          new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
          j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
          'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
          })(window,document,'script','dataLayer','GTM-MS8297');

          window.dataLayer = window.dataLayer || [];
        </script><meta http-equiv="origin-trial" content="A7bG5hJ4XpMV5a3V1wwAR0PalkFSxLOZeL9D/YBYdupYUIgUgGhfVJ1zBFOqGybb7gRhswfJ+AmO7S2rNK2IOwkAAAB7eyJvcmlnaW4iOiJodHRwczovL3d3dy5nb29nbGV0YWdtYW5hZ2VyLmNvbTo0NDMiLCJmZWF0dXJlIjoiUHJpdmFjeVNhbmRib3hBZHNBUElzIiwiZXhwaXJ5IjoxNjY5NzY2Mzk5LCJpc1RoaXJkUGFydHkiOnRydWV9"><script type="text/javascript" async="" src="https://googleads.g.doubleclick.net/pagead/viewthroughconversion/853521996/?random=1661205611591&amp;cv=9&amp;fst=1661205611591&amp;num=1&amp;bg=ffffff&amp;guid=ON&amp;resp=GooglemKTybQhCsO&amp;u_h=1080&amp;u_w=2560&amp;u_ah=1023&amp;u_aw=2560&amp;u_cd=24&amp;u_his=4&amp;u_tz=-180&amp;u_java=false&amp;u_nplug=0&amp;u_nmime=0&amp;gtm=2wg8h0&amp;sendb=1&amp;ig=1&amp;frm=0&amp;url=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline%2F&amp;tiba=Roche%20%7C%20Pipeline&amp;hn=www.googleadservices.com&amp;async=1&amp;rfmt=3&amp;fmt=4"></script><meta http-equiv="origin-trial" content="Azy2GzGQxPvGmQwVDdEL1jRuKSXIdSSASA06JCA6PCeaVHpFYf8Rw5/q+9adc9CrBTxfCeUwxkuDM4PWEmdqywwAAACKeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZWFkc2VydmljZXMuY29tOjQ0MyIsImZlYXR1cmUiOiJQcml2YWN5U2FuZGJveEFkc0FQSXMiLCJleHBpcnkiOjE2NjEyOTkxOTksImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9"><script type="text/javascript" async="" src="https://www.googleadservices.com/pagead/conversion/641333617/?random=1661205611593&amp;cv=9&amp;fst=1661205611593&amp;num=1&amp;value=0&amp;label=EWVACPL48tIBEPHy57EC&amp;bg=ffffff&amp;guid=ON&amp;resp=GooglemKTybQhCsO&amp;u_h=1080&amp;u_w=2560&amp;u_ah=1023&amp;u_aw=2560&amp;u_cd=24&amp;u_his=4&amp;u_tz=-180&amp;u_java=false&amp;u_nplug=0&amp;u_nmime=0&amp;gtm=2wg8h0&amp;sendb=1&amp;ig=1&amp;frm=0&amp;url=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline%2F&amp;tiba=Roche%20%7C%20Pipeline&amp;auid=1834472716.1661205611&amp;hn=www.googleadservices.com&amp;bttype=purchase&amp;async=1&amp;rfmt=3&amp;fmt=4"></script></head><body style="position: relative;" data-aos-easing="ease" data-aos-duration="400" data-aos-delay="0"><roche-modal id="global-modal" class="sc-roche-modal-h hydrated" appearance="default"><div class="content-wrapper sc-roche-modal sc-roche-modal-s"><div class="close sc-roche-modal"></div></div></roche-modal><div id="___gatsby"><div tabindex="-1" id="gatsby-focus-wrapper" style="outline: none;"><div style="height: 100%; position: absolute; top: 0px; left: 0px;"></div><roche-global-config data-is-home-page="false" data-all-space-locales="[&quot;en&quot;,&quot;de&quot;]" data-alternates="[]" data-tag-page-url="/topic" data-base-domain="roche" data-brightcove-account-id="6205269558001" data-brightcove-player-id="9bQkMnKAjA" data-cludo-customer-id="473" data-cludo-engine-id="12688" data-cognito-userpool-client-id="4c8b744o367afv48n85cidkgt8" data-cognito-userpool-id="eu-central-1_oUXROgnTJ" data-locale="en" data-non-default-theme-subcategories="[&quot;events&quot;,&quot;life-talks&quot;]" data-page-id="storyblok:roche-dot-com:live:34bc087b-3647-46f2-8023-db4b7ff47366" data-recaptcha-key="6LfnSAoUAAAAAG49XsPZF3YJHzE3KiAuQuoivYZb" data-translation-url="/translations/en.json?version=1661179095599" data-twitter-handle="@roche" data-white-listed-domains="[&quot;roche.com&quot;]" data-hub-pages="{}" data-is-share-hidden="false" data-gapi-client-id="63339946847-k26jidt6gvpot2ekip4je2ic0bjfe4qh.apps.googleusercontent.com" data-gapi-key="AIzaSyA9wwU3OfBHTOWZs_jrPLr6laHG6YQwvnc" data-storyblok-story-id="78842718"></roche-global-config><roche-animation-manager class="hydrated"></roche-animation-manager><roche-offcanvas-panel id="roche-offcanvas-menu" class="hydrated"><roche-navigation-mobile world-wide-link="/worldwide" global-search-link="/" class="hydrated"><!----><div class="header"><roche-offcanvas-trigger class="header__close hydrated" offcanvas-id="roche-offcanvas-menu" tracking-event-name="navigation_offcanvas_click"><roche-icon class="hydrated"></roche-icon></roche-offcanvas-trigger><a class="header__link" href="/worldwide"><roche-icon class="header__link-icon hydrated"></roche-icon><span>Worldwide</span></a></div><nav><ul><li class="" style="height: 41px"><span>About Roche<roche-icon icon="chevron-down" height="24px" class="hydrated"></roche-icon></span><ul><li><a href="/about/">Explore<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/about/strategy/">Strategy</a></li><li class=""><a href="/about/business/">Business</a></li><li class=""><a href="/about/sustainability/">Sustainability</a></li><li class=""><a href="/about/leadership/">Leadership</a></li><li class=""><a href="/about/governance/">Governance</a></li><li class=""><a href="/about/history">History</a></li></ul></li><li class="open" style="height: 309px"><span>Solutions<roche-icon icon="chevron-down" height="24px" class="hydrated"></roche-icon></span><ul><li><a href="/solutions/">Explore<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/solutions/focus-areas/">Focus areas</a></li><li class=""><a href="/solutions/pharma/">Pharma solutions</a></li><li class=""><a href="/solutions/diagnostics/">Diagnostics solutions</a></li><li class="current-page"><a href="/solutions/pipeline/">Pipeline</a></li></ul></li><li class="" style="height: 41px"><span>Innovation<roche-icon icon="chevron-down" height="24px" class="hydrated"></roche-icon></span><ul><li><a href="/innovation/">Explore<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/innovation/structure/">Team &amp; structure</a></li><li class=""><a href="/innovation/process/">Innovation process</a></li><li class=""><a href="/innovation/ethical-standards/">Ethical standards</a></li><li class=""><a href="/innovation/partnering/">Partnering</a></li></ul></li><li class="" style="height: 41px"><a href="/stories/">Stories</a></li></ul><ul><li class="" style="height: 41px"><a href="/media/">Media</a></li><li class="" style="height: 41px"><a href="/investors/">Investors</a></li><li class="open" style="height: 41px"><a href="https://careers.roche.com">Careers</a></li></ul><roche-language-switch layout="inline-list" class="hydrated"></roche-language-switch></nav></roche-navigation-mobile></roche-offcanvas-panel><roche-header is-microsite="false" fixed="false" global-search-link="/search" class="hydrated"><roche-navigation slot="primary" class="hydrated"><!----><nav><ul><li class=""><span><a href="/about/"> About Roche </a></span><ul><li class=""><a href="/about/">About Roche<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/about/strategy/">Strategy</a></li><li class=""><a href="/about/business/">Business</a></li><li class=""><a href="/about/sustainability/">Sustainability</a></li><li class=""><a href="/about/leadership/">Leadership</a></li><li class=""><a href="/about/governance/">Governance</a></li><li class=""><a href="/about/history">History</a></li></ul></li><li class=""><span><a href="/solutions/"> Solutions </a></span><ul><li class=""><a href="/solutions/">Solutions<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/solutions/focus-areas/">Focus areas</a></li><li class=""><a href="/solutions/pharma/">Pharma solutions</a></li><li class=""><a href="/solutions/diagnostics/">Diagnostics solutions</a></li><li class="current-page"><a href="/solutions/pipeline/">Pipeline</a></li></ul></li><li class=""><span><a href="/innovation/"> Innovation </a></span><ul><li class=""><a href="/innovation/">Innovation<roche-icon icon="arrow-right" height="24px" class="hydrated"></roche-icon></a></li><li class=""><a href="/innovation/structure/">Team &amp; structure</a></li><li class=""><a href="/innovation/process/">Innovation process</a></li><li class=""><a href="/innovation/ethical-standards/">Ethical standards</a></li><li class=""><a href="/innovation/partnering/">Partnering</a></li></ul></li><li></li><li class=""><a href="/stories/">Stories</a></li></ul></nav></roche-navigation><roche-navigation slot="secondary" class="hydrated"><!----><nav><ul><li class=""><a href="/media/">Media</a></li><li class=""><a href="/investors/">Investors</a></li><li class=""><a href="https://careers.roche.com">Careers</a></li><li></li><li class=""><a href="/worldwide"><roche-icon icon="globe" height="20px" class="hydrated"></roche-icon></a></li><li class=""><a href="/search"><roche-icon icon="search" height="20px" class="hydrated"></roche-icon></a></li></ul></nav></roche-navigation></roche-header><roche-grid data-breadcrumbs="true" no-padding="" class="hydrated"><roche-breadcrumbs aria-label="Breadcrumb" class="hydrated" js-first-column-child=""><roche-generic-link type="breadcrumbs" target="_self" url="/solutions" text="Solutions" icon="" size="medium" class="hydrated" data-label="Breadcrumb" data-value="1"></roche-generic-link></roche-breadcrumbs></roche-grid><roche-grid layout="12" full-width="false" color="" data-staging-hero="hero--variant-b" class="hydrated" no-padding=""><roche-staging-hero content="" variant="hero--variant-b" headline="Product Development Portfolio" uid="2b8fe749-6a40-4c28-b778-8f8d0e1a6cfe" id="2b8fe749-6a40-4c28-b778-8f8d0e1a6cfe" storyid="78842718" class="hydrated" js-first-column-child=""></roche-staging-hero></roche-grid><roche-grid layout="12" full-width="false" color="" class="hydrated"><roche-richtext uid="f7730483-52ff-46b0-a7c2-0b3d94d6d7b7" slot="" class="hydrated" js-first-column-child=""><!----><p>Last update: 21st of July 2022</p></roche-richtext><roche-accordion-tabs type="tabs" appearance="default" start-position="" uid="1bed1053-d58f-4e3d-8e81-c430a06be0b7" id="1bed1053-d58f-4e3d-8e81-c430a06be0b7" storyid="78842718" class="hydrated" blur-ends="none"><!----><ul class="tabs tabs--visible"><li><button class="tabs__item active">Pipeline</button></li><li><button class="tabs__item">Diagnostics</button></li></ul><roche-accordion-tabs-item icon="" headline="Pipeline" uid="81ad1b25-f415-4714-9450-45c188614658" id="81ad1b25-f415-4714-9450-45c188614658" storyid="78842718" type="tabs" open="" appearance="default" class="hydrated"><roche-accordion-tabs type="tabs" appearance="pipeline" start-position="" uid="03e936fd-256b-4b20-8631-acd94f1a986e" id="03e936fd-256b-4b20-8631-acd94f1a986e" storyid="78842718" class="hydrated" blur-ends="none"><!----><ul class="tabs tabs--visible"><li><button class="tabs__item active">Current Version</button></li><li><button class="tabs__item">See Changes</button></li></ul><roche-accordion-tabs-item icon="" headline="Current Version" uid="f24b5f67-0000-422b-b6a0-68b7d67a513d" id="f24b5f67-0000-422b-b6a0-68b7d67a513d" storyid="78842718" type="tabs" open="" appearance="default" class="hydrated"><div><roche-grid layout="8-1-3" overflow-visible="true" full-width="true" class="hydrated"><roche-pipeline-table is-small="false" slot="left" group-list-by="all" class="hydrated" js-first-column-child="" content="[{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6333&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;CD19 X CD28&quot;,&quot;Autogenerated&quot;:&quot;99&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;CD19 X CD28 in combination with glofitimab&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory Non Hodgkin's Lymphoma (NHL)&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory Non Hodgkin's Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6290&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;MAGE-A4 ImmTAC&quot;,&quot;Autogenerated&quot;:&quot;63&quot;,&quot;partner&quot;:&quot;Immunocore&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;The trial (NCT03973333) is designed to study the safety and preliminary activity of MAGE-A4 ImmTAC as a monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6501&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;141&quot;,&quot;partner&quot;:&quot;Lineage Cell Therapeutics&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;OpRegen is a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders under development by Lineage Cell Therapeutics in collaboration with Roche&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy&quot;,&quot;indicationLong&quot;:&quot;geographic atrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6526&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;camonsertib&quot;,&quot;Autogenerated&quot;:&quot;195&quot;,&quot;partner&quot;:&quot;Repare Therapeutics&quot;,&quot;comment&quot;:&quot;added at HY 2022&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;92&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;Added Q1 2017. Ph III, V + azacitidine. viale-A&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase III clinical trial is evaluating Venclexta in combination with the hypomethylating agent azacitidine for the treatment of patients with previously untreated acute myeloid leukemia who are not eligible for standard induction therapy.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line acute myeloid leukemia (AML)&quot;,&quot;indicationLong&quot;:&quot;first line acute myeloid leukemia in combination with azacitidine&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6315&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;120&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;immunologic disorders&quot;,&quot;indicationLong&quot;:&quot;immunologic disorders&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6323&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;IL15/IL15Ra-Fc&quot;,&quot;Autogenerated&quot;:&quot;64&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;IL15/IL15Ra-Fc alone, and in combination with Tecentriq&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumours&quot;,&quot;indicationLong&quot;:&quot;solid tumours&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7845&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;fenebrutinib&quot;,&quot;Autogenerated&quot;:&quot;103&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG7845 (GDC-0853) is a novel Bruton’s tyrosine kinase (BTK) inhibitor that helps block B cell proliferation. RG7845 binds to BTK in a novel way that is believed to increase its effectiveness.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsing multiple sclerosis (RMS)&quot;,&quot;indicationLong&quot;:&quot;Relapsing multiple sclerosis (RMS) \\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7845&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;fenebrutinib&quot;,&quot;Autogenerated&quot;:&quot;102&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG7845 (GDC-0853) is a novel Bruton’s tyrosine kinase (BTK) inhibitor that helps block B cell proliferation. RG7845 binds to BTK in a novel way that is believed to increase its effectiveness.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;primary progressive multiple sclerosis (PPMS)&quot;,&quot;indicationLong&quot;:&quot;Primary progressive multiple sclerosis (PPMS)\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6180&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;autogene cevumeran&quot;,&quot;Autogenerated&quot;:&quot;36&quot;,&quot;partner&quot;:&quot;BioNTech AG&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;autogene cevumeran (Individualised Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA (mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune response against that patient’s tumor. A phase II clinical trial is evaluating iNeST for the treatment of first line melanoma.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;first line melanoma&quot;,&quot;indicationLong&quot;:&quot;first line melanoma\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7854&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;TLR7 agonist&quot;,&quot;Autogenerated&quot;:&quot;147&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;TLR7 agonist (RG7854) is an oral, small molecule immuno-modulator activating the TLR (toll-like receptor) 7 and to a weaker extent TLR8. It is developed as best-in-disease for finite chronic hepatitis B combination therapy. A phase I clinical trial is evaluating RG7854 for the treatment of chronic hepatitis B infection.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;chronic hepatitis B&quot;,&quot;indicationLong&quot;:&quot;chronic hepatitis B infection&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6114&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Inavolisib&quot;,&quot;Autogenerated&quot;:&quot;33&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;metastatic ER-positive and HER2-negative breast cancer&quot;,&quot;indicationLong&quot;:&quot;metastatic ER-positive and HER2-negative breast cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6416&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;bepranemab&quot;,&quot;Autogenerated&quot;:&quot;186&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;A Phase II Study to evaluate the efficacy, safety, and tolerability of Bepranemab (UCB0107) in study participants with prodromal to mild Alzheimer’s Disease (AD)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Alzheimer's disease&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;22&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;NCT03726879 IMpassion050&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, RG7446) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating ddAC Trastuzumab/Pertuzumab + chemotherapy + Tecentriq followed by surgery and chemotherapy +Tecentriq in the treatment of neoadjuvant HER2+ breast cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;neoadjuvant HER2-positive breast cancer&quot;,&quot;indicationLong&quot;:&quot;neoadjuvant HER2-positive breast cancer&quot;},{&quot;tradeName&quot;:&quot;Evrysdi&quot;,&quot;name&quot;:&quot;RG7916&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;risdiplam&quot;,&quot;Autogenerated&quot;:&quot;172&quot;,&quot;partner&quot;:&quot;PTC Therapeutics, SMA Foundation&quot;,&quot;comment&quot;:&quot;Q3 2017: Filing date added.&quot;,&quot;description&quot;:&quot;Risdiplam (RG7916) is an investigational oral SMN2 splicing modifier being studied in the treatment of spinal muscular atrophy. Multiple phase II and phase II/III are evaluating risdiplan for the treatment of patients with spinal muscular atrophy.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;spinal muscular atrophy (SMA)&quot;,&quot;indicationLong&quot;:&quot;spinal muscular atrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6120&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;VEGF-Ang2 DutaFab&quot;,&quot;Autogenerated&quot;:&quot;139&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6120 (VEGF-Ang2 DutaFab) is a bispecific Fab molecule targeting vascular endothelial growth factor (VEGF) and Angiopoietin 2 (Ang-2). Built on the DutaFab platform, RG6120 is specifically designed to be compatible with the Port Delivery System.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neovascular age related macular degeneration (wAMD)&quot;,&quot;indicationLong&quot;:&quot;neovascular age-related macular degeneration&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;18&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells. A phase I clinical trial is evaluating mosunetuzumab for the treatment of hematologic tumors.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;hematologic tumors&quot;,&quot;indicationLong&quot;:&quot;hematologic tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6357&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;other&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;SPARK&quot;,&quot;genericName&quot;:&quot;SPK-8011&quot;,&quot;Autogenerated&quot;:&quot;191&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;hemophilia A&quot;,&quot;indicationLong&quot;:&quot;hemophilia A&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7906&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;ralmitaront&quot;,&quot;Autogenerated&quot;:&quot;174&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;psychiatric disorders&quot;,&quot;indicationLong&quot;:&quot;psychiatric disorders&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;109&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Commodore 1&quot;,&quot;description&quot;:&quot;Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;paroxysmal nocturnal hemoglobinuria (PNH) patients switching from a C5 inhibitor&quot;,&quot;indicationLong&quot;:&quot;Paroxysmal Nocturnal Hemoglobinuria (PNH) patients switching from a C5 inhibitor\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6006&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;Abx MCP&quot;,&quot;Autogenerated&quot;:&quot;156&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6006 (Abx MCP) is a small molecule, novel chemical class antibiotic for the treatment of Acinetobacter baumannii infections.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Acinetobacter baumannii infections&quot;,&quot;indicationLong&quot;:&quot;Acinetobacter baumannii infections&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;16&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added HY 2018 impassion132&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential first-line treatment, in combination with capecitabine or carboplatin/gemcitabine, for metastatic triple-negative breast cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line metastatic triple-negative breast cancer (TNBC) in combination with capecitabine or carboplatin / gemcitabine&quot;,&quot;indicationLong&quot;:&quot;first line metastatic triple-negative breast cancer in combination with capecitabine or carboplatin/gemcitabine&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Glofitamab&quot;,&quot;Autogenerated&quot;:&quot;40&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;2L+ SCT-ineligible diffuse large B-cell lymphoma (DLBCL)&quot;,&quot;indicationLong&quot;:&quot;2L+ SCT-ineligible Diffuse Large B-Cell Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6433&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;SHP2i&quot;,&quot;Autogenerated&quot;:&quot;90&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;Solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6179&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;135&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;indicationLong&quot;:&quot;diabetic macular edema&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;104&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;lupus nephritis&quot;,&quot;indicationLong&quot;:&quot;lupus nephritis&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;13&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMpower110&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.  a phase III clinical trial is evaluating Tecentriq as a potential first-line treatment for patients with non-squamous or squamous non-small cell lung cancer whose tumours express PDL1.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line non-squamous and squamous non-small cell lung cancer (NSCLC), PDL1-selected patients&quot;,&quot;indicationLong&quot;:&quot;first line non-squamous and squamous non-small cell lung cancer, PDL1-selected patients&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6418&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;selnoflast (NLRP3 inhibitor)&quot;,&quot;Autogenerated&quot;:&quot;121&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Inflammation&quot;,&quot;indicationLong&quot;:&quot;Inflammation&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6341&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;198&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;missed in list; added at HY 2022 although FPI in Q4 2021&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;asthma&quot;,&quot;indicationLong&quot;:&quot;asthma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6264&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;pertuzumab FDC SC&quot;,&quot;Autogenerated&quot;:&quot;54&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2017 as NME Perjeta FDC Sub cut plus Herceptin&quot;,&quot;description&quot;:&quot;Pertuzumab is a humanized monoclonal antibody designed to prevent HER2 dimerization, a process that is believed to play an important role in the growth and formation of several different cancer types. The mechanism of action of pertuzumab is thought to be complementary to Herceptin, as both bind to the HER2 receptor but on different regions. A phase III is evaluating a subcutaneous administration of the fixed-dose combination of Perjeta and Herceptin for the treatment of early HER2-positive breast cancer.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;early HER2-positive breast cancer&quot;,&quot;indicationLong&quot;:&quot;early HER2-positive breast cancer in combination with Herceptin&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;AMY109&quot;,&quot;Autogenerated&quot;:&quot;189&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added in Q1 2018&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;endometriosis&quot;,&quot;indicationLong&quot;:&quot;endometriosis&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6286&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;79&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Locally advanced or metastatic colorectal cancer (CRC)&quot;,&quot;indicationLong&quot;:&quot;Locally advanced or metastatic colorectal cancer\\n&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;8&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;contact-03&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with cabozantinib for the treatment of advanced renal cell carcinoma after immune checkpoint inhibitor treatment&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Advanced renal cell carcinoma after immune checkpoint inhibitor treatment&quot;,&quot;indicationLong&quot;:&quot;Advanced renal cell carcinoma after immune checkpoint inhibitor treatment in combination with cabozantinib&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;170&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Satralizumab (RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.  A phase III clinical trial is evaluating satralizumab for the treatment of patients with Myasthenia Gravis&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Myasthenia Gravis&quot;,&quot;indicationLong&quot;:&quot;Myasthenia Gravis&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;108&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Description updated 2 May 2017, following disc. w. A. Jahreis (PTL), Z. Dobbie (pRED Comms) and Chugai.&quot;,&quot;description&quot;:&quot;Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases. A phase I/II clinical trial is evaluating crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;paroxysmal nocturnal hemoglobinuria (PNH)&quot;,&quot;indicationLong&quot;:&quot;paroxysmal nocturnal hemoglobinuria&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6351&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;194&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;retinal disease&quot;,&quot;indicationLong&quot;:&quot;retinal disease&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;131&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;macular edema secondary to branch retinal vein occlusion (RVO)&quot;,&quot;indicationLong&quot;:&quot;Macular edema secondary to branch retinal vein occlusion\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;48&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SERD 3 added as a NME FY 2017 GDC-9545&quot;,&quot;description&quot;:&quot;RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A phase I clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative metastatic breast cancer.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;ER-positive and HER2-negative metastatic breast cancer&quot;,&quot;indicationLong&quot;:&quot;ER-positive and HER2-negative metastatic breast cancer&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;9&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;contact-01&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with cabozantinib for the treatment of 2L non small cell lung cancer (NSCLC)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;2L non small cell lung cancer (NSCLC) treatment in combination with cabozantinib&quot;,&quot;indicationLong&quot;:&quot;2L non small cell lung cancer (NSCLC) treatment in combination with cabozantinib&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6354&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;recombinant human pentraxin-2&quot;,&quot;Autogenerated&quot;:&quot;118&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Phase II study of pentraxin-2 (rhPTX-2; PRM-151) in idiopathic pulmonary fibrosis&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Idiopathic pulmonary fibrosis&quot;,&quot;indicationLong&quot;:&quot;Idiopathic pulmonary fibrosis&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7827&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;FAP 4-1BBL&quot;,&quot;Autogenerated&quot;:&quot;59&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in HY 2108&quot;,&quot;description&quot;:&quot;RG7827 (FAP 4-1BBL FP) is an agonistic immune modulator and targeted T-cell co-stimulator, which inhibits tumor growth by activating tumor-specific T-cells. RG7827 has an antibody-like structure, with one arm binding to FAP, which is a protein found in the stroma of many solid tumor types, and the other arm carrying the signaling molecule, 4-1BBL. A phase I clinical trial is evaluating RG7827 for the treatment of solid tumors.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;106&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;MAJESTY&quot;,&quot;description&quot;:&quot;Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;membranous nephropathy&quot;,&quot;indicationLong&quot;:&quot;membranous Nephropathy&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;169&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Q3 2017 -- INN added, filing date changed to 2019 (previously 2018).&quot;,&quot;description&quot;:&quot;Satralizumab (RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.  A phase III clinical trial is evaluating satralizumab as monotherapy or as an add-on therapy for the treatment of patients with neuromyelitis optica spectrum disorder.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neuromyelitis optica spectrum disorder&quot;,&quot;indicationLong&quot;:&quot;neuromyelitis optica spectrum disorder&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;110&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;atypical hemolytic uremic syndrome (aHUS)&quot;,&quot;indicationLong&quot;:&quot;Atypical Hemolytic Uremic Syndrome&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7440&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;ipatasertib&quot;,&quot;Autogenerated&quot;:&quot;1&quot;,&quot;partner&quot;:&quot;Array BioPharma&quot;,&quot;comment&quot;:&quot;Advanced to ph III at Q2/HY 2017.&quot;,&quot;description&quot;:&quot;Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell growth and survival.  A phase III clinical trial is evaluating ipatasertib for the treatment of first line castration-resistant prostate cancer.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;first line castration-resistant prostate cancer&quot;,&quot;indicationLong&quot;:&quot;first line castration-resistant prostate cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6147&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;galegenimab (HtrA1)&quot;,&quot;Autogenerated&quot;:&quot;136&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added as NME Q3 2017&quot;,&quot;description&quot;:&quot;HtrA1&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy&quot;,&quot;indicationLong&quot;:&quot;geographic atrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6287&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;116&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Inflammatory bowel disease (IBD)&quot;,&quot;indicationLong&quot;:&quot;Inflammatory bowel disease&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;31&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;canova&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601, GDC-0199, ABT-199) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth and resistance.  A phase III clinical trial is evaluating Venclexta for the treatment of relapsed or refractory t(11;14)-positive multiple myeloma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory t(11;14)-positive multiple myeloma&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory t(11;14)-positive multiple myeloma\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6102&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;Brain shuttle gantenerumab&quot;,&quot;Autogenerated&quot;:&quot;180&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q3 2019&quot;,&quot;description&quot;:&quot;Brain shuttle technology to transfer gantenerumab across the blood brain barrier and increase antibody concentrations in the brain&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Alzheimer's&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;133&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm. Two phase III clinical trials are evaluating faricimab for the treatment of diabetic macular edema.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;indicationLong&quot;:&quot;diabetic macular edema&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6330&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;KRAS G12C&quot;,&quot;Autogenerated&quot;:&quot;80&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;metastatic solid tumors with KRAS G12C mutation&quot;,&quot;indicationLong&quot;:&quot;metastatic solid tumors with KRAS G12C mutation\\n&quot;},{&quot;tradeName&quot;:&quot;Alecensa&quot;,&quot;name&quot;:&quot;RG7853&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;alectinib&quot;,&quot;Autogenerated&quot;:&quot;6&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;BFAST trial NCT03178552 added FY2017&quot;,&quot;description&quot;:&quot;Alecensa (alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting downstream malignant pathways that contribute to tumorigenesis and disease progression. A phase II/III clinical trial is evaluating Alecensa for the treatment of non-squamous non-small cell lung cancer patients who are ALK+ selected using a liquid biopsy.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line ALK-positive (liquid biopsy) non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;first line ALK-positive non-small cell lung cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6289&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;187&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Alzheimer's disease&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6413&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;casivirimab&quot;,&quot;Autogenerated&quot;:&quot;155&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay&quot;,&quot;indicationLong&quot;:&quot;Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6292&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;Anti-CD25&quot;,&quot;Autogenerated&quot;:&quot;62&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2020&quot;,&quot;description&quot;:&quot;RG6292 is a monoclonal antibody that targets CD25 (IL-2Rα). The antibody mediates the depletion of regulatory T-cells (Tregs), a major suppressor of the anti-cancer immune response. RG6292 does not interfere with IL-2 signaling of other immune cells which are acting against the tumor. Phase I clinical trials in solid tumors are evaluating RG6292 as monotherapy (NCT 04158583) and in combination with atezolizumab (NCT04642365).&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6346&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;HBV siRNA&quot;,&quot;Autogenerated&quot;:&quot;151&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;RG6346 (DCR-HBVS) is a liver-targeted siRNA that employs RNA interference (RNAi) for selective knock-down of Hepatitis B virus gene expression in infected hepatocytes, inhibiting the production of viral factors required for viral replication. RG6346 leverages Dicerna Pharmaceuticals, Inc.’s proprietary GalXC™ RNAi technology. RG6346 is in a phase I clinical trial for the treatment of non-cirrhotic chronic HBV infection.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Hepatitis B virus&quot;,&quot;indicationLong&quot;:&quot;Hepatitis B virus&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;105&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;systemic lupus erythematosus (SLE)&quot;,&quot;indicationLong&quot;:&quot;Systemic Lupus Erythematosus&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6007&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;HLA-A2-WT1 X CD3&quot;,&quot;Autogenerated&quot;:&quot;87&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6007 (HLA-A2-WT1 x CD3) is a T cell receptor (TCR)-like T-cell bispecific antibody targeting the HLA-A2-WT1 complex on tumor cells and CD3 on T-cells.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Adult acute myeloid leukemia (AML)&quot;,&quot;indicationLong&quot;:&quot;Adult acute myeloid leukemia&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;75&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Randomised Phase II (SKYSCRAPER-04) in metastatic and/or recurrent PD-L1+ cervical cancer in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;cervical cancer&quot;,&quot;indicationLong&quot;:&quot;cervical cancer in combination with tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;76&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Randomised Phase II (SKYSCRAPER-09) 1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma (SCCHN)&quot;,&quot;indicationLong&quot;:&quot;1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;SPYK04&quot;,&quot;Autogenerated&quot;:&quot;97&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;SPYK04 is a small molecule drug developed in-house by Chugai&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;84&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Tecentriq plus lurbinectedin in the treatment of 1L extensive stage-small cell lung cancer in the maintenance setting&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;maintenance 1Lextensive stage-small cell lung cancer (SCLC) in combination with lurbinectedin&quot;,&quot;indicationLong&quot;:&quot;maintenance 1L extensive stage-small cell lung cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6139&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;Anti-PD1 X LAG3&quot;,&quot;Autogenerated&quot;:&quot;60&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6139 ( PD1-LAG3) is a bispecific antibody that binds to two co-inhibitory checkpoint receptors, PD-1 and LAG-3, to reinvigorate dysfunctional T-cells enabling them to attack the tumor. A phase I clinical trial is evaluating RG6139 for the treatment of solid tumors&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;143&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of pediatric patients with the flu.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;influenza, pediatric patients (1-12yr)&quot;,&quot;indicationLong&quot;:&quot;influenza, pediatric patients  (1-12yr)&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6354&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;recombinant human pentraxin-2&quot;,&quot;Autogenerated&quot;:&quot;117&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Phase II study of pentraxin-2 (rhPTX-2; PRM-151) in myelofibrosis&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;myelofibrosis&quot;,&quot;indicationLong&quot;:&quot;myelofibrosis&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;144&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial for the treatment of pediatric patients with the flu.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;influenza, pediatric patients (0-1yr)&quot;,&quot;indicationLong&quot;:&quot;influenza, pediatric patients  (0-1yr)&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7854&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;TLR7 agonist&quot;,&quot;Autogenerated&quot;:&quot;148&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;TLR7 agonist (RG7854) being studied in the Roche Hepatitis B PIRANGA combination platform&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;chronic hepatitis B&quot;,&quot;indicationLong&quot;:&quot;chronic hepatitis B infection&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6076&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;CD19-4-1BBL&quot;,&quot;Autogenerated&quot;:&quot;61&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q3 2019&quot;,&quot;description&quot;:&quot;CD19-4-1BBL(RG6076) is a fusion protein targeting the 4-1BB ligand to cells bearing CD19 acting as an NK- and T-cell co-stimulator.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;heme tumours&quot;,&quot;indicationLong&quot;:&quot;heme tumours&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;38&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;imotion010&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is evaluating Tecentriq for the treatment of adjuvant renal cell carcinoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant renal cell carcinoma (RCC)&quot;,&quot;indicationLong&quot;:&quot;adjuvant renal cell carcinoma&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;28&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in Q1 2018 NCT03434379\\n&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with Avastin in people with previously untreated Hepatocellular carcinoma (HCC)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line hepatocellular carcinoma (HCC)&quot;,&quot;indicationLong&quot;:&quot;first line hepatocellular carcinoma in combination with Avastin&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6234&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;GPRC5D x CD3&quot;,&quot;Autogenerated&quot;:&quot;89&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;multiple myeloma&quot;,&quot;indicationLong&quot;:&quot;multiple myeloma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6174&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;114&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added NME FY 2017 GDC-0334&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;inflammatory diseases&quot;,&quot;indicationLong&quot;:&quot;inflammatory diseases&quot;,&quot;phase&quot;:&quot;&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6129&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;HLA-A2-MAGE-A4 X CD3&quot;,&quot;Autogenerated&quot;:&quot;94&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Bispecific Antibody targeting HLA-A2 restricted Mage-A4 epitope and CD3&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6344&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;BRAF inhibitor (3)&quot;,&quot;Autogenerated&quot;:&quot;98&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6358&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;other&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;SPARK&quot;,&quot;genericName&quot;:&quot;SPK-8016&quot;,&quot;Autogenerated&quot;:&quot;192&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;hemophilia A with inhibitors to factor VIII&quot;,&quot;indicationLong&quot;:&quot;hemophilia A with inhibitors to factor VIII&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant + Phesgo&quot;,&quot;Autogenerated&quot;:&quot;53&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022; heredERA&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;ER-positive and HER2-positive  1L breast cancer&quot;,&quot;indicationLong&quot;:&quot;ER-positive and HER2-positive  1L breast cancer&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;130&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm. Two phase III clinical trials are evaluating faricimab for the treatment of neovascular age related macular degeneration.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neovascular age related macular degeneration (wAMD)&quot;,&quot;indicationLong&quot;:&quot;neovascular age related macular degeneration&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;IONIS&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;ASO factor B&quot;,&quot;Autogenerated&quot;:&quot;137&quot;,&quot;partner&quot;:&quot;Ionis&quot;,&quot;comment&quot;:&quot;added Q2 2019 - managed by Ionis&quot;,&quot;description&quot;:&quot;ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by binding with factor B mRNA. ASO factor B is being studied for the treatment of geographic atrophy. A phase II clinical trial is evaluating ASO factor B for the treatment of geographic atrophy.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy&quot;,&quot;indicationLong&quot;:&quot;geographic atrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6341&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;113&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;asthma&quot;,&quot;indicationLong&quot;:&quot;asthma&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;30&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. A phase II clinical trial is evaluating Venclexta in combination with the carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory acute myeloid leukemia.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory multiple myeloma in combination with carfilzomib&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory multiple myeloma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6180&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;autogene cevumeran&quot;,&quot;Autogenerated&quot;:&quot;35&quot;,&quot;partner&quot;:&quot;BioNTech AG&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;autogene cevumeran (Individualized Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA (mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune response against that patient’s tumor. A phase I clinical trial is evaluating iNeST for the treatment of solid tumors.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;52&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;metastatic ER+ breast cancer&quot;,&quot;indicationLong&quot;:&quot;metastatic ER+ breast cancer\\n&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;24&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;impower132&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Atezolizumab (anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being tested in a phase III clinical trial as a potential first-line treatment, in combination with chemotherapy and pemetrexed, for non-squamous non-small cell lung cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line non-squamous NSCLC, combination with chemotherapy and pemetrexed&quot;,&quot;indicationLong&quot;:&quot;first line non-squamous non-small cell lung cancer, combination with chemotherapy and pemetrexed&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;145&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a phase III clinical trial of post exposure prophylaxis.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;influenza, post exposure prophylaxis&quot;,&quot;indicationLong&quot;:&quot;influenza, post exposure prophylaxis&quot;},{&quot;tradeName&quot;:&quot;Xolair&quot;,&quot;name&quot;:&quot;RG3648&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;omalizumab&quot;,&quot;Autogenerated&quot;:&quot;107&quot;,&quot;partner&quot;:&quot;Novartis&quot;,&quot;comment&quot;:&quot;food allergy added Q3 2019&quot;,&quot;description&quot;:&quot;Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E). In nasal polyps (NP) IgE is increased in mucosal tissue and frequently in serum.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Food allergy&quot;,&quot;indicationLong&quot;:&quot;Food allergy&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;146&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;influenza, direct transmission&quot;,&quot;indicationLong&quot;:&quot;influenza, direct transmission&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6237&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Group&quot;,&quot;genericName&quot;:&quot;latent myostatin + Evrysdi&quot;,&quot;Autogenerated&quot;:&quot;179&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022; new NME&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;&quot;,&quot;indicationLong&quot;:&quot;spinal muscular atrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7935&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;prasinezumab&quot;,&quot;Autogenerated&quot;:&quot;171&quot;,&quot;partner&quot;:&quot;Prothena&quot;,&quot;comment&quot;:&quot;Q3 2017: Filing date added.&quot;,&quot;description&quot;:&quot;Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration. A phase II clinical trial is evaluating prasinezumab for the treatment of patients with Parkinson's disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Parkinson's disease&quot;,&quot;indicationLong&quot;:&quot;Parkinson's disease&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6279&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;PD1-IL2v&quot;,&quot;Autogenerated&quot;:&quot;77&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;The immunocytokine PD1-IL2v is an antibody fusion protein blocking PD1 combined with an engineered interleukin-2 variant (IL2v) inducing immune-modulating activity&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumours&quot;,&quot;indicationLong&quot;:&quot;Solid tumours&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6189&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;FAP-CD40&quot;,&quot;Autogenerated&quot;:&quot;91&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;Solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;CD137 agonist switch antibody&quot;,&quot;Autogenerated&quot;:&quot;81&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Kadcyla&quot;,&quot;name&quot;:&quot;RG3502&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;trastuzumab emtansine&quot;,&quot;Autogenerated&quot;:&quot;88&quot;,&quot;partner&quot;:&quot;ImmunoGen&quot;,&quot;comment&quot;:&quot;KATE 3&quot;,&quot;description&quot;:&quot;Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;2L+ HER-2 positive PD-L1 positive metastatic breast cancer in combination with Tecentriq&quot;,&quot;indicationLong&quot;:&quot;2L+ HER-2 positive PD-L1 positive mBC in combination with Tecentriq \\n&quot;},{&quot;tradeName&quot;:&quot;Evrysdi&quot;,&quot;name&quot;:&quot;RG7916&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;risdiplam&quot;,&quot;Autogenerated&quot;:&quot;173&quot;,&quot;partner&quot;:&quot;PTC Therapeutics, SMA Foundation&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Risdiplam (RG7916) is an investigational oral SMN2 splicing modifier being studied in the treatment of spinal muscular atrophy. Multiple phase II and phase II/III are evaluating risdiplan for the treatment of patients with spinal muscular atrophy.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;spinal muscular atrophy (SMA) pediatric <2 months&quot;,&quot;indicationLong&quot;:&quot;spinal muscular atrophy pediatric <2 months&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6312&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;140&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy&quot;,&quot;indicationLong&quot;:&quot;geographic atrophy&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;27&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in Q1 2018 NCT03452137 IMvoke010\\n\\n&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in patients with adjuvant squamous cell carcinoma of the head and neck (SCCHN).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant squamous cell carcinoma of the head and neck (SCCHN)&quot;,&quot;indicationLong&quot;:&quot;adjuvant squamous cell carcinoma of the head and neck&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;LUNA18&quot;,&quot;Autogenerated&quot;:&quot;96&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;LUNA18 is an oral cyclic peptide RAS inhibitor, and a Phase I clinical trial has been initiated for solid tumors by Chugai&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;132&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;macular edema secondary to central retinal vein occlusion (RVO)&quot;,&quot;indicationLong&quot;:&quot;Macular edema secondary to central retinal vein occlusion\\n&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6413&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;casivirimab&quot;,&quot;Autogenerated&quot;:&quot;152&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;ambulatory patients with COVID-19&quot;,&quot;indicationLong&quot;:&quot;ambulatory patients with COVID-19&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;126&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with subfoveal neovascular age-related macular degeneration. The primary outcome measure of the trial is the time until a patient first requires a refill of the implant.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;age-related macular degeneration (AMD)&quot;,&quot;indicationLong&quot;:&quot;age-related macular degeneration&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;128&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant for the treatment of patients with subfoveal neovascular age-related macular degeneration. The primary outcome measure of the trial is the time until a patient first requires a refill of the implant.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;diabetic retinopathy&quot;,&quot;indicationLong&quot;:&quot;diabetic retinopathy without center-involved diabetic macular edema\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;glypican-3 X CD3&quot;,&quot;Autogenerated&quot;:&quot;0&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;71&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;NCT02794571\\nNCT04045028\\n&quot;,&quot;description&quot;:&quot;tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor. A phase I clinical trial is evaluating tiragolumab in combination with Tecentriq for the treatment of solid tumors.\\n&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;heme and solid tumors&quot;,&quot;indicationLong&quot;:&quot;Heme and solid tumors combinations&quot;},{&quot;tradeName&quot;:&quot;Kadcyla&quot;,&quot;name&quot;:&quot;RG3502-10&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;trastuzumab emtansine&quot;,&quot;Autogenerated&quot;:&quot;5&quot;,&quot;partner&quot;:&quot;ImmunoGen&quot;,&quot;comment&quot;:&quot;ASTEFANIA&quot;,&quot;description&quot;:&quot;Kadcyla (trastuzumab emtansine) is a novel antibody-drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;high risk patients with adjuvant HER2-positive breast cancer in combination with Tecentriq&quot;,&quot;indicationLong&quot;:&quot;high risk patients with adjuvant HER2-positive breast cancer in combination with Tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG1450&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;gantenerumab&quot;,&quot;Autogenerated&quot;:&quot;165&quot;,&quot;partner&quot;:&quot;Morphosys&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;early Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Cognitively unimpaired participants at risk for or at the earliest stages of Alzheimer’s disease&quot;},{&quot;tradeName&quot;:&quot;Actemra/RoACTEMRA&quot;,&quot;name&quot;:&quot;RG1569&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tocilizumab&quot;,&quot;Autogenerated&quot;:&quot;119&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Actemra/RoACTEMRA (tocilizumab) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Covid-19 pneumonia&quot;,&quot;indicationLong&quot;:&quot;Covid-19 pneumonia&quot;},{&quot;tradeName&quot;:&quot;Kadcyla&quot;,&quot;name&quot;:&quot;RG3502&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;trastuzumab emtansine&quot;,&quot;Autogenerated&quot;:&quot;4&quot;,&quot;partner&quot;:&quot;ImmunoGen&quot;,&quot;comment&quot;:&quot;KATHERINE&quot;,&quot;description&quot;:&quot;Kadcyla (trastuzumab emtansine) is a novel antibody-drug conjugate that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant HER2-positive breast cancer&quot;,&quot;indicationLong&quot;:&quot;adjuvant HER2-positive breast cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6100&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;semorinemab&quot;,&quot;Autogenerated&quot;:&quot;175&quot;,&quot;partner&quot;:&quot;AC Immune&quot;,&quot;comment&quot;:&quot;Updated w. partner name (5 Oct 2017). Transitioned to ph II, filing date added (Q3 2017 update).&quot;,&quot;description&quot;:&quot;RG6100 (Anti Tau) is an investigational medicine being evaluated as a potential treatment for Alzheimer’s disease. A phase II clinical trial is evaluating RG6100 for the treatment of patients with Alzheimer's disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Alzheimer's disease&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;44&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;newly diagnosed higher-risk myelodysplastic syndrome (MDS)&quot;,&quot;indicationLong&quot;:&quot;Newly diagnosed higher-risk myelodysplastic syndrome&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6392&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;95&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;oncology&quot;,&quot;indicationLong&quot;:&quot;Oncology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Glofitamab&quot;,&quot;Autogenerated&quot;:&quot;41&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;3L+ diffuse large B-cell lymphoma (DLBCL)&quot;,&quot;indicationLong&quot;:&quot;3L+ Diffuse Large B-Cell Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;51&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant ER+ breast cancer&quot;,&quot;indicationLong&quot;:&quot;adjuvant ER+ breast cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6156&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;EGFRvIII X CD3&quot;,&quot;Autogenerated&quot;:&quot;100&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;glioblastoma (GBM)&quot;,&quot;indicationLong&quot;:&quot;glioblastoma&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6413&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;casivirimab&quot;,&quot;Autogenerated&quot;:&quot;154&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;hospitalized adult patients with COVID-19&quot;,&quot;indicationLong&quot;:&quot;hospitalized patients with COVID-19&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7816&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;alogabat (GABA-Aa5 PAM)&quot;,&quot;Autogenerated&quot;:&quot;176&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added as NME in FY 2017&quot;,&quot;description&quot;:&quot;RG7816 is a small molecule highly selective positive allosteric modulator of the GABAA α5 receptor, which is expressed in key brain regions for autism spectrum disorder. Two phase I clinical trial is evaluating RG7816 for the treatment of patients with autism spectrum disorder.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;autism spectrum disorder&quot;,&quot;indicationLong&quot;:&quot;autism spectrum disorder&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;83&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Tecentriq plus Venclexta in the treatment of 1L extensive stage-small cell lung cancer in the maintenance setting&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;maintenance 1L extensive stage-small cell lung cancer (SCLC)&quot;,&quot;indicationLong&quot;:&quot;maintenance 1L extensive stage-small cell lung cancer\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;68&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SKYSCRAPER-03\\n&quot;,&quot;description&quot;:&quot;Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;stage III unresectable 1L non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;stage III unresectable 1L non-small cell lung cancer (NSCLC) in combination with Tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6163&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;188&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;psychiatric disorders&quot;,&quot;indicationLong&quot;:&quot;psychiatric disorders&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;SQZ&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;PBMC Vaccine&quot;,&quot;Autogenerated&quot;:&quot;65&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumours&quot;,&quot;indicationLong&quot;:&quot;solid tumours&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6185&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;belvarafenib&quot;,&quot;Autogenerated&quot;:&quot;34&quot;,&quot;partner&quot;:&quot;Hanmi Pharmaceutical&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;belvarafenib (RG6185, GDC-5573, HM95573) is a selective small-molecule inhibitor of the RAF family kinases designed to inhibit the MAPK pathway, which is frequently activated in human tumors and drives tumor growth. A phase I clinical trial is evaluating RG6185 for the treatment of solid tumors.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7880&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;efmarodocokin alfa (IL22-Fc)&quot;,&quot;Autogenerated&quot;:&quot;101&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG7880 (IL22-Fc, UTTR1147A) is a recombinant human protein with potential application across multiple inflammatory and metabolic diseases. A phase II clinical trial is evaluating RG7880 for the treatment of aGVHD&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;inflammatory diseases&quot;,&quot;indicationLong&quot;:&quot;aGVHD&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6013&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;other&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;emicizumab&quot;,&quot;Autogenerated&quot;:&quot;193&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Emicizumab (RG6013, ACE910) is a bispecific antibody that mimics coagulation factor VIII, an essential blood clotting protein. It is being investigated as a therapy for people with mild ot moderate hemophilia A, a congenital bleeding disorder that is caused by deficiency or dysfunction of coagulation factor VIII.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Mild to moderate hemophilia A, without FVIII inhibitors&quot;,&quot;indicationLong&quot;:&quot;Mild to moderate hemophilia A, patients without FVIII inhibitors&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;111&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;sickle cell disease (SCD)&quot;,&quot;indicationLong&quot;:&quot;sickle cell disease&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6194&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;HER2 X CD3&quot;,&quot;Autogenerated&quot;:&quot;58&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added as NME in HY 2018&quot;,&quot;description&quot;:&quot;RG6194 is a bispecific antibody designed to target both the HER2-positive cells and CD3 on T cells. This dual-targeting antibody is designed to induce a polyclonal T-cell response against HER2-positive tumors. A phase I clinical trial is evaluating RG6194 for the treatment of metastatic HER2-positive cancers.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;metastatic HER2-positive cancers&quot;,&quot;indicationLong&quot;:&quot;metastatic HER2-positive cancers&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7637&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;182&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neurodevelopmental disorders&quot;,&quot;indicationLong&quot;:&quot;neurodevelopmental disorders&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6412&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;imdevimab&quot;,&quot;Autogenerated&quot;:&quot;159&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;ambulatory adult patients with COVID-19&quot;,&quot;indicationLong&quot;:&quot;ambulatory adult patients with COVID-19&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6237&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;latent myostatin&quot;,&quot;Autogenerated&quot;:&quot;178&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;neuromuscular disorders&quot;,&quot;indicationLong&quot;:&quot;neuromuscular disorders&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;46&quot;,&quot;partner&quot;:&quot;Cotellic in collaboration with Exelixis, BL-8040 in collaboration with BioLineRX, PEGPH20 in collaboration with Halozyme&quot;,&quot;comment&quot;:&quot;Added in ph I for Q2/HY 2017.&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is a monoclonal antibody that targets PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. MORPHEUS pancreatic cancer study is testing a number of cancer immunotherapy combinations to inform future development. MORPHEUS is a phase Ib/II adaptive development platform established by Roche to assess the efficacy and safety of combination cancer immunotherapies.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;solid tumors (MORPHEUS platform)&quot;,&quot;indicationLong&quot;:&quot;Solid tumors (MORPHEUS platform)&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;19&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;2L+ Follicular Lymphoma&quot;,&quot;indicationLong&quot;:&quot;2L+ Follicular Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;112&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Commodore 2&quot;,&quot;description&quot;:&quot;Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor naive patients&quot;,&quot;indicationLong&quot;:&quot;Paroxysmal Nocturnal Hemoglobinuria (PNH) C5 inhibitor naive patients\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6084&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;PD-L1 LNA&quot;,&quot;Autogenerated&quot;:&quot;150&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;PD-L1 LNA&quot;,&quot;description&quot;:&quot;RG6084 (PD-L1 LNA) is a liver-directed locked nucleic acid oligonucleotide targeting the PD-L1/PD-1 immune checkpoint inhibitory pathway, which is overexpressed in the liver of patients with chronic hepatitis B.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;chronic hepatitis B&quot;,&quot;indicationLong&quot;:&quot;chronic hepatitis B infection&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;26&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMvigor130. Indication and Description updated to reflect expansion of population to include cis-eligible patients and TCQ monotherapy arm.&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with chemotherapy or as monotherapy in patients with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line metastatic urothelial carcinoma&quot;,&quot;indicationLong&quot;:&quot;first line metastatic urothelial carcinoma&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6412&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;imdevimab&quot;,&quot;Autogenerated&quot;:&quot;158&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;hospitalised adult patients with COVID-19&quot;,&quot;indicationLong&quot;:&quot;hospitalised adult patients with COVID-19&quot;},{&quot;tradeName&quot;:&quot;Phesgo OBI&quot;,&quot;name&quot;:&quot;RG6264&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;pertuzumab FDC SC&quot;,&quot;Autogenerated&quot;:&quot;55&quot;,&quot;partner&quot;:&quot;West Pharmaceuticals&quot;,&quot;comment&quot;:&quot;added at HY 2022&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;HER2-positive breast cancer&quot;,&quot;indicationLong&quot;:&quot;HER2-positive breast cancer&quot;},{&quot;tradeName&quot;:&quot;Polivy&quot;,&quot;name&quot;:&quot;RG7596&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;polatuzumab vedotin&quot;,&quot;Autogenerated&quot;:&quot;7&quot;,&quot;partner&quot;:&quot;Seattle Genetics&quot;,&quot;comment&quot;:&quot;Phase III POLARIX NCT03274492 added FY 2017&quot;,&quot;description&quot;:&quot;Polivy (Polatuzumab vedotin) is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody anti-CD79b, conjugated to a potent anti-cancer agent that is selectively delivered to tumor cells. A phase III clinical trial is evaluating Polivy for the treatment of first line diffuse large B-cell lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line diffuse large B-cell lymphoma (DLBCL)&quot;,&quot;indicationLong&quot;:&quot;first line diffuse large B-cell lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6182&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;184&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neurodegenerative diseases&quot;,&quot;indicationLong&quot;:&quot;neurodegenerative diseases&quot;},{&quot;tradeName&quot;:&quot;Rozlytrek&quot;,&quot;name&quot;:&quot;RG6268&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;entrectinib&quot;,&quot;Autogenerated&quot;:&quot;56&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in Q1 2018 NCT02568267 STARTK2&quot;,&quot;description&quot;:&quot;Rozlytrek (entrectinib, RG6268) is a potent, selective CNS active tyrosine kinase inhibitor being developed for NTRK or ROS1 tumors. Activating ROS1 rearrangements are concentrated in NSCLC, accounting for 1-2% of NSCLC. rain. A phase II clinical trial is evaluating Rozlytrek for the treatment of non-small cell lung cancer positive for activating ROS1 rearrangements.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;non-small cell lung cancer (NSCLC) positive for ROS1 activating rearrangements&quot;,&quot;indicationLong&quot;:&quot;non-small cell lung cancer positive for activating ROS1 rearrangements&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;11&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;Q3 2017: filing date changed from 2018+ to 2019. CLL-14&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. Gazyva (obinutuzumab), is the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody specifically designed to selectively target the CD20 protein on malignant B-cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;first line chronic lymphocytic leukemia in combination with Gazyva&quot;,&quot;indicationLong&quot;:&quot;first line chronic lymphocytic leukemia in combination with Gazyva&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058-11&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;70&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SKYSCRAPER-08&quot;,&quot;description&quot;:&quot;Randomised Phase III (SKYSCRAPER-08) of tiragolumab plus Tecentriq in 1L esophageal cancer in China. Tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;1L esophageal cancer&quot;,&quot;indicationLong&quot;:&quot;first line esophageal cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;anti-FIXa/FX&quot;,&quot;Autogenerated&quot;:&quot;190&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;NXT007 is an optimized anti-FIXa/FX bispecific monoclonal antibody. NXT007 has an enhanced hemostatic activity and improved pharmacokinetics by antibody engineering technologies. The bispecific antibody is in phase I/II clinical study for healthy volunteers and hemophilia A.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;hemophilia A&quot;,&quot;indicationLong&quot;:&quot;hemophilia A&quot;},{&quot;tradeName&quot;:&quot;Gavreto&quot;,&quot;name&quot;:&quot;RG6396&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;pralsetinib&quot;,&quot;Autogenerated&quot;:&quot;85&quot;,&quot;partner&quot;:&quot;Blueprint Medicines&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;RET fusion-positive non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;RET fusion-positive NSCLC&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;69&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SKYSCRAPER-07\\n&quot;,&quot;description&quot;:&quot;Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;locally advanced esophageal cancer&quot;,&quot;indicationLong&quot;:&quot;locally advanced esophageal cancer \\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG1450&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;gantenerumab&quot;,&quot;Autogenerated&quot;:&quot;164&quot;,&quot;partner&quot;:&quot;Morphosys&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Gantenerumab (RG1450) is a fully human monoclonal antibody that binds and neutralises disease-relevant aggregated forms of amyloid-beta: those that accumulate as plaques in the brain and those which interfere with brain-cell functioning.  A phase III clinical trial is evaluating gantenerumab for the treatment of Alzheimer's disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;prodromal to mild Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;prodromal to mild Alzheimer's disease&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;20&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;3L+ Follicular Lymphoma&quot;,&quot;indicationLong&quot;:&quot;3L+ Follicular Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Glofitamab&quot;,&quot;Autogenerated&quot;:&quot;39&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q1 2017&quot;,&quot;description&quot;:&quot;Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma. A phase I clinical trial is evaluating RG6026 for the treatment of relapsed or refractory non-Hodgkin's lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory non-Hodgkin's lymphoma (NHL)&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory non-Hodgkin's lymphoma&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;45&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;impassion031&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is investigating Tecentriq in combination with nab-paclitaxel (Abraxane) as a potential neoadjuvant (before surgery) treatment for triple-negative breast cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;neoadjuvant triple-negative breast cancer (TNBC)&quot;,&quot;indicationLong&quot;:&quot;neoadjuvant triple-negative breast cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6149&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;astegolimab&quot;,&quot;Autogenerated&quot;:&quot;123&quot;,&quot;partner&quot;:&quot;Amgen&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;astegolimab (RG6149, anti-ST2, AMG 282) is a fully human monoclonal antibody designed to inhibit binding of interleukin-33 (IL-33) to the ST2 receptor. A phase II clinical trial is evaluating RG6149 for the treatment of chronic obstructive disease&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;chronic obstructive disease&quot;,&quot;indicationLong&quot;:&quot;chronic obstructive disease&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;124&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;systemic lupus erythematosus (SLE)&quot;,&quot;indicationLong&quot;:&quot;Systemic lupus erythematosus&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6319&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development&quot;,&quot;genericName&quot;:&quot;LepB inhibitor&quot;,&quot;Autogenerated&quot;:&quot;161&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;complicated urinary track infection&quot;,&quot;indicationLong&quot;:&quot;complicated urinary track infection&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6356&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;microdystrophin (SRP-9001)&quot;,&quot;Autogenerated&quot;:&quot;181&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Phase II gene therapy in Duchenne muscular dystrophy (DMD)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Duchenne muscular dystrophy (DMD)&quot;,&quot;indicationLong&quot;:&quot;Duchenne muscular dystrophy&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058-10&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;74&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Randomised Phase II in neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC) in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC) in combination with Tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;codrituzumab&quot;,&quot;Autogenerated&quot;:&quot;37&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Hepatocellular carcinoma (HCC)&quot;,&quot;indicationLong&quot;:&quot;Hepatocellular carcinoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6440&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;TGF-beta (SOF10)&quot;,&quot;Autogenerated&quot;:&quot;93&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Phase I study in solid tumors of RG6440 an Anti-TGF-beta monoclonal antibody&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;Solid tumors&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2&quot;,&quot;name&quot;:&quot;RG6412&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;imdevimab&quot;,&quot;Autogenerated&quot;:&quot;160&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay&quot;,&quot;indicationLong&quot;:&quot;Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;29&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in FY 2019 IMbrave050\\n&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with Avastin in adjuvant Hepatocellular carcinoma (HCC)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant hepatocellular carcinoma (HCC)&quot;,&quot;indicationLong&quot;:&quot;adjuvant hepatocellular carcinoma in combination with Avastin&quot;},{&quot;tradeName&quot;:&quot;Gavreto&quot;,&quot;name&quot;:&quot;RG6396&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;pralsetinib&quot;,&quot;Autogenerated&quot;:&quot;86&quot;,&quot;partner&quot;:&quot;Blueprint Medicines&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;RET positive thyroid cancer&quot;,&quot;indicationLong&quot;:&quot;RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer&quot;},{&quot;tradeName&quot;:&quot;Lunsumio + Polivy&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab + Polivy&quot;,&quot;Autogenerated&quot;:&quot;21&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022, SUNMO&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;2L+ SCT ineligible DLBCL&quot;,&quot;indicationLong&quot;:&quot;2L+ SCT ineligible DLBCL&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;25&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMscin001&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Atezolizumab (anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;Non-small cell lung cancer subcutaneous formulation&quot;,&quot;indicationLong&quot;:&quot;Non-small cell lung cancer subcutaneous formulation&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7921&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;134&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in Q2 2019&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;neovascular age related macular degeneration (wAMD)&quot;,&quot;indicationLong&quot;:&quot;neovascular age related macular degeneration&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6042&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tominersen&quot;,&quot;Autogenerated&quot;:&quot;177&quot;,&quot;partner&quot;:&quot;Ionis&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington's Disease. tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's Disease. Multiple clinical trials are evaluating tominersen for the treatment of patients with Huntington's Disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Huntington's Disease&quot;,&quot;indicationLong&quot;:&quot;Huntington's Disease&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6035&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;BS-CD20&quot;,&quot;Autogenerated&quot;:&quot;185&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Brain shuttle technology to transferAnti-CD20 antibody across the blood brain barrier and increase antibody concentrations in the brain/CNS&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;multiple sclerosis (MS)&quot;,&quot;indicationLong&quot;:&quot;multiple sclerosis&quot;},{&quot;tradeName&quot;:&quot;Alecensa&quot;,&quot;name&quot;:&quot;RG7853&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;alectinib&quot;,&quot;Autogenerated&quot;:&quot;12&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2018&quot;,&quot;description&quot;:&quot;Alecensa (Alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting downstream malignant pathways that contribute to tumorigenesis and disease progression. A phase III clinical trial is evaluating Alecensa for the treatment of adjuvant ALK-positive non-small cell lung cancer.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;adjuvant ALK-positive non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;adjuvant ALK-positive non-small cell lung cancer&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446-42&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;17&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMvigor011&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;ctDNA+ high risk muscle-invasive bladder cancer&quot;,&quot;indicationLong&quot;:&quot;ctDNA+ high risk muscle-invasive bladder cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;67&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SKYSCRAPER-01\\n&quot;,&quot;description&quot;:&quot;Randomised Phase III (SKYSCRAPER-02) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer (NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;1L non-small cell lung cancer (NSCLC) TPS>50%&quot;,&quot;indicationLong&quot;:&quot;1L non-small cell lung cancer (NSCLC) in combination with Tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7802&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;cibisatamab&quot;,&quot;Autogenerated&quot;:&quot;10&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;cibisatamab (RG7802) is a bispecific antibody designed to simultaneously target carcinoembryonic antigen (CEA) expressed on tumor cells and the CD3 receptor present on T cells, triggering T cell activation, migration and tumor killing. A phase I clinical trial is evaluating cibisatamab for the treatment of CEA-expressing solid tumors, as a single agent and in combination with atezolizumab.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;indicationLong&quot;:&quot;solid tumors&quot;},{&quot;tradeName&quot;:&quot;Rozlytrek&quot;,&quot;name&quot;:&quot;RG6268&quot;,&quot;filingDate&quot;:&quot;2019&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;entrectinib&quot;,&quot;Autogenerated&quot;:&quot;57&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added in Q1 2018 NCT02568267 STARTK2\\n&quot;,&quot;description&quot;:&quot;Rozlytrek (entrectinib, RG6268) is a potent, selective CNS active tyrosine kinase inhibitor being developed for NTRK or ROS1 tumors. Activating rearrangements in NTRK have been identified across >30 different solid tumor types, including head and neck, thyroid, sarcoma, and brain. A phase II clinical trial is evaluating Rozlytrek for the treatment of solid tumors positive for NTRK1 activating rearrangements.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;solid tumors positive for NTRK1 activating rearrangements&quot;,&quot;indicationLong&quot;:&quot;solid tumors positive for NTRK1 activating rearrangements&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6160&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;cevostamab&quot;,&quot;Autogenerated&quot;:&quot;47&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added as NME Q3 2017&quot;,&quot;description&quot;:&quot;cevostamab (FcRH5 X CD3)&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory multiple myeloma&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory multiple myeloma&quot;},{&quot;tradeName&quot;:&quot;Ocrevus SC&quot;,&quot;name&quot;:&quot;RG1594&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;ocrelizumab&quot;,&quot;Autogenerated&quot;:&quot;196&quot;,&quot;partner&quot;:&quot;Halozyme&quot;,&quot;comment&quot;:&quot;added at HY 2022; Ocarina II&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)&quot;,&quot;indicationLong&quot;:&quot;relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)&quot;},{&quot;tradeName&quot;:&quot;Ocrevus higher dose&quot;,&quot;name&quot;:&quot;RG1594&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;ocrelizumab&quot;,&quot;Autogenerated&quot;:&quot;197&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Gavotte, Musette&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)&quot;,&quot;indicationLong&quot;:&quot;relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;15&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMpassion030&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer.  Tecentriq (anti-PDL1, RG7446, Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential adjuvant treatment, in combination with paclitaxel, for triple-negative breast cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant triple-negative breast cancer (TNBC) in combination with paclitaxel&quot;,&quot;indicationLong&quot;:&quot;adjuvant triple-negative breast cancer in combination with paclitaxel&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7907&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;virology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;CpAM&quot;,&quot;Autogenerated&quot;:&quot;149&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;CpAM&quot;,&quot;description&quot;:&quot;CpAM (RG7907) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional core proteins, thereby effectively inhibiting HBV replication. A phase I clinical trial is evaluating RG7907 for the treatment of chronic hepatitis B infection.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;chronic hepatitis B&quot;,&quot;indicationLong&quot;:&quot;chronic hepatitis B infection&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7412&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crenezumab&quot;,&quot;Autogenerated&quot;:&quot;166&quot;,&quot;partner&quot;:&quot;AC Immune&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Crenezumab (RG7412) is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the main constituent of amyloid plaque in the brains of patients with Alzheimer's disease and is proposed to be causative in the development of the disease. A phase II clinical trial is evaluating crenezumab in \\nhealthy individuals with a history of familial Alzheimer’s disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease&quot;,&quot;indicationLong&quot;:&quot;Alzheimer's disease&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Glofitamab&quot;,&quot;Autogenerated&quot;:&quot;42&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;1L ctDNA higher risk diffuse large B-cell lymphoma (DLBCL)&quot;,&quot;indicationLong&quot;:&quot;1L ctDNA higher risk Diffuse Large B-Cell Lymphoma&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6091&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;rugonersen (UBE3-LNA)&quot;,&quot;Autogenerated&quot;:&quot;183&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;UBE3A-LNA is a locked nucleic acid developed for the treatment of Angelman syndrome which is caused by a lack of UBE3A expression in the brain. The LNA targets the paternal antisense RNA and enables the expression of UB3A in neurons.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Angelman syndrome&quot;,&quot;indicationLong&quot;:&quot;Angelman syndrome&quot;},{&quot;tradeName&quot;:&quot;Venclexta/Venclyxto&quot;,&quot;name&quot;:&quot;RG7601&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;venetoclax&quot;,&quot;Autogenerated&quot;:&quot;43&quot;,&quot;partner&quot;:&quot;AbbVie, Walter and Eliza Hall Institute&quot;,&quot;comment&quot;:&quot;Added to ph I Q1 2017. V + HMA (azacitidine). Myelodysplastic syndromes (MDS) after HMA failure.&quot;,&quot;description&quot;:&quot;Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and resistance. A phase I clinical trial is evaluating Venclexta as a single agent and in combination with the hypomethylating agent azacitidine in patients with relapsed or refractory myelodysplastic syndromes.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory myelodysplastic syndromes (MDS) in combination with azacitidine&quot;,&quot;indicationLong&quot;:&quot;relapsed or refractory myelodysplastic syndromes in combination with azacitidine&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;14&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMpower010&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, Atezolizumab ) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as a potential adjuvant treatment, following surgery and adjuvant cisplatin-based chemotherapy, for patients with non-small cell lung cancer whose tumors express PDL1.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;adjuvant non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;adjuvant non-small cell lung cancer&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;72&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Randomised Phase II (Cityscape) in 1L non-small cell lung cancer (NSCLC) in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;1L non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;1L non-small cell lung cancer (NSCLC) in combination with tecentriq&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;IONIS-1&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;&quot;,&quot;genericName&quot;:&quot;ASO factor B&quot;,&quot;Autogenerated&quot;:&quot;122&quot;,&quot;partner&quot;:&quot;Ionis&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by binding with factor B mRNA. ASO factor B is being studied for the treatment of IgA-nephropathy. A phase II clinical trial is evaluating ASO factor B for the treatment of IgA-nephropathy.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;IgA-nephropathy&quot;,&quot;indicationLong&quot;:&quot;IgA-nephropathy\\n&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6359&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;metabolic&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;SPARK&quot;,&quot;genericName&quot;:&quot;SPK-3006&quot;,&quot;Autogenerated&quot;:&quot;162&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;Pompe disease&quot;,&quot;indicationLong&quot;:&quot;Pompe disease&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6058&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tiragolumab&quot;,&quot;Autogenerated&quot;:&quot;73&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Randomised Phase II in 1L non-squamous non-small cell lung cancer (NSCLC) in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;1L non-squamous non-small cell lung cancer (NSCLC)&quot;,&quot;indicationLong&quot;:&quot;1L non-squamous non-small cell lung cancer (NSCLC) in combination with tecentriq&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2025+&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;127&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery system implant refilled every 36 weeks for the treatment of patients with subfoveal neovascular age-related macular degeneration. The primary outcome measure of the trial is the time until a patient first requires a refill of the implant.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;age-related macular degeneration (AMD) - 36 week refill interval&quot;,&quot;indicationLong&quot;:&quot;age-related macular -36 week refill interval&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;129&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;Pagoda&quot;,&quot;description&quot;:&quot;Ranibizumab (RG6321), the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the port delivery system implant for the treatment of patients with diabetic macular edema (DME).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;indicationLong&quot;:&quot;diabetic macular edema&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7774&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;138&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;indicationShort&quot;:&quot;retinal disease&quot;,&quot;indicationLong&quot;:&quot;retinal disease&quot;}]"><div class="pipeline-table"><roche-table-sort-header appearance="pipeline" class="hydrated"><div class="table__header"><div class="table__headline table__headline--sortable"><span class="table__headline--sortable__item">compound<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span><span class="table__headline--sortable__item">generic name<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span></div><div class="table__headline table__headline--sortable"><span class="table__headline--sortable__item">trade name<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span></div><div class="table__headline table__headline--sortable"><span class="table__headline--sortable__item">indication<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span></div><div class="table__headline table__headline--sortable"><span class="table__headline--sortable__item">phase 
1 2 3 f<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span></div><div class="table__headline table__headline--sortable"><span class="table__headline--sortable__item">expected 
filing<roche-icon data-sort-icon="chevron-down" class="hydrated"></roche-icon></span></div></div></roche-table-sort-header><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="CD19 X CD28" indication-short="relapsed or refractory Non Hodgkin's Lymphoma (NHL)" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="MAGE-A4 ImmTAC" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="geographic atrophy" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="camonsertib" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="first line acute myeloid leukemia (AML)" filing-date="2020" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="immunologic disorders" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="IL15/IL15Ra-Fc" indication-short="solid tumours" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="fenebrutinib" indication-short="relapsing multiple sclerosis (RMS)" filing-date="2025+" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="fenebrutinib" indication-short="primary progressive multiple sclerosis (PPMS)" filing-date="2025+" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="autogene cevumeran" indication-short="first line melanoma" filing-date="2025+" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="TLR7 agonist" indication-short="chronic hepatitis B" filing-date="" therapeutic-area="virology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Inavolisib" indication-short="metastatic ER-positive and HER2-negative breast cancer" filing-date="2024" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="bepranemab" indication-short="Alzheimer's disease" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="neoadjuvant HER2-positive breast cancer" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Evrysdi" generic-name="risdiplam" indication-short="spinal muscular atrophy (SMA)" filing-date="2019" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="VEGF-Ang2 DutaFab" indication-short="neovascular age related macular degeneration (wAMD)" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Lunsumio" generic-name="mosunetuzumab" indication-short="hematologic tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="SPK-8011" indication-short="hemophilia A" filing-date="" therapeutic-area="other" project-type="nme" managed-by="SPARK"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="ralmitaront" indication-short="psychiatric disorders" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crovalimab" indication-short="paroxysmal nocturnal hemoglobinuria (PNH) patients switching from a C5 inhibitor" filing-date="" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Abx MCP" indication-short="Acinetobacter baumannii infections" filing-date="" therapeutic-area="virology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="first line metastatic triple-negative breast cancer (TNBC) in combination with capecitabine or carboplatin / gemcitabine" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Glofitamab" indication-short="2L+ SCT-ineligible diffuse large B-cell lymphoma (DLBCL)" filing-date="2025+" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="SHP2i" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="diabetic macular edema (DME)" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Gazyva/Gazyvaro" generic-name="obinutuzumab" indication-short="lupus nephritis" filing-date="2024" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="first line non-squamous and squamous non-small cell lung cancer (NSCLC), PDL1-selected patients" filing-date="2020" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="selnoflast (NLRP3 inhibitor)" indication-short="Inflammation" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="asthma" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="pertuzumab FDC SC" indication-short="early HER2-positive breast cancer" filing-date="2020" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="AMY109" indication-short="endometriosis" filing-date="" therapeutic-area="other" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="Locally advanced or metastatic colorectal cancer (CRC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="Advanced renal cell carcinoma after immune checkpoint inhibitor treatment" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Enspryng" generic-name="satralizumab" indication-short="Myasthenia Gravis" filing-date="2024" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crovalimab" indication-short="paroxysmal nocturnal hemoglobinuria (PNH)" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="retinal disease" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Vabysmo" generic-name="faricimab" indication-short="macular edema secondary to branch retinal vein occlusion (RVO)" filing-date="2023" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="giredestrant" indication-short="ER-positive and HER2-negative metastatic breast cancer" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="2L non small cell lung cancer (NSCLC) treatment in combination with cabozantinib" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="recombinant human pentraxin-2" indication-short="Idiopathic pulmonary fibrosis" filing-date="2024" therapeutic-area="immunology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="FAP 4-1BBL" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Gazyva/Gazyvaro" generic-name="obinutuzumab" indication-short="membranous nephropathy" filing-date="2025+" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Enspryng" generic-name="satralizumab" indication-short="neuromyelitis optica spectrum disorder" filing-date="2019" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crovalimab" indication-short="atypical hemolytic uremic syndrome (aHUS)" filing-date="2024" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="ipatasertib" indication-short="first line castration-resistant prostate cancer" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="galegenimab (HtrA1)" indication-short="geographic atrophy" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="Inflammatory bowel disease (IBD)" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="relapsed or refractory t(11;14)-positive multiple myeloma" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Brain shuttle gantenerumab" indication-short="Alzheimer's disease" filing-date="2025+" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Vabysmo" generic-name="faricimab" indication-short="diabetic macular edema (DME)" filing-date="2021" therapeutic-area="ophthalmology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="KRAS G12C" indication-short="metastatic solid tumors with KRAS G12C mutation" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Alecensa" generic-name="alectinib" indication-short="first line ALK-positive (liquid biopsy) non-small cell lung cancer (NSCLC)" filing-date="2020" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="Alzheimer's disease" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="casivirimab" indication-short="Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay" filing-date="2021" therapeutic-area="virology" project-type="nme" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Anti-CD25" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="HBV siRNA" indication-short="Hepatitis B virus" filing-date="" therapeutic-area="virology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Gazyva/Gazyvaro" generic-name="obinutuzumab" indication-short="systemic lupus erythematosus (SLE)" filing-date="2025+" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="HLA-A2-WT1 X CD3" indication-short="Adult acute myeloid leukemia (AML)" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="cervical cancer" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma (SCCHN)" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="SPYK04" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="maintenance 1Lextensive stage-small cell lung cancer (SCLC) in combination with lurbinectedin" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Anti-PD1 X LAG3" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Xofluza" generic-name="baloxavir marboxil" indication-short="influenza, pediatric patients (1-12yr)" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="recombinant human pentraxin-2" indication-short="myelofibrosis" filing-date="2025+" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Xofluza" generic-name="baloxavir marboxil" indication-short="influenza, pediatric patients (0-1yr)" filing-date="2023" therapeutic-area="virology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="TLR7 agonist" indication-short="chronic hepatitis B" filing-date="" therapeutic-area="virology" project-type="ai" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="CD19-4-1BBL" indication-short="heme tumours" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="adjuvant renal cell carcinoma (RCC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="first line hepatocellular carcinoma (HCC)" filing-date="2020" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="GPRC5D x CD3" indication-short="multiple myeloma" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="inflammatory diseases" filing-date="" therapeutic-area="immunology" project-type="ai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="HLA-A2-MAGE-A4 X CD3" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="BRAF inhibitor (3)" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="SPK-8016" indication-short="hemophilia A with inhibitors to factor VIII" filing-date="" therapeutic-area="other" project-type="nme" managed-by="SPARK"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="giredestrant + Phesgo" indication-short="ER-positive and HER2-positive  1L breast cancer" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Vabysmo" generic-name="faricimab" indication-short="neovascular age related macular degeneration (wAMD)" filing-date="2021" therapeutic-area="ophthalmology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="ASO factor B" indication-short="geographic atrophy" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="asthma" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="relapsed or refractory multiple myeloma in combination with carfilzomib" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="autogene cevumeran" indication-short="solid tumors" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="giredestrant" indication-short="metastatic ER+ breast cancer" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="first line non-squamous NSCLC, combination with chemotherapy and pemetrexed" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Xofluza" generic-name="baloxavir marboxil" indication-short="influenza, post exposure prophylaxis" filing-date="2020" therapeutic-area="virology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Xolair" generic-name="omalizumab" indication-short="Food allergy" filing-date="2023" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Xofluza" generic-name="baloxavir marboxil" indication-short="influenza, direct transmission" filing-date="2023" therapeutic-area="virology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="latent myostatin + Evrysdi" indication-short="" filing-date="2025+" therapeutic-area="" project-type="nme" managed-by="Roche Group"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="prasinezumab" indication-short="Parkinson's disease" filing-date="2025+" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="PD1-IL2v" indication-short="solid tumours" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="FAP-CD40" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="CD137 agonist switch antibody" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Kadcyla" generic-name="trastuzumab emtansine" indication-short="2L+ HER-2 positive PD-L1 positive metastatic breast cancer in combination with Tecentriq" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Evrysdi" generic-name="risdiplam" indication-short="spinal muscular atrophy (SMA) pediatric <2 months" filing-date="2021" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="geographic atrophy" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="adjuvant squamous cell carcinoma of the head and neck (SCCHN)" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="LUNA18" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Vabysmo" generic-name="faricimab" indication-short="macular edema secondary to central retinal vein occlusion (RVO)" filing-date="2023" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="casivirimab" indication-short="ambulatory patients with COVID-19" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Susvimo" generic-name="Port Delivery System with ranibizumab" indication-short="age-related macular degeneration (AMD)" filing-date="2020" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Susvimo" generic-name="Port Delivery System with ranibizumab" indication-short="diabetic retinopathy" filing-date="2023" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="glypican-3 X CD3" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="heme and solid tumors" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Kadcyla" generic-name="trastuzumab emtansine" indication-short="high risk patients with adjuvant HER2-positive breast cancer in combination with Tecentriq" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="gantenerumab" indication-short="early Alzheimer's disease" filing-date="2025+" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Actemra/RoACTEMRA" generic-name="tocilizumab" indication-short="Covid-19 pneumonia" filing-date="2021" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Kadcyla" generic-name="trastuzumab emtansine" indication-short="adjuvant HER2-positive breast cancer" filing-date="2019" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="semorinemab" indication-short="Alzheimer's disease" filing-date="2025+" therapeutic-area="neuroscience" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="newly diagnosed higher-risk myelodysplastic syndrome (MDS)" filing-date="2024" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="oncology" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Glofitamab" indication-short="3L+ diffuse large B-cell lymphoma (DLBCL)" filing-date="2022" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="giredestrant" indication-short="adjuvant ER+ breast cancer" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="EGFRvIII X CD3" indication-short="glioblastoma (GBM)" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="casivirimab" indication-short="hospitalized adult patients with COVID-19" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="alogabat (GABA-Aa5 PAM)" indication-short="autism spectrum disorder" filing-date="2025+" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="maintenance 1L extensive stage-small cell lung cancer (SCLC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="stage III unresectable 1L non-small cell lung cancer (NSCLC)" filing-date="2024" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="psychiatric disorders" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="PBMC Vaccine" indication-short="solid tumours" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="belvarafenib" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="efmarodocokin alfa (IL22-Fc)" indication-short="inflammatory diseases" filing-date="2025+" therapeutic-area="immunology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="emicizumab" indication-short="Mild to moderate hemophilia A, without FVIII inhibitors" filing-date="2022" therapeutic-area="other" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crovalimab" indication-short="sickle cell disease (SCD)" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="HER2 X CD3" indication-short="metastatic HER2-positive cancers" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="neurodevelopmental disorders" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="imdevimab" indication-short="ambulatory adult patients with COVID-19" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="latent myostatin" indication-short="neuromuscular disorders" filing-date="" therapeutic-area="neuroscience" project-type="ai" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="solid tumors (MORPHEUS platform)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Lunsumio" generic-name="mosunetuzumab" indication-short="2L+ Follicular Lymphoma" filing-date="2025" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crovalimab" indication-short="paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor naive patients" filing-date="2022" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="PD-L1 LNA" indication-short="chronic hepatitis B" filing-date="" therapeutic-area="virology" project-type="ai" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="first line metastatic urothelial carcinoma" filing-date="2022" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="imdevimab" indication-short="hospitalised adult patients with COVID-19" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Phesgo OBI" generic-name="pertuzumab FDC SC" indication-short="HER2-positive breast cancer" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Polivy" generic-name="polatuzumab vedotin" indication-short="first line diffuse large B-cell lymphoma (DLBCL)" filing-date="2021" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="neurodegenerative diseases" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Rozlytrek" generic-name="entrectinib" indication-short="non-small cell lung cancer (NSCLC) positive for ROS1 activating rearrangements" filing-date="2019" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="first line chronic lymphocytic leukemia in combination with Gazyva" filing-date="2019" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="1L esophageal cancer" filing-date="2022" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="anti-FIXa/FX" indication-short="hemophilia A" filing-date="" therapeutic-area="other" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Gavreto" generic-name="pralsetinib" indication-short="RET fusion-positive non-small cell lung cancer (NSCLC)" filing-date="2020" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="locally advanced esophageal cancer" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="gantenerumab" indication-short="prodromal to mild Alzheimer's disease" filing-date="2022" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Lunsumio" generic-name="mosunetuzumab" indication-short="3L+ Follicular Lymphoma" filing-date="2021" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Glofitamab" indication-short="relapsed or refractory non-Hodgkin's lymphoma (NHL)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="neoadjuvant triple-negative breast cancer (TNBC)" filing-date="2020" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="astegolimab" indication-short="chronic obstructive disease" filing-date="" therapeutic-area="immunology" project-type="ai" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Lunsumio" generic-name="mosunetuzumab" indication-short="systemic lupus erythematosus (SLE)" filing-date="" therapeutic-area="immunology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="LepB inhibitor" indication-short="complicated urinary track infection" filing-date="" therapeutic-area="" project-type="nme" managed-by="Genentech Research and Early Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="microdystrophin (SRP-9001)" indication-short="Duchenne muscular dystrophy (DMD)" filing-date="2024" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="codrituzumab" indication-short="Hepatocellular carcinoma (HCC)" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="TGF-beta (SOF10)" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Chugai"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="REGEN-COV-2" generic-name="imdevimab" indication-short="Prevention of SARS CoV-2 Infection, asymptomatic in healthy adults who are household contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay" filing-date="2021" therapeutic-area="virology" project-type="ai" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="adjuvant hepatocellular carcinoma (HCC)" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Gavreto" generic-name="pralsetinib" indication-short="RET positive thyroid cancer" filing-date="2020" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Lunsumio + Polivy" generic-name="mosunetuzumab + Polivy" indication-short="2L+ SCT ineligible DLBCL" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="Non-small cell lung cancer subcutaneous formulation" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="neovascular age related macular degeneration (wAMD)" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tominersen" indication-short="Huntington's Disease" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="BS-CD20" indication-short="multiple sclerosis (MS)" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Alecensa" generic-name="alectinib" indication-short="adjuvant ALK-positive non-small cell lung cancer (NSCLC)" filing-date="2023" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="ctDNA+ high risk muscle-invasive bladder cancer" filing-date="2024" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="1L non-small cell lung cancer (NSCLC) TPS>50%" filing-date="2023" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="cibisatamab" indication-short="solid tumors" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Rozlytrek" generic-name="entrectinib" indication-short="solid tumors positive for NTRK1 activating rearrangements" filing-date="2019" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="cevostamab" indication-short="relapsed or refractory multiple myeloma" filing-date="" therapeutic-area="oncology" project-type="nme" managed-by="Genentech Research and Early Development (gRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Ocrevus SC" generic-name="ocrelizumab" indication-short="relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)" filing-date="2023" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Ocrevus higher dose" generic-name="ocrelizumab" indication-short="relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)" filing-date="2025+" therapeutic-area="neuroscience" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="adjuvant triple-negative breast cancer (TNBC) in combination with paclitaxel" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="CpAM" indication-short="chronic hepatitis B" filing-date="" therapeutic-area="virology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="crenezumab" indication-short="Alzheimer's disease" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="Glofitamab" indication-short="1L ctDNA higher risk diffuse large B-cell lymphoma (DLBCL)" filing-date="2025+" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="rugonersen (UBE3-LNA)" indication-short="Angelman syndrome" filing-date="" therapeutic-area="neuroscience" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Venclexta/Venclyxto" generic-name="venetoclax" indication-short="relapsed or refractory myelodysplastic syndromes (MDS) in combination with azacitidine" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Tecentriq" generic-name="atezolizumab" indication-short="adjuvant non-small cell lung cancer (NSCLC)" filing-date="2021" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="1L non-small cell lung cancer (NSCLC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="ASO factor B" indication-short="IgA-nephropathy" filing-date="" therapeutic-area="immunology" project-type="nme" managed-by=""></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="SPK-3006" indication-short="Pompe disease" filing-date="" therapeutic-area="metabolic" project-type="nme" managed-by="SPARK"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="tiragolumab" indication-short="1L non-squamous non-small cell lung cancer (NSCLC)" filing-date="" therapeutic-area="oncology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Susvimo" generic-name="Port Delivery System with ranibizumab" indication-short="age-related macular degeneration (AMD) - 36 week refill interval" filing-date="2025+" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="Susvimo" generic-name="Port Delivery System with ranibizumab" indication-short="diabetic macular edema (DME)" filing-date="2023" therapeutic-area="ophthalmology" project-type="ai" managed-by="Roche Late Stage Product Development"></roche-pipeline-table-row><roche-pipeline-table-row class="table__row hydrated" trade-name="" generic-name="NME" indication-short="retinal disease" filing-date="" therapeutic-area="ophthalmology" project-type="nme" managed-by="Pharma Research and Early Development (pRED)"></roche-pipeline-table-row></div></roche-pipeline-table><div slot="right" js-first-column-child="" style="position: sticky; top: 1rem; margin-top: -98px; z-index: 100;"><roche-text-link text="Download current view as CSV" left-icon="download" href="https://staging.apis.cwp.roche.com/externaldatasources/pipeline/export" target="_blank" class="hydrated"></roche-text-link><roche-input name="search" type="search" label="Search" value="" required="true" class="hydrated"></roche-input><roche-dropdown name="groupListBy" label="Group list by" selected="0" required="true" options="[{&quot;label&quot;:&quot;All&quot;,&quot;value&quot;:&quot;all&quot;},{&quot;label&quot;:&quot;Therapeutic Area&quot;,&quot;value&quot;:&quot;therapeuticArea&quot;},{&quot;label&quot;:&quot;Partner&quot;,&quot;value&quot;:&quot;partner&quot;},{&quot;label&quot;:&quot;Phase&quot;,&quot;value&quot;:&quot;phase&quot;},{&quot;label&quot;:&quot;Managed By&quot;,&quot;value&quot;:&quot;managedBy&quot;},{&quot;label&quot;:&quot;Expected Filing&quot;,&quot;value&quot;:&quot;filingDate&quot;}]" class="hydrated"></roche-dropdown><roche-accordion-tabs appearance="pipeline" type="accordion" no-margin="true" class="hydrated"><!----><ul class="tabs"><li><button class="tabs__item">Therapeutic Area</button></li><li><button class="tabs__item">Project Type</button></li><li><button class="tabs__item">Phase</button></li><li><button class="tabs__item">Expected Filing Date</button></li></ul><roche-accordion-tabs-item headline="Therapeutic Area" appearance="pipeline" is-overflow-y-scrollable="true" type="accordion" class="hydrated"><roche-select label-wrapper="true" select-all="true" multi-select="true" name="therapeuticArea" options="[{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Immunology&quot;,&quot;value&quot;:&quot;immunology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Metabolic&quot;,&quot;value&quot;:&quot;metabolic&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Neuroscience&quot;,&quot;value&quot;:&quot;neuroscience&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Oncology&quot;,&quot;value&quot;:&quot;oncology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Ophthalmology&quot;,&quot;value&quot;:&quot;ophthalmology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Other&quot;,&quot;value&quot;:&quot;other&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticArea&quot;,&quot;label&quot;:&quot;Virology&quot;,&quot;value&quot;:&quot;virology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;}]" class="hydrated"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline="Project Type" appearance="pipeline" is-overflow-y-scrollable="false" type="accordion" class="hydrated"><roche-select label-wrapper="true" select-all="true" multi-select="true" name="projectType" options="[{&quot;group&quot;:&quot;projectType&quot;,&quot;label&quot;:&quot;Additional Indication&quot;,&quot;value&quot;:&quot;ai&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;additional&quot;},{&quot;group&quot;:&quot;projectType&quot;,&quot;label&quot;:&quot;New Molecular Entity&quot;,&quot;value&quot;:&quot;nme&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;molecular-item&quot;}]" class="hydrated"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline="Phase" appearance="pipeline" is-overflow-y-scrollable="true" type="accordion" class="hydrated"><roche-select label-wrapper="true" select-all="true" multi-select="true" name="phase" options="[{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Filed&quot;,&quot;value&quot;:&quot;Filed&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 1&quot;,&quot;value&quot;:&quot;Phase 1&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 2&quot;,&quot;value&quot;:&quot;Phase 2&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 3&quot;,&quot;value&quot;:&quot;Phase 3&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null}]" class="hydrated"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline="Expected Filing Date" appearance="pipeline" is-overflow-y-scrollable="true" type="accordion" class="hydrated"><roche-select label-wrapper="true" select-all="true" multi-select="true" name="filingDate" options="[{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2019&quot;,&quot;value&quot;:&quot;2019&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2020&quot;,&quot;value&quot;:&quot;2020&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2021&quot;,&quot;value&quot;:&quot;2021&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2022&quot;,&quot;value&quot;:&quot;2022&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2023&quot;,&quot;value&quot;:&quot;2023&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2024&quot;,&quot;value&quot;:&quot;2024&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2025&quot;,&quot;value&quot;:&quot;2025&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2025+&quot;,&quot;value&quot;:&quot;2025+&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null}]" class="hydrated"></roche-select></roche-accordion-tabs-item></roche-accordion-tabs></div></roche-grid></div></roche-accordion-tabs-item><roche-accordion-tabs-item icon="" headline="See Changes" uid="2fed21d8-ce3e-4c4c-a9d0-519999c0984a" id="2fed21d8-ce3e-4c4c-a9d0-519999c0984a" storyid="78842718" type="tabs" appearance="default" class="hydrated"><roche-pipeline-changes-table content="[{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;retinal disease&quot;,&quot;genericName&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Target and exact indication not disclosed&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6351&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;genericName&quot;:&quot;camonsertib&quot;,&quot;comment&quot;:&quot;In-licensed from Repare Therapeutics July 2022&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6526&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;HER2-positive breast cancer&quot;,&quot;genericName&quot;:&quot;Phesgo OBI&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6264&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Cardio Metabolism&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;metabolic diseases&quot;,&quot;genericName&quot;:&quot;&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6338&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;metastatic castration-resistant prostate cancer and solid tumors&quot;,&quot;genericName&quot;:&quot;ipatasertib + rucaparib&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7440&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;prostate cancer previously treated with androgen receptor-targeted therapy&quot;,&quot;genericName&quot;:&quot;ipatasertib&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7440&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;spinal muscular atrophy&quot;,&quot;genericName&quot;:&quot;latent myostatin + Evrysdi&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6237&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;asthma&quot;,&quot;genericName&quot;:&quot;anti-tryptase&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6173&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;ER-positive and HER2-negative  2/3L metastatic breast cancer&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;comment&quot;:&quot;acelERA&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;RMS &amp; PPMS&quot;,&quot;genericName&quot;:&quot;Ocrevus SC&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG1594&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;ER-positive and HER2-positive  1L breast cancer&quot;,&quot;genericName&quot;:&quot;giredestrant + Phesgo&quot;,&quot;comment&quot;:&quot;heredERA&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG6171&quot;},{&quot;indicationLong&quot;:&quot;Cognitively unimpaired participants at risk for or at the earliest stages of Alzheimer’s disease&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;early alzheimer’s&quot;,&quot;genericName&quot;:&quot;gantenerumab&quot;,&quot;comment&quot;:&quot;Skyline&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG1450&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;2L+ SCT ineligible DLBCL&quot;,&quot;genericName&quot;:&quot;mosunetuzumab + Polivy&quot;,&quot;comment&quot;:&quot;SUNMO&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;RG7828&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;3L FL&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;region&quot;:&quot;EU&quot;,&quot;name&quot;:&quot;RG7828&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;SMA presymptomatic pediatric <2mo&quot;,&quot;genericName&quot;:&quot;risdiplam&quot;,&quot;comment&quot;:&quot;Rainbowfish&quot;,&quot;region&quot;:&quot;US&quot;,&quot;name&quot;:&quot;RG7916&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;1L DLBCL&quot;,&quot;genericName&quot;:&quot;polatuzumab vedotin&quot;,&quot;comment&quot;:&quot;POLARIX&quot;,&quot;region&quot;:&quot;EU&quot;,&quot;name&quot;:&quot;RG7596&quot;},{&quot;indicationLong&quot;:&quot;&quot;,&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;adjuvant NSCLC&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;comment&quot;:&quot;IMpower010&quot;,&quot;region&quot;:&quot;EU&quot;,&quot;name&quot;:&quot;RG7446&quot;}]" class="hydrated"></roche-pipeline-changes-table></roche-accordion-tabs-item></roche-accordion-tabs></roche-accordion-tabs-item><roche-accordion-tabs-item icon="" headline="Diagnostics" uid="a0ee39d1-4024-4867-943c-60eb804c7ff0" id="a0ee39d1-4024-4867-943c-60eb804c7ff0" storyid="78842718" type="tabs" appearance="default" class="hydrated"><div><roche-pipeline-diagnostics content="[{&quot;area&quot;:&quot;Software&quot;,&quot;description&quot;:&quot;EMR integration&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Decision Support&quot;,&quot;productName&quot;:&quot;NAVIFY Tumor Board v 1.x&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;Completion of the existing growth hormone menu of hGH and IGF-1&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Endocrinology&quot;,&quot;productName&quot;:&quot;IGFBP3&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;Highly specific immunoassay for the in vitro qualitative detection of IgG antibodies to Zika virus in human serum and plasma&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Infectious Diseases&quot;,&quot;productName&quot;:&quot;Zika IgG&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;Highest throughput CT/NG test on the market with workflow efficiency benefits&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Microbiology&quot;,&quot;productName&quot;:&quot;cobas CT/NG&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;High volume solution for MTB/MAI testing; efficient approach to disease management (mixed testing) for infectious disease&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Microbiology&quot;,&quot;productName&quot;:&quot;cobas 6800/8800 MTB/MAI&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;Card-like sample collection device; separates plasma from whole blood; for use with CAP/CTM HIV- 1 &amp; cobas HIV-1 (6800/8800)&quot;,&quot;color&quot;:&quot;Red&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Virology&quot;,&quot;productName&quot;:&quot;Plasma Separation Card&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2018&quot;,&quot;description&quot;:&quot;3 separate tissue based assay kits for solid tumors&quot;,&quot;color&quot;:&quot;Yellow&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Sequencing&quot;,&quot;productName&quot;:&quot;AVENIO FFPET RUO oncology kits&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;Serum Work Area solution for medium throughput to lower high throughout labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Central Laboratory&quot;,&quot;productName&quot;:&quot;cobas pro integrated solution&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;World's first fully digital morphology analyzer and cell counter&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Specialty Testing&quot;,&quot;productName&quot;:&quot;cobas m 511&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;Connection of cobas c 513 to CCM Automation System for high volume HbA1c testing&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Workflow&quot;,&quot;productName&quot;:&quot;CCM connectivity to cobas c513&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;New and differentiated Advanced Staining System&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Tissue Dx&quot;,&quot;productName&quot;:&quot;BenchMark ULTRA Plus&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;Reliable low-volume scanner with superior image quality&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Digital Pathology&quot;,&quot;productName&quot;:&quot;VENTANA DP200&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2018&quot;,&quot;description&quot;:&quot;Small and tubeless insulin delivery device operated through a remote control which includes a blood glucose meter&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Diabetes care&quot;,&quot;productName&quot;:&quot;Solo Patch Pump&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;One global laboratory middleware solution realizing a very high degree of integration in the laboratory&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Central Laboratory&quot;,&quot;productName&quot;:&quot;cobas Infinity Central Lab 3.0&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Whole slide analysis image analysis algorithm (HER2, ER, PR, Ki-67)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Tissue Dx&quot;,&quot;productName&quot;:&quot;Algorithm - Breast Panel&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Whole slide analysis image analysis algorithm (SP263)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Tissue Dx&quot;,&quot;productName&quot;:&quot;Algorithm - PD-L1 Lung&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Software as a medical device for annotating, variant classification, clinical interpretation and reporting from comprehensive genomic profile testing&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE/US&quot;,&quot;title&quot;:&quot;Sequencing&quot;,&quot;productName&quot;:&quot;NAVIFY Mutation Profiler&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Informing on treatment options based on local drugs labels, medical guidelines and clinical trial outcomes&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE/US&quot;,&quot;title&quot;:&quot;Sequencing&quot;,&quot;productName&quot;:&quot;NAVIFY Therapy Matcher&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Integrating a GEHC DICOM imaging viewer into the Tumor Board to support the radiologist&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Decision Support&quot;,&quot;productName&quot;:&quot;NAVIFY Tumor Board V2&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;Integration of patient's longitudinal history, diagnosis, and treatment planning by leveraging relevant guidelines&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;&quot;,&quot;productName&quot;:&quot;NAVIFY Oncology Workflow V1&quot;},{&quot;area&quot;:&quot;Software planned for 2019&quot;,&quot;description&quot;:&quot;For non-insulin dependent T2 PwDs, allowing for meter-free blood glucose monitoring using Accu-Chek Active test strips and a smartphone camera&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Accu-Chek Sugar View 2.0 (non-ISO)&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2019&quot;,&quot;description&quot;:&quot;Pre-analytical platform to support cobas 6800/8800&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE/US&quot;,&quot;title&quot;:&quot;Workflow&quot;,&quot;productName&quot;:&quot;cobas prime&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2019&quot;,&quot;description&quot;:&quot;Quantitative determination of protein C in citrated plasma on cobas t 511/ t 711 analyzers&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Coagulation&quot;,&quot;productName&quot;:&quot;Protein C Chrom&quot;},{&quot;area&quot;:&quot;Tests/Assays planned for 2019&quot;,&quot;description&quot;:&quot;Fully automated, brightfield ISH assay to determine eligibility for HER2 targeted therapy&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Tissue Dx&quot;,&quot;productName&quot;:&quot;VENTANA HER2 Dual ISH&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Assay for diagnosis of HER2 low expression breast cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;HER2 Low Breast&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;PRAME&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Self sample collection device for patients at home to collect sample for cervical cancer testing&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;HPV Self Sampling&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Antigen/antibody combined assay for faster diagnosis of hepatitis C&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas® HCV Duo&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer’s Disease&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys pTau/AB42 ratio Gen2 (CSF)&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Automated RT-PCR assay for use on the cobas® 6800/8800 systems&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; OUS&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas® SARS-CoV-2 DUO&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas® 5800 Menu Expansion&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Digital solution (mobile app and dashboard) providing insights for chronic kidney disease patient management&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Chronic Kidney Disease InSight&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Digital solution (mobile app and workflow) improving the management of screening programs for cervical cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Cervical Cancer Screening&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;cobas® infinity edge suite&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Data integration platform for laboratory customers across disciplines&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Lab Insights Platform&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Diabetic population dashboard for healthcare professional administrators and payers&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Payer Dashboard&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Module providing basal rate data and expanded smartphone compatibility for all Android and iPhone users&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;mySugar Pump V2.0&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;Automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys® SARS-CoV-2 Antigen&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;A set of 5 intended use extensions in the Coronary Arterial Disease, Atrial Fibrillation and Heart Failure Space&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys® NT-proBNP IU&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;A set of 5 intended use extensions in the Coronary Arterial Disease, Atrial Fibrillation and Heart Failure Space&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys® TnT–hs 3 claim extensions in Coronary Arterial Disease&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;Decentralized kit of the FoundationOne test&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;AVENIO FoundationOne kit (RUO)&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;New targeted sequencing portfolio using primer extension for small targets&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;KAPA HyperPETE kit&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;BenchMark ULTRA PLUS&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;High capacity pathology slide scanner for high volume digitization applications&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;DP600&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Serum work area analyzer for low-to-medium sized labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas® pure integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Real-time PCR molecular testing for low volume labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas® 5800&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;Digital LightCycler&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Handheld device combining professional Glucose Meter and a digital platform to host Roche owned and 3rd party digital clinical decision support applications&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;POC&quot;,&quot;productName&quot;:&quot;cobas® pulse&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;First IVD release and version of Open API of the clinical pathologist workflow module for NAVIFY Digital Pathology &amp; on-premise uPath&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;uPath 2.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Whole slide image analysis algorithms (ER (SP1), Ki-67 (30-9), and PR (1E2))&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;RUO Algorithms&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Modular Oncology decision support solution&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Insights&quot;,&quot;productName&quot;:&quot;NAVIFY Oncology 1.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Solution for providers to communicate SARS-CoV-2 rapid antigen test results to a mobile app&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE3&quot;,&quot;title&quot;:&quot;Insights&quot;,&quot;productName&quot;:&quot;NAVIFY Pass 1.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Algorithm for early detection of HCC in patients with chronic liver disease&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys® GAAD Algorithm&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Module within RDCP that enables remote Health Care Professional - Patient with Diabetes interaction, including a patient dashboard, check-in and chat functionality&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Remote Patient Monitoring&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Meter-free blood glucose testing using a smartphone and app&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Accu-Chek SugarView&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Low-to-medium volume SWA&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas® pure integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;New high throughput configurations of the cobas pro instrument&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas® pro integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Successor of Accu-Chek® Inform II&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Point of Care&quot;,&quot;productName&quot;:&quot;cobas® pulse&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Fully automated low throughput PCR system&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas® 5800&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Automated sequencing library preparation and target enrichment instrument&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;AVENIO Edge System&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;New features for the Instant meter to increase performance and user experience&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Accu-Chek Instant Forward&quot;}]" is-mobile="false" class="hydrated"><div class="pipeline-table"><roche-table-sort-header appearance="diagnostics" class="hydrated"><div class="table__header"><div class="table__headline"><span class="table__headline--sortable__item">area</span></div><div class="table__headline"><span class="table__headline--sortable__item">product name</span></div><div class="table__headline"><span class="table__headline--sortable__item">description</span></div><div class="table__headline"><span class="table__headline--sortable__item">market</span></div></div></roche-table-sort-header><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="Elecsys® GAAD Algorithm" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="Accu-Chek SugarView" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="Remote Patient Monitoring" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Insights" product-name="NAVIFY Pass 1.0" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Insights" product-name="NAVIFY Oncology 1.0" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="RUO Algorithms" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="uPath 2.0" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="mySugar Pump V2.0" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="Payer Dashboard" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Lab Insights" product-name="Lab Insights Platform" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Lab Insights" product-name="cobas® infinity edge suite"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Lab Insights" product-name="Cervical Cancer Screening"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Lab Insights" product-name="Chronic Kidney Disease InSight" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="cobas® pure integrated solutions" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="Digital LightCycler" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="cobas® 5800" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="DP600" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="BenchMark ULTRA PLUS" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="POC" product-name="cobas® pulse" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Central Laboratory" product-name="cobas pro integrated solution" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes care" product-name="Solo Patch Pump" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Digital Pathology" product-name="VENTANA DP200" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Specialty Testing" product-name="cobas m 511" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Tissue Dx" product-name="BenchMark ULTRA Plus" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Workflow" product-name="CCM connectivity to cobas c513" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Workflow" product-name="cobas prime" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="cobas® pro integrated solutions" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="cobas® pure integrated solutions" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="Accu-Chek Instant Forward" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="AVENIO Edge System" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="cobas® 5800" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Point of Care" product-name="cobas® pulse" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Decision Support" product-name="NAVIFY Tumor Board v 1.x" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="" product-name="NAVIFY Oncology Workflow V1" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Central Laboratory" product-name="cobas Infinity Central Lab 3.0" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Decision Support" product-name="NAVIFY Tumor Board V2" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Diabetes Care" product-name="Accu-Chek Sugar View 2.0 (non-ISO)" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Sequencing" product-name="NAVIFY Therapy Matcher" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Sequencing" product-name="NAVIFY Mutation Profiler" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Tissue Dx" product-name="Algorithm - PD-L1 Lung" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Tissue Dx" product-name="Algorithm - Breast Panel" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="Elecsys® TnT–hs 3 claim extensions in Coronary Arterial Disease" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="Elecsys® NT-proBNP IU"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="Elecsys® SARS-CoV-2 Antigen" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="KAPA HyperPETE kit" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="AVENIO FoundationOne kit (RUO)" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="Elecsys pTau/AB42 ratio Gen2 (CSF)" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Core Lab" product-name="cobas® HCV Duo" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="cobas® 5800 Menu Expansion" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Molecular Lab" product-name="cobas® SARS-CoV-2 DUO" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="HPV Self Sampling" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="PRAME"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Pathology Lab" product-name="HER2 Low Breast" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Endocrinology" product-name="IGFBP3" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Infectious Diseases" product-name="Zika IgG" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Microbiology" product-name="cobas 6800/8800 MTB/MAI" is-title-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Microbiology" product-name="cobas CT/NG" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Sequencing" product-name="AVENIO FFPET RUO oncology kits" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Virology" product-name="Plasma Separation Card" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-headline appearance="pipeline" class="hydrated"></roche-headline><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Coagulation" product-name="Protein C Chrom" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class="table__row hydrated" diagnostic-title="Tissue Dx" product-name="VENTANA HER2 Dual ISH" is-title-visible="" is-border-visible=""></roche-pipeline-diagnostics-row></div><roche-pipeline-caption caption-string="[{&quot;abbreviation&quot;:&quot;CE - &quot;,&quot;description&quot;:&quot;European Conformity;&quot;},{&quot;abbreviation&quot;:&quot;US - &quot;,&quot;description&quot;:&quot;FDA Approval;&quot;},{&quot;abbreviation&quot;:&quot;WW - &quot;,&quot;description&quot;:&quot;Worldwide including CE, US and China;&quot;},{&quot;sup&quot;:&quot;1 &quot;,&quot;abbreviation&quot;:&quot;OUS - &quot;,&quot;description&quot;:&quot;Outside the US; PCR:  Polymerase Chain Reaction; RT: Real Time;&quot;},{&quot;sup&quot;:&quot;2 &quot;,&quot;abbreviation&quot;:&quot;EUA - &quot;,&quot;description&quot;:&quot;Emergency Use Authorization;&quot;},{&quot;sup&quot;:&quot;3 &quot;,&quot;description&quot;:&quot;Only selected countries&quot;}]" class="hydrated"></roche-pipeline-caption></roche-pipeline-diagnostics></div></roche-accordion-tabs-item></roche-accordion-tabs></roche-grid><roche-grid layout="6-6" full-width="false" color="" class="hydrated"><roche-headline level="2" headline="Downloads" slot="left" uid="dce537d1-fea8-44b0-9821-59c01cd6e68b" id="dce537d1-fea8-44b0-9821-59c01cd6e68b" storyid="78842718" appearance="default" class="hydrated" js-first-column-child=""></roche-headline><roche-teaser layout="teaser-variant-a-without-image" teaser-title="Roche Group Development pipeline" teaser-description="PDF" teaser-url="https://assets.cwp.roche.com/f/126832/x/8eaa872b21/irp220721-annex.pdf" is-download-link="true" loaded="" slot="right" class="hydrated" js-first-column-child="" style="height: 106px;"></roche-teaser><roche-teaser layout="teaser-variant-a-without-image" teaser-title="Roche Group Pharmaceuticals pipeline" teaser-description="PDF" teaser-url="https://assets.cwp.roche.com/f/126832/x/0b31bc9ac4/pharmahy22.pdf" is-download-link="true" loaded="" slot="right" class="hydrated" style="height: 106px;"></roche-teaser><roche-teaser layout="teaser-variant-a-without-image" teaser-title="Roche Group Diagnostics pipeline" teaser-description="PDF" teaser-url="https://assets.cwp.roche.com/f/126832/x/9571e7632b/diahy22.pdf" is-download-link="true" loaded="" slot="right" class="hydrated" style="height: 106px;"></roche-teaser></roche-grid><roche-grid layout="12" full-width="false" color="theme-aware" class="hydrated"><roche-side-by-side vertical-alignment="top" horizontal-alignment="left" uid="f27efc18-9db9-4ec8-bc57-187293cdd47c" id="f27efc18-9db9-4ec8-bc57-187293cdd47c" storyid="78842718" class="hydrated" js-first-column-child=""><roche-headline level="2" headline="Discover more" uid="f8830b61-dafd-43c7-917c-ab19a7e971af" id="f8830b61-dafd-43c7-917c-ab19a7e971af" storyid="78842718" appearance="default" class="hydrated"></roche-headline></roche-side-by-side><roche-teaser-wall can-load-more="false" is-fetching="true" slot="" class="hydrated"><roche-filters filter-by="tag" can-initialize="false" slot="slotted-filters" active-filter-index="0" no-filterable-content-found="" class="hydrated"></roche-filters><roche-teaser layout="teaser-variant-a-without-image" teaser-url="/innovation/process/clinical-trials/" loaded="" slot="teasers" class="hydrated" teaser-image="https://assets.cwp.roche.com/f/126832/1999x1335/63356c31be/clinical-trials-stage.jpg/m/$0x$1/filters:format(webp):quality(90)/" teaser-title="Clinical trials" teaser-overline="Innovation" teaser-description="Clinical trials are essential to determine whether new drugs or diagnostics are safe and effective when used to diagnose or treat people. "></roche-teaser><roche-teaser layout="teaser-variant-a-without-image" teaser-url="/innovation/partnering/" loaded="" slot="teasers" class="hydrated" teaser-image="https://assets.cwp.roche.com/f/126832/608x342/641e9544f5/partnering-teaser.jpg/m/$0x$1/filters:format(webp):quality(90)/" teaser-title="Partnering" teaser-overline="Innovation" teaser-description="At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients."></roche-teaser><roche-teaser layout="teaser-variant-a-without-image" teaser-url="/investors/reports/" loaded="" slot="teasers" class="hydrated" teaser-image="https://assets.cwp.roche.com/f/126832/370x208/7c3248e819/teaser-placeholder.jpg/m/$0x$1/filters:format(webp):quality(90)/" teaser-title="Reporting" teaser-overline="Investors" teaser-description="Access Roche's financial and non-financial reports for the latest updates on Roche's performance. "></roche-teaser><roche-teaser layout="teaser-variant-b-without-image" teaser-title="Genentech Pipeline" teaser-overline="-" teaser-description="Our R&amp;D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics." teaser-image="https://assets.cwp.roche.com/f/126832/370x208/d02ede24cf/teaser-placeholder.jpg/m/$0x$1/filters:format(webp):quality(90)/" teaser-url="https://www.gene.com/medical-professionals/pipeline" loaded="" is-external-link="true" slot="teasers" class="hydrated"></roche-teaser></roche-teaser-wall></roche-grid><roche-footer copyright="F. Hoffmann-La Roche Ltd" slottedhelpfullinks="[{&quot;_uid&quot;:&quot;15c50df2-174a-42a0-8080-c0b980939a3f&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://diagnostics.roche.com/us/en/landing-pages/roche-covid-19-updates.html&quot;,&quot;anchor&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://diagnostics.roche.com/us/en/landing-pages/roche-covid-19-updates.html&quot;},&quot;text&quot;:&quot;Covid-19&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-helpful&quot;},{&quot;_uid&quot;:&quot;20847b16-1bd4-426d-8cf8-20bd58c89875&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;09677c3a-69f8-4b1b-a758-614fe9fdaaa0&quot;,&quot;url&quot;:&quot;&quot;,&quot;anchor&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;solutions/pharma/&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Pharma Solutions&quot;,&quot;id&quot;:78840932,&quot;uuid&quot;:&quot;09677c3a-69f8-4b1b-a758-614fe9fdaaa0&quot;,&quot;slug&quot;:&quot;pharma&quot;,&quot;full_slug&quot;:&quot;solutions/pharma/&quot;,&quot;url&quot;:&quot;solutions/pharma/&quot;}},&quot;text&quot;:&quot;Pharma solutions&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-helpful&quot;},{&quot;_uid&quot;:&quot;c5d2bb0b-86a0-433c-b38d-e5ecab106d36&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://careers.roche.com&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://careers.roche.com&quot;},&quot;text&quot;:&quot;Roche careers&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-helpful&quot;},{&quot;_uid&quot;:&quot;2d35a8f7-4855-400a-9aa6-6ada7029bb8d&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;fd80268e-30d5-44bf-bc69-52cb6e9c3b31&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;media/library-images/&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Media library&quot;,&quot;id&quot;:77262493,&quot;uuid&quot;:&quot;fd80268e-30d5-44bf-bc69-52cb6e9c3b31&quot;,&quot;slug&quot;:&quot;library-images&quot;,&quot;full_slug&quot;:&quot;media/library-images&quot;,&quot;url&quot;:&quot;media/library-images&quot;}},&quot;text&quot;:&quot;Media library&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-helpful&quot;},{&quot;_uid&quot;:&quot;3501b21b-f967-4c9c-89d0-4d0d488c2d9c&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;f92a5860-6ebd-4f84-abda-346ae5812ded&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;investors/annualreport21&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Roche’s Annual Report 2021&quot;,&quot;id&quot;:104379749,&quot;uuid&quot;:&quot;f92a5860-6ebd-4f84-abda-346ae5812ded&quot;,&quot;slug&quot;:&quot;annualreport21&quot;,&quot;full_slug&quot;:&quot;investors/annualreport21&quot;,&quot;url&quot;:&quot;investors/annualreport21&quot;}},&quot;text&quot;:&quot;Annual report 2021&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-helpful&quot;}]" slottedquicklinks="[{&quot;_uid&quot;:&quot;28f424a7-8490-4e16-9850-101a1facf270&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;28bd0cd5-e3f1-4bff-8f3a-6788c1b8c62d&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;contact/&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Contact&quot;,&quot;id&quot;:88529489,&quot;uuid&quot;:&quot;28bd0cd5-e3f1-4bff-8f3a-6788c1b8c62d&quot;,&quot;slug&quot;:&quot;contact&quot;,&quot;full_slug&quot;:&quot;contact/&quot;,&quot;url&quot;:&quot;contact/&quot;}},&quot;text&quot;:&quot;Contact&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-quick&quot;,&quot;icon&quot;:&quot;chevron-right&quot;,&quot;size&quot;:&quot;huge&quot;,&quot;icon-position&quot;:&quot;after&quot;},{&quot;_uid&quot;:&quot;9f30015a-ac2b-4e9b-85bc-d035ee835096&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;9be47f11-2447-4b3b-8d82-74c41d785b66&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;worldwide&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Roche affiliates worldwide&quot;,&quot;id&quot;:78853453,&quot;uuid&quot;:&quot;9be47f11-2447-4b3b-8d82-74c41d785b66&quot;,&quot;slug&quot;:&quot;worldwide&quot;,&quot;full_slug&quot;:&quot;worldwide&quot;,&quot;url&quot;:&quot;worldwide&quot;}},&quot;text&quot;:&quot;Locations&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-quick&quot;,&quot;icon&quot;:&quot;chevron-right&quot;,&quot;size&quot;:&quot;huge&quot;,&quot;icon-position&quot;:&quot;after&quot;}]" slottedsociallinks="[{&quot;_uid&quot;:&quot;e1fbf890-4c07-466c-8f8b-912db4b4ac83&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602&quot;},&quot;text&quot;:&quot; linkedin&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;linkedin&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602&quot;},&quot;type&quot;:&quot;footer-social&quot;},{&quot;_uid&quot;:&quot;aaab0e05-4ec7-4f30-800d-d90d59204209&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.facebook.com/roche&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.facebook.com/roche&quot;},&quot;text&quot;:&quot; facebook&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;facebook&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.facebook.com/roche&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.facebook.com/roche&quot;},&quot;type&quot;:&quot;footer-social&quot;},{&quot;_uid&quot;:&quot;6fc63edb-5faa-4884-8d50-bd73a3d1be83&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://twitter.com/roche&quot;,&quot;_uid&quot;:&quot;838c1b79-0264-4f1d-9159-34f371c1d16d&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://twitter.com/roche&quot;},&quot;text&quot;:&quot; twitter&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;twitter&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://twitter.com/roche&quot;,&quot;_uid&quot;:&quot;838c1b79-0264-4f1d-9159-34f371c1d16d&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://twitter.com/roche&quot;},&quot;type&quot;:&quot;footer-social&quot;},{&quot;_uid&quot;:&quot;0e201e1b-d091-49ca-8e49-4936a3f8cd4e&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.instagram.com/roche/&quot;,&quot;_uid&quot;:&quot;ede86d3e-ab7e-474c-98fd-a1d06ec97031&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.instagram.com/roche/&quot;},&quot;text&quot;:&quot; instagram&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;instagram&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.instagram.com/roche/&quot;,&quot;_uid&quot;:&quot;ede86d3e-ab7e-474c-98fd-a1d06ec97031&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.instagram.com/roche/&quot;},&quot;type&quot;:&quot;footer-social&quot;},{&quot;_uid&quot;:&quot;c67b8ae0-3365-4067-bd43-0046bfc5e5d4&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.youtube.com/roche&quot;,&quot;_uid&quot;:&quot;e375c3d5-5a45-4e3c-965b-efd733b1ad8c&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.youtube.com/roche&quot;},&quot;text&quot;:&quot; youtube&quot;,&quot;target&quot;:&quot;_blank&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;youtube&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;&quot;,&quot;url&quot;:&quot;https://www.youtube.com/roche&quot;,&quot;_uid&quot;:&quot;e375c3d5-5a45-4e3c-965b-efd733b1ad8c&quot;,&quot;linktype&quot;:&quot;url&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;https://www.youtube.com/roche&quot;},&quot;type&quot;:&quot;footer-social&quot;}]" slottedservicelinks="[{&quot;_uid&quot;:&quot;100cd194-b973-4dc7-82bb-f26b8986ca33&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;53935e07-5c1a-49d5-bc84-1ae0d5906c0c&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;privacy-policy/&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Privacy Policy&quot;,&quot;id&quot;:78853289,&quot;uuid&quot;:&quot;53935e07-5c1a-49d5-bc84-1ae0d5906c0c&quot;,&quot;slug&quot;:&quot;privacy-policy&quot;,&quot;full_slug&quot;:&quot;privacy-policy/&quot;,&quot;url&quot;:&quot;privacy-policy/&quot;}},&quot;text&quot;:&quot;Privacy policy&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-service&quot;},{&quot;_uid&quot;:&quot;17dd679e-7112-4f33-801c-3078fee59b74&quot;,&quot;link&quot;:{&quot;id&quot;:&quot;324b1d2a-47fb-4aeb-9fc7-b7405fbbacb7&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;legal-statement&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Legal Statement&quot;,&quot;id&quot;:78853228,&quot;uuid&quot;:&quot;324b1d2a-47fb-4aeb-9fc7-b7405fbbacb7&quot;,&quot;slug&quot;:&quot;legal-statement&quot;,&quot;full_slug&quot;:&quot;legal-statement&quot;,&quot;url&quot;:&quot;legal-statement&quot;}},&quot;text&quot;:&quot;Legal statement&quot;,&quot;target&quot;:&quot;_self&quot;,&quot;component&quot;:&quot;roche-text-link&quot;,&quot;left_icon&quot;:&quot;&quot;,&quot;right_icon&quot;:&quot;&quot;,&quot;type&quot;:&quot;footer-service&quot;},{&quot;_uid&quot;:&quot;83495d76-0d3e-4153-98e2-b6209d72dbee&quot;,&quot;text&quot;:&quot;Cookies&quot;,&quot;component&quot;:&quot;roche-cookie-banner-link&quot;,&quot;type&quot;:&quot;footer-service&quot;}]" slottedtext="[{&quot;_uid&quot;:&quot;7a5d8624-33b8-43eb-97ea-4a67ff2e648a&quot;,&quot;text&quot;:{&quot;type&quot;:&quot;doc&quot;,&quot;content&quot;:[{&quot;type&quot;:&quot;paragraph&quot;,&quot;content&quot;:[{&quot;text&quot;:&quot;This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.&quot;,&quot;type&quot;:&quot;text&quot;}]}]},&quot;footnote&quot;:false,&quot;component&quot;:&quot;roche-richtext&quot;,&quot;type&quot;:&quot;footer&quot;}]" slottedstockprice="[{&quot;_uid&quot;:&quot;b138b0ed-a9e2-4497-989f-44c5ab736cff&quot;,&quot;href&quot;:{&quot;id&quot;:&quot;79577731-69f6-47a3-bd42-e52d5940cd18&quot;,&quot;url&quot;:&quot;&quot;,&quot;linktype&quot;:&quot;story&quot;,&quot;fieldtype&quot;:&quot;multilink&quot;,&quot;cached_url&quot;:&quot;investors/shares/&quot;,&quot;story&quot;:{&quot;name&quot;:&quot;Share information&quot;,&quot;id&quot;:77268536,&quot;uuid&quot;:&quot;79577731-69f6-47a3-bd42-e52d5940cd18&quot;,&quot;slug&quot;:&quot;shares&quot;,&quot;full_slug&quot;:&quot;investors/shares&quot;,&quot;url&quot;:&quot;investors/shares&quot;}},&quot;component&quot;:&quot;roche-stock-price&quot;}]" uid="d5df0f57-ee7a-4568-bcc4-a11328a0d8c7" id="d5df0f57-ee7a-4568-bcc4-a11328a0d8c7" class="hydrated"><roche-richtext uid="7a5d8624-33b8-43eb-97ea-4a67ff2e648a" slot="text" type="footer" class="hydrated"><!----><p>This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.</p></roche-richtext><roche-text-link link="/contact/" text="Contact" target="_self" left-icon="" right-icon="" type="footer-quick" icon="chevron-right" size="huge" icon-position="after" href="/contact/" slot="quick-links" class="hydrated"></roche-text-link><roche-text-link link="/worldwide" text="Locations" target="_self" left-icon="" right-icon="" type="footer-quick" icon="chevron-right" size="huge" icon-position="after" href="/worldwide" slot="quick-links" class="hydrated"></roche-text-link><roche-stock-price price="324" currency="CHF" change="0.65" relative-change="0.2" href="/investors/shares" slot="stock-price" class="hydrated"></roche-stock-price><roche-text-link link="https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602" text=" linkedin" target="_blank" left-icon="linkedin" right-icon="" href="https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602" type="footer-social" slot="social-links" class="hydrated"></roche-text-link><roche-text-link link="https://www.facebook.com/roche" text=" facebook" target="_blank" left-icon="facebook" right-icon="" href="https://www.facebook.com/roche" type="footer-social" slot="social-links" class="hydrated"></roche-text-link><roche-text-link link="https://twitter.com/roche" text=" twitter" target="_blank" left-icon="twitter" right-icon="" href="https://twitter.com/roche" type="footer-social" slot="social-links" class="hydrated"></roche-text-link><roche-text-link link="https://www.instagram.com/roche/" text=" instagram" target="_blank" left-icon="instagram" right-icon="" href="https://www.instagram.com/roche/" type="footer-social" slot="social-links" class="hydrated"></roche-text-link><roche-text-link link="https://www.youtube.com/roche" text=" youtube" target="_blank" left-icon="youtube" right-icon="" href="https://www.youtube.com/roche" type="footer-social" slot="social-links" class="hydrated"></roche-text-link><roche-text-link link="https://diagnostics.roche.com/us/en/landing-pages/roche-covid-19-updates.html" text="Covid-19" target="_self" left-icon="" right-icon="" type="footer-helpful" href="https://diagnostics.roche.com/us/en/landing-pages/roche-covid-19-updates.html" slot="helpful-links" class="hydrated"></roche-text-link><roche-text-link link="/solutions/pharma/" text="Pharma solutions" target="_self" left-icon="" right-icon="" type="footer-helpful" href="/solutions/pharma/" slot="helpful-links" class="hydrated"></roche-text-link><roche-text-link link="https://careers.roche.com" text="Roche careers" target="_blank" left-icon="" right-icon="" type="footer-helpful" href="https://careers.roche.com" slot="helpful-links" class="hydrated"></roche-text-link><roche-text-link link="/media/library-images" text="Media library" target="_self" left-icon="" right-icon="" type="footer-helpful" href="/media/library-images" slot="helpful-links" class="hydrated"></roche-text-link><roche-text-link link="/investors/annualreport21" text="Annual report 2021" target="_self" left-icon="" right-icon="" type="footer-helpful" href="/investors/annualreport21" slot="helpful-links" class="hydrated"></roche-text-link><roche-text-link link="/privacy-policy/" text="Privacy policy" target="_self" left-icon="" right-icon="" type="footer-service" href="/privacy-policy/" slot="service-links" class="hydrated"></roche-text-link><roche-text-link link="/legal-statement" text="Legal statement" target="_self" left-icon="" right-icon="" type="footer-service" href="/legal-statement" slot="service-links" class="hydrated"></roche-text-link><roche-text-link text="Cookies" type="footer-service" slot="service-links" class="hydrated"></roche-text-link></roche-footer><roche-fouc-preventer class="hydrated"></roche-fouc-preventer></div><div id="gatsby-announcer" aria-live="assertive" aria-atomic="true" style="position: absolute; top: 0px; width: 1px; height: 1px; padding: 0px; overflow: hidden; clip: rect(0px, 0px, 0px, 0px); white-space: nowrap; border: 0px;"></div></div><script id="gatsby-script-loader">window.pagePath="/solutions/pipeline/",window.___webpackCompilationHash="ebca54826a94c74e517e"</script><script id="gatsby-chunk-mapping">window.___chunkMapping={app:["/app-3bf15779ba576c4bb747.js"],"component---src-pages-en-media-switzerland-informationen-[slug]-tsx":["/component---src-pages-en-media-switzerland-informationen-[slug]-tsx-28826504a945d67cb4be.js"],"component---src-pages-fr-presse-suisse-informationen-[slug]-tsx":["/component---src-pages-fr-presse-suisse-informationen-[slug]-tsx-c0f42d44fedbecf390b0.js"],"component---src-pages-investors-updates-[slug]-tsx":["/component---src-pages-investors-updates-[slug]-tsx-77fdffc80e09402c666e.js"],"component---src-pages-media-releases-[slug]-tsx":["/component---src-pages-media-releases-[slug]-tsx-332fb33ffd0240cedcbc.js"],"component---src-pages-medien-schweiz-informationen-[slug]-tsx":["/component---src-pages-medien-schweiz-informationen-[slug]-tsx-56e1d3bd64388c328fa4.js"],"component---src-pages-preview-login-wall-tsx":["/component---src-pages-preview-login-wall-tsx-ecd8ae9810186866a7c2.js"],"component---src-pages-test-releases-[slug]-tsx":["/component---src-pages-test-releases-[slug]-tsx-5612909d1f523e0a8d9a.js"],"component---src-pages-topic-[tag]-tsx":["/component---src-pages-topic-[tag]-tsx-b9e00017d87cdf252c02.js"],"component---src-pages-worldwide-[slug]-tsx":["/component---src-pages-worldwide-[slug]-tsx-826686911a0e82391944.js"],"component---src-templates-default-tsx":["/component---src-templates-default-tsx-82677ed8e9dcc6cdc598.js"]}</script><script src="/app-3bf15779ba576c4bb747.js" async=""></script><script src="/framework-f8e298a9f517dfed0cc7.js" async=""></script><script src="/webpack-runtime-74a31ca3fe534e47466b.js" async=""></script><div id="onetrust-consent-sdk"><div class="onetrust-pc-dark-filter ot-fade-in" style="display: none;transition: visibility 0s 400ms, opacity 400ms linear;
                    opacity: 0;visibility: hidden;z-index:2147483645;"></div><div id="onetrust-banner-sdk" class="otFlat top vertical-align-content" aria-modal="true" tabindex="0" style="display: none;top: 0px; bottom: auto;visibility: hidden;
                    opacity: 0;transition: visibility 0s 400ms, opacity 400ms linear;"><div role="alertdialog" aria-describedby="onetrust-policy-text" aria-label="Our use of cookies"><div class="ot-sdk-container"><div class="ot-sdk-row"><div id="onetrust-group-container" class="ot-sdk-eight ot-sdk-columns"><div class="banner_logo"></div><div id="onetrust-policy"><h2 id="onetrust-policy-title">Our use of cookies</h2><p id="onetrust-policy-text">We use cookies and other technologies (“cookies”) to improve our website. Besides the strictly necessary cookies, we would like to use cookies (1) to learn how our website is used and how it performs, including cross-site statistics, (2) to provide you with additional functionalities and personalisation (3) to provide you social media interactions and (4) for targeting and marketing purposes. By clicking “Accept all”, you consent to the use of all cookies and the corresponding data processing which may include your browser-information and IP-address as well as the disclosure of personal data to third parties as further described in our Cookie/Privacy Policy. For more information, configuration and to withdraw your consent, please click “Cookie preferences”.<a href="https://www.roche.com/privacy_policy.htm" aria-label="More information about your privacy">Cookie/Privacy Policy</a></p></div></div><div id="onetrust-button-group-parent" class="ot-sdk-three ot-sdk-columns"><div id="onetrust-button-group"><button id="onetrust-pc-btn-handler">Cookie preferences</button>  <button id="onetrust-accept-btn-handler">Accept all</button></div></div></div></div><!-- Close Button --><div id="onetrust-close-btn-container"><button class="onetrust-close-btn-handler onetrust-close-btn-ui banner-close-button ot-close-icon" aria-label="Close"></button></div><!-- Close Button END--></div></div><div id="onetrust-pc-sdk" class="otPcCenter ot-hide ot-fade-in" aria-modal="true" role="alertdialog" aria-describedby="ot-pc-desc" lang="en" aria-label="Our use of cookies" style="display: none;
                    transition: visibility 0s 400ms, opacity 400ms linear;
                    opacity: 0;visibility: hidden;"><!-- Close Button --><div class="ot-pc-header"><!-- Logo Tag --><div class="ot-pc-logo" role="img" aria-label="Company Logo" style="background-image: url(&quot;https://cdn.cookielaw.org/logos/d83b6e8f-2787-46e5-b85f-ad52b3a0acb6/7f22e260-5ce1-40ca-9a30-08f7645292d3/f613888c-c5ea-47e2-8686-0870b32cc9ce/rochelogo.png&quot;);
                background-position: left;"></div></div><!-- Close Button --><div id="ot-pc-content" class="ot-pc-scrollbar"><h2 id="ot-pc-title">Our use of cookies</h2><div id="ot-pc-desc">We may use cookies and other technologies (“cookies”) in order to create statistics that help us to improve the quality of our website, including site statistics, to improve your user-experience, e.g. by displaying you third party content , to provide you social media interactions and for marketing purposes. By clicking “Accept all”, you consent to such data processing by Roche and the corresponding transfer of data to third parties. You can also easily configure for what purposes you consent the data being processed. Please press “Confirm selection” after you have made your selection. If you do not make any selection, the data processing is limited to the extent necessary for the use of the website. Please note that based on these settings, not all functionalities of the page may be available. To withdraw your consent, please click “Cookie preferences” below and at the bottom of this website. Further information is available in our <a href="https://www.roche.com/privacy_policy.htm" rel="noopener noreferrer" target="_blank" style="color:#037cca">Cookie Policy</a>.</div><button id="accept-recommended-btn-handler">Accept all</button><section class="ot-sdk-row ot-cat-grp"><h3 id="ot-category-title"> Manage Consent Preferences</h3><div class="ot-cat-item ot-vs-config ot-always-active-group" data-optanongroupid="C0001"><!-- Group name --><h4 class="ot-cat-header" id="ot-header-id-C0001">Strictly Necessary Cookies</h4><div class="ot-always-active">Always active</div><!-- Group description --><p class="ot-category-desc" id="ot-desc-id-C0001">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you that amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, but blocking these cookies will prevent the site from working. These cookies do not store any personal information.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details button opens Cookie List menu" data-parent-id="C0001">View cookies‎</button></div></div><div class="ot-cat-item ot-vs-config" data-optanongroupid="C0002"><!-- Group name --><h4 class="ot-cat-header" id="ot-header-id-C0002">Performance Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0002" id="ot-group-id-C0002" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0002" aria-labelledby="ot-header-id-C0002" checked=""> <label class="ot-switch" for="ot-group-id-C0002"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Performance Cookies</span></label> </div><!-- Group description --><p class="ot-category-desc" id="ot-desc-id-C0002">These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. We may collect your session ID, IP address, device identifiers, and your activity with the website. We may provide these cookies to third party service providers to help us run these analytics. All information these cookies collect is aggregated and do not relate to you personally. If you block or opt out of these cookies, we will not know when you have visited our site, and will not be able to monitor its performance.
<p>
If you are located in Europe, the personal data may be sent to a country (e.g. United States) that has not been deemed to provide an adequate level of data protection or appropriate safeguards. By accepting these cookies, you consent to the data processing for analytics purposes and to the transfer of your personal data to the United States each time you visit our site.
</p></p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details button opens Cookie List menu" data-parent-id="C0002">View cookies‎</button></div></div><div class="ot-cat-item ot-vs-config" data-optanongroupid="C0003"><!-- Group name --><h4 class="ot-cat-header" id="ot-header-id-C0003">Functional Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0003" id="ot-group-id-C0003" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0003" aria-labelledby="ot-header-id-C0003" checked=""> <label class="ot-switch" for="ot-group-id-C0003"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Functional Cookies</span></label> </div><!-- Group description --><p class="ot-category-desc" id="ot-desc-id-C0003">These cookies enable our websites to provide enhanced functionality and personalization. They may be set by us or by third party service providers whose services we have added to our pages. If you reject these cookies, then some or all of these services may not function properly.

</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details button opens Cookie List menu" data-parent-id="C0003">View cookies‎</button></div></div><div class="ot-cat-item ot-vs-config" data-optanongroupid="C0004"><!-- Group name --><h4 class="ot-cat-header" id="ot-header-id-C0004">Targeting Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0004" id="ot-group-id-C0004" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0004" aria-labelledby="ot-header-id-C0004" checked=""> <label class="ot-switch" for="ot-group-id-C0004"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Targeting Cookies</span></label> </div><!-- Group description --><p class="ot-category-desc" id="ot-desc-id-C0004">These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details button opens Cookie List menu" data-parent-id="C0004">View cookies‎</button></div></div><div class="ot-cat-item ot-vs-config" data-optanongroupid="C0005"><!-- Group name --><h4 class="ot-cat-header" id="ot-header-id-C0005">Social Media Cookies</h4><div class="ot-tgl"><input type="checkbox" name="ot-group-id-C0005" id="ot-group-id-C0005" aria-checked="true" role="switch" class="category-switch-handler" data-optanongroupid="C0005" aria-labelledby="ot-header-id-C0005" checked=""> <label class="ot-switch" for="ot-group-id-C0005"><span class="ot-switch-nob" aria-checked="false" role="switch"></span> <span class="ot-label-txt">Social Media Cookies</span></label> </div><!-- Group description --><p class="ot-category-desc" id="ot-desc-id-C0005">These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks (such as Facebook, Twitter, LinkedIn). They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.</p><div class="ot-hlst-cntr"><button class="ot-link-btn category-host-list-handler" aria-label="Cookie Details button opens Cookie List menu" data-parent-id="C0005">View cookies‎</button></div></div><!-- Groups sections starts --><!-- Group section ends --><!-- Accordion Group section starts --><!-- Accordion Group section ends --></section></div><section id="ot-pc-lst" class="ot-hide ot-hosts-ui ot-pc-scrollbar ot-enbl-chr"><div id="ot-pc-hdr"><div id="ot-lst-title"><button class="ot-link-btn back-btn-handler" aria-label="Back"><svg id="ot-back-arw" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 444.531 444.531" xml:space="preserve"><title>Back Button</title><g><path fill="#656565" d="M213.13,222.409L351.88,83.653c7.05-7.043,10.567-15.657,10.567-25.841c0-10.183-3.518-18.793-10.567-25.835
                    l-21.409-21.416C323.432,3.521,314.817,0,304.637,0s-18.791,3.521-25.841,10.561L92.649,196.425
                    c-7.044,7.043-10.566,15.656-10.566,25.841s3.521,18.791,10.566,25.837l186.146,185.864c7.05,7.043,15.66,10.564,25.841,10.564
                    s18.795-3.521,25.834-10.564l21.409-21.412c7.05-7.039,10.567-15.604,10.567-25.697c0-10.085-3.518-18.746-10.567-25.978
                    L213.13,222.409z"></path></g></svg></button><h3>Performance Cookies</h3></div><div class="ot-lst-subhdr"><div class="ot-search-cntr"><p role="status" class="ot-scrn-rdr"></p><label for="vendor-search-handler" class="ot-scrn-rdr"></label> <input id="vendor-search-handler" type="text" name="vendor-search-handler"> <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 -30 110 110" aria-hidden="true"><title>Search Icon</title><path fill="#2e3644" d="M55.146,51.887L41.588,37.786c3.486-4.144,5.396-9.358,5.396-14.786c0-12.682-10.318-23-23-23s-23,10.318-23,23
            s10.318,23,23,23c4.761,0,9.298-1.436,13.177-4.162l13.661,14.208c0.571,0.593,1.339,0.92,2.162,0.92
            c0.779,0,1.518-0.297,2.079-0.837C56.255,54.982,56.293,53.08,55.146,51.887z M23.984,6c9.374,0,17,7.626,17,17s-7.626,17-17,17
            s-17-7.626-17-17S14.61,6,23.984,6z"></path></svg></div><div class="ot-fltr-cntr"><button id="filter-btn-handler" aria-label="Filter" aria-haspopup="true"><svg role="presentation" aria-hidden="true" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 402.577 402.577" xml:space="preserve"><title>Filter Icon</title><g><path fill="#fff" d="M400.858,11.427c-3.241-7.421-8.85-11.132-16.854-11.136H18.564c-7.993,0-13.61,3.715-16.846,11.136
      c-3.234,7.801-1.903,14.467,3.999,19.985l140.757,140.753v138.755c0,4.955,1.809,9.232,5.424,12.854l73.085,73.083
      c3.429,3.614,7.71,5.428,12.851,5.428c2.282,0,4.66-0.479,7.135-1.43c7.426-3.238,11.14-8.851,11.14-16.845V172.166L396.861,31.413
      C402.765,25.895,404.093,19.231,400.858,11.427z"></path></g></svg></button></div><div id="ot-anchor"></div><section id="ot-fltr-modal"><div id="ot-fltr-cnt"><button id="clear-filters-handler">Clear</button><div class="ot-fltr-scrlcnt ot-pc-scrollbar"><div class="ot-fltr-opts"><div class="ot-fltr-opt"><div class="ot-chkbox"><input id="chkbox-id" type="checkbox" aria-checked="false" class="category-filter-handler"> <label for="chkbox-id"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div><div class="ot-fltr-btns"><button id="filter-apply-handler">Apply</button> <button id="filter-cancel-handler">Cancel</button></div></div></div></section></div></div><section id="ot-lst-cnt" class="ot-host-cnt ot-pc-scrollbar"><div id="ot-sel-blk"><div class="ot-sel-all"><div class="ot-sel-all-hdr"><span class="ot-consent-hdr">Consent</span> <span class="ot-li-hdr">Leg.Interest</span></div><div class="ot-sel-all-chkbox"><div class="ot-chkbox" id="ot-selall-hostcntr"><input id="select-all-hosts-groups-handler" type="checkbox" aria-checked="false"> <label for="select-all-hosts-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-vencntr"><input id="select-all-vendor-groups-handler" type="checkbox" aria-checked="false"> <label for="select-all-vendor-groups-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div><div class="ot-chkbox" id="ot-selall-licntr"><input id="select-all-vendor-leg-handler" type="checkbox" aria-checked="false"> <label for="select-all-vendor-leg-handler"><span class="ot-label-txt">checkbox label</span></label> <span class="ot-label-status">label</span></div></div></div></div><div class="ot-sdk-row"><div class="ot-sdk-column"><ul id="ot-host-lst"><li class="ot-host-item"><button class="ot-host-box" aria-expanded="false"></button><section class="ot-acc-hdr"><div class="ot-host-hdr"><h3 class="ot-host-name"></h3><h4 class="ot-host-desc"></h4><span class="ot-host-expand">View Cookies</span></div><!-- toggles and arrow --><div class="ot-tgl-cntr"></div></section><div class="ot-acc-txt"><div class="ot-host-opts"><!-- HOST LIST VIEW UPDATE *** --><ul class="ot-host-opt"><li class="ot-host-info"><div><div>Name</div><div>cookie name</div></div></li></ul><!-- HOST LIST VIEW UPDATE END *** --></div></div></li></ul></div></div></section></section><div class="ot-pc-footer"><div class="ot-btn-container"><button class="ot-pc-refuse-all-handler">Reject all</button> <button class="save-preference-btn-handler onetrust-close-btn-handler">Confirm selection</button></div><!-- Footer logo --><div class="ot-pc-footer-logo"><a href="https://www.onetrust.com/products/cookie-consent/" target="_blank" rel="noopener noreferrer" aria-label="Powered by OneTrust Opens in a new Tab"><img alt="Powered by Onetrust" src="https://cdn.cookielaw.org/logos/static/poweredBy_ot_logo.svg" title="Powered by OneTrust Opens in a new Tab"></a></div></div><!-- Cookie subgroup container --><!-- Vendor list link --><!-- Cookie lost link --><!-- Toggle HTML element --><!-- Checkbox HTML --><!-- plus minus--><!-- Arrow SVG element --><!-- Accordion basic element --><span class="ot-scrn-rdr" aria-atomic="true" aria-live="polite">Your Privacy [`dialog closed`]</span><!-- Vendor Service container and item template --><iframe class="ot-text-resize" title="onetrust-text-resize" style="position: absolute; top: -50000px; width: 100em;" aria-hidden="true"></iframe></div></div><script type="text/javascript" id="">void 0!=google_tag_manager["GTM-MS8297"].macro(23)&&(window.Storage?(sessionStorage.setItem("channel_fix",google_tag_manager["GTM-MS8297"].macro(24)),dataLayer.push({event:"event_channelfix_storage"})):(google_tag_manager["GTM-MS8297"].macro(25)("channel_fix",google_tag_manager["GTM-MS8297"].macro(26),void 0,void 0,google_tag_manager["GTM-MS8297"].macro(31)),dataLayer.push({event:"event_channelfix_cookie"})));</script> <script type="text/javascript" id="">var cookie_old=google_tag_manager["GTM-MS8297"].macro(32);dataLayer.push({event:"prev_page_content_tag_event",prev_page_content_tag_var:cookie_old});var cookie="null",domain=document.location.hostname.substr(document.location.hostname.indexOf(google_tag_manager["GTM-MS8297"].macro(34)));document.cookie="content_tags_prev_page\x3d"+cookie+";path\x3d/;domain\x3d"+domain;</script><script type="text/javascript" id="">window.Storage?(sessionStorage.setItem("ref_dom",google_tag_manager["GTM-MS8297"].macro(39)),sessionStorage.setItem("ref_host",google_tag_manager["GTM-MS8297"].macro(40))):(google_tag_manager["GTM-MS8297"].macro(41)("ref_dom",google_tag_manager["GTM-MS8297"].macro(46),void 0,void 0,google_tag_manager["GTM-MS8297"].macro(51)),google_tag_manager["GTM-MS8297"].macro(52)("ref_host",google_tag_manager["GTM-MS8297"].macro(53),void 0,void 0,google_tag_manager["GTM-MS8297"].macro(58)));</script><script type="text/javascript" id="">var pathnow=google_tag_manager["GTM-MS8297"].macro(59),cookiebefore=google_tag_manager["GTM-MS8297"].macro(60),storage=google_tag_manager["GTM-MS8297"].macro(62);
if(window.Storage){if(null==storage)var new_storage=pathnow;else{var tmp1=storage.split("|");idx=tmp1.indexOf(pathnow);if(0<=idx){var tmp2=tmp1.splice(0,idx+1);new_storage=tmp2.join("|")}else new_storage=storage+"|"+pathnow}sessionStorage.setItem("userjourney",new_storage);dataLayer.push({event:"event_userjourney_storage"})}else{if(void 0==cookiebefore)var new_cookie_string=pathnow;else{var tmp3=cookiebefore.split("|");idx=tmp3.indexOf(pathnow);if(0<=idx){var tmp4=tmp3.splice(0,idx+1);new_cookie_string=
tmp4.join("|")}else new_cookie_string=cookiebefore+"|"+pathnow}var domain=google_tag_manager["GTM-MS8297"].macro(67);google_tag_manager["GTM-MS8297"].macro(68)("userjourney",new_cookie_string,7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(73));dataLayer.push({event:"event_userjourney_cookie"})};</script><script type="text/javascript" id="">dataLayer.push({event:"3rd_party_trigger"});</script><script type="text/javascript" id="">var storage=google_tag_manager["GTM-MS8297"].macro(75),cookie1=google_tag_manager["GTM-MS8297"].macro(76),cookie2=google_tag_manager["GTM-MS8297"].macro(77),lookupip=google_tag_manager["GTM-MS8297"].macro(78),clientip=google_tag_manager["GTM-MS8297"].macro(79);
window.Storage&&null!=storage&&storage.match(/^intern.*/)?dataLayer.push({event:"ce_internal_user_storage"}):window.Storage&&"undefined"!=typeof cookie2&&cookie2.match(/^intern.*/)?localStorage.setItem("intern_check","intern"):"undefined"!=typeof cookie2&&cookie2.match(/^intern.*/)?(dataLayer.push({event:"ce_internal_user_cookie"}),google_tag_manager["GTM-MS8297"].macro(80)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(85))):window.Storage&&"undefined"!=typeof cookie1&&cookie1.match(/^intern.*/)?localStorage.setItem("intern_check",
"intern"):"undefined"!=typeof cookie1&&cookie1.match(/^intern.*/)?google_tag_manager["GTM-MS8297"].macro(86)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(91)):window.Storage&&"undefined"!=typeof lookupip&&lookupip.match(/^intern.*/)?localStorage.setItem("intern_check","intern"):"undefined"!=typeof lookupip&&lookupip.match(/^intern.*/)&&google_tag_manager["GTM-MS8297"].macro(92)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(97));</script><script type="text/javascript" id="">var xmlhttp=new XMLHttpRequest,url="https://api.ipify.org?format\x3djsonp";xmlhttp.onreadystatechange=function(){if(4==this.readyState&&200==this.status){rx=/^callback\((.*)\);$/g;var a=JSON.parse(rx.exec(this.responseText)[1]);dataLayer.push({event:"ce_ipify",client_IP:a.ip})}};xmlhttp.open("GET",url,!1);xmlhttp.send();</script>
<script type="text/javascript" id="">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","864118870904956");fbq("track","PageView");</script>
<noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=864118870904956&amp;ev=PageView&amp;noscript=1"></noscript>
<script type="text/javascript" id="">var cookiesteps=google_tag_manager["GTM-MS8297"].macro(103),storagesteps=google_tag_manager["GTM-MS8297"].macro(105);
if(window.Storage&&null!=storagesteps)for(var steps=storagesteps.split("|"),length_journey=steps.length,i=0;i<steps.length-1;i++)dataLayer.push({event:"event_userjourney_step",user_journey_step_nr:(-(length_journey-i-1)).toLocaleString("en-US",{minimumIntegerDigits:2,useGrouping:!1}),user_journey_step_url:steps[i]});else if("undefined"!=typeof cookiesteps)for(steps=cookiesteps.split("|"),length_journey=steps.length,i=0;i<steps.length-1;i++)dataLayer.push({event:"event_userjourney_step",user_journey_step_nr:(-(length_journey-
i-1)).toLocaleString("en-US",{minimumIntegerDigits:2,useGrouping:!1}),user_journey_step_url:steps[i]});</script><script type="text/javascript" id="">(function(){var a=google_tag_manager["GTM-MS8297"].macro(107),b=google_tag_manager[google_tag_manager["GTM-MS8297"].macro(108)];window.dataLayer.push({event:a+".1st"});window.dataLayer.push({event:a+".2nd",eventCallback:function(){b.onHtmlSuccess()}})})();</script><script type="text/javascript" id="">var storage=google_tag_manager["GTM-MS8297"].macro(111),cookie1=google_tag_manager["GTM-MS8297"].macro(112),cookie2=google_tag_manager["GTM-MS8297"].macro(113),lookupip=google_tag_manager["GTM-MS8297"].macro(114),clientip=google_tag_manager["GTM-MS8297"].macro(115);
window.Storage&&null!=storage&&storage.match(/^intern.*/)?dataLayer.push({event:"ce_internal_user_storage"}):window.Storage&&"undefined"!=typeof cookie2&&cookie2.match(/^intern.*/)?localStorage.setItem("intern_check","intern"):"undefined"!=typeof cookie2&&cookie2.match(/^intern.*/)?(dataLayer.push({event:"ce_internal_user_cookie"}),google_tag_manager["GTM-MS8297"].macro(116)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(121))):window.Storage&&"undefined"!=typeof cookie1&&cookie1.match(/^intern.*/)?localStorage.setItem("intern_check",
"intern"):"undefined"!=typeof cookie1&&cookie1.match(/^intern.*/)?google_tag_manager["GTM-MS8297"].macro(122)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(127)):window.Storage&&"undefined"!=typeof lookupip&&lookupip.match(/^intern.*/)?localStorage.setItem("intern_check","intern"):"undefined"!=typeof lookupip&&lookupip.match(/^intern.*/)&&google_tag_manager["GTM-MS8297"].macro(128)("intern_check","intern",7776E6,void 0,google_tag_manager["GTM-MS8297"].macro(133));</script>
<script type="text/javascript" id="">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init",google_tag_manager["GTM-MS8297"].macro(135));fbq("set","agent","tmgoogletagmanager",google_tag_manager["GTM-MS8297"].macro(136));fbq("track","PageView");</script>

<script type="text/javascript" id="">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init",google_tag_manager["GTM-MS8297"].macro(138));fbq("set","agent","tmgoogletagmanager",google_tag_manager["GTM-MS8297"].macro(139));fbq("track","PageView");</script>
<script type="text/javascript" id="">window.current_view_percent=function(){var b=window.innerHeight,c=document.body,a=document.documentElement;c=Math.max(c.scrollHeight,c.offsetHeight,a.clientHeight,a.scrollHeight,a.offsetHeight);a=window.pageYOffset+b;return b=(a-b)/(c-b)};
window.scroll_handler=function(){var b=window.current_view_percent(),c=window.innerHeight,a=document.body,d=document.documentElement;a=Math.max(a.scrollHeight,a.offsetHeight,d.clientHeight,d.scrollHeight,d.offsetHeight);b=25*Math.floor(100*b/25);c<.75*a&&b>window.last_view_pct&&(window.last_view_pct=b,window.dataLayer.push({event:"true_scroll_tracking"}))};document.addEventListener("scroll",window.scroll_handler,!0);window.last_view_pct=-1;window.scroll_handler();</script><img src="https://t.co/i/adsct?bci=3&amp;eci=2&amp;event_id=df3d08ea-2b42-48d8-b4cb-f0e1c9a74022&amp;events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&amp;p_id=Twitter&amp;p_user_id=0&amp;pl_id=97edf318-5cc6-4b2d-bee4-17df85710de7&amp;tw_document_href=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline%2F%23f24b5f67-0000-422b-b6a0-68b7d67a513d&amp;tw_iframe_status=0&amp;tw_order_quantity=0&amp;tw_sale_amount=0&amp;txn_id=o0zmu&amp;type=javascript&amp;version=2.3.26" height="1" width="1" style="display: none;"><img src="https://analytics.twitter.com/i/adsct?bci=3&amp;eci=2&amp;event_id=df3d08ea-2b42-48d8-b4cb-f0e1c9a74022&amp;events=%5B%5B%22pageview%22%2C%7B%7D%5D%5D&amp;p_id=Twitter&amp;p_user_id=0&amp;pl_id=97edf318-5cc6-4b2d-bee4-17df85710de7&amp;tw_document_href=https%3A%2F%2Fwww.roche.com%2Fsolutions%2Fpipeline%2F%23f24b5f67-0000-422b-b6a0-68b7d67a513d&amp;tw_iframe_status=0&amp;tw_order_quantity=0&amp;tw_sale_amount=0&amp;txn_id=o0zmu&amp;type=javascript&amp;version=2.3.26" height="1" width="1" style="display: none;"><script type="text/javascript" id="">var tags_element="null";if("undefined"!=typeof tags_element&&"null"!=google_tag_manager["GTM-MS8297"].macro(149)){var tags=tags_element.split(", ");tags.forEach(function(a){dataLayer.push({event:"page_content_tag_event",page_content_tag:a})})};</script></body></html>